The hipA Gene: Molecular Mechanisms and Clinical Implications of Bacterial Persistence

Abstract

This article comprehensively examines the hipA gene, a key regulator of bacterial multidrug tolerance and persistence. We explore the foundational molecular biology of the HipA toxin, a serine/threonine kinase that phosphorylates glutamyl-tRNA synthetase (GltX), triggering a dormant state that allows bacterial subpopulations to survive antibiotic treatment. The content details methodological approaches for studying persisters, addresses challenges in distinguishing persistence from resistance, and validates hipA's clinical relevance, particularly in chronic urinary tract infections. Aimed at researchers and drug development professionals, this review synthesizes current knowledge on HipA-mediated persistence and discusses emerging therapeutic strategies targeting this sophisticated bacterial survival mechanism.

Unraveling hipA: From Historical Discovery to Core Molecular Machinery

Bacterial persistence represents a significant challenge in clinical medicine, underlying chronic and relapsing infections. This phenomenon, where a small subpopulation of genetically susceptible bacteria survives antibiotic treatment by entering a transient, non-growing state, was first identified over 80 years ago. The seminal discovery of the hipA mutant in 1983 marked the beginning of genetic research into persistence mechanisms, providing the first molecular handle on this complex phenotype. This whitepaper details the historical context of persister discovery, characterizes the initial hipA mutant, and explores the evolution of our understanding of its molecular function within the broader framework of bacterial multidrug tolerance. We present comprehensive experimental protocols for studying persistence, quantitative analyses of persister fractions, and essential research tools that have enabled mechanistic insights into this clinically relevant bacterial survival strategy.

Bacterial persistence describes a phenomenon wherein a small subpopulation of cells within an isogenic population survives challenges with antibiotics or other stressors better than the majority of the population [1]. Unlike antibiotic resistance, which results from genetic mutations and enables growth in the presence of antibiotics, persistence is a transient, non-heritable phenotype characterized by reduced cellular metabolism and dormancy [2] [3]. This phenotypic tolerance allows persister cells to survive bactericidal antibiotic concentrations that kill their genetically identical siblings.

The clinical relevance of persistence is profound. Persisters are strongly associated with recalcitrant chronic infections such as tuberculosis, recurrent urinary tract infections, and biofilm-associated infections on medical implants [2] [4]. They contribute to treatment failure and infection relapse, as they can resume growth after antibiotic removal, leading to recurrent disease cycles [3]. Furthermore, evidence suggests that the persister state may serve as a reservoir from which genetically resistant mutants can emerge, compounding the public health threat [3].

Table 1: Key Characteristics Distinguishing Bacterial Persistence from Resistance and Other States

Characteristic	Antibiotic Resistance	Antibiotic Tolerance	Persistence	VBNC State
Minimum Inhibitory Concentration (MIC)	Increased	Unchanged	Unchanged	Unchanged
Genetic Basis	Heritable mutations	Can be genetic or phenotypic	Non-heritable, phenotypic	Non-heritable, phenotypic
Population Heterogeneity	Homogeneous	Often homogeneous	Heterogeneous (subpopulation)	Heterogeneous (subpopulation)
Metabolic State	Active	Variable (often slow-growing)	Dormant/slow-growing	Deeply dormant
Culturability after Stress	Yes	Yes	Yes	Requires specific resuscitation signals
Impact on Treatment	Requires alternative drugs	May require longer treatment duration	Causes relapse and chronic infection	May cause relapse

Historical Discovery of Persisters

Initial Observations and Definition

The phenomenon of bacterial persistence was first systematically documented in the 1940s during the early clinical use of penicillin:

• 1942: Gladys Hobby observed that penicillin killed approximately 99% of bacteria (pneumococci, hemolytic streptococci, and staphylococci), but a small fraction (~1%) survived the treatment [2].
• 1944: Joseph Bigger, who was studying this phenomenon in Staphylococcus aureus, formally named the surviving cells "persisters" [2] [5]. He described them as non-growing, dormant bacteria that survived penicillin attack and demonstrated that their progeny remained fully susceptible to the antibiotic [2]. Bigger even proposed an intermittent treatment scheme to target these persistent cells [2].

For several decades following these initial discoveries, persisters remained a laboratory curiosity without a known molecular basis. The field saw incremental advances, including the description of "antibiotic tolerance" in Streptococcus pneumoniae by Alexandre Tomasz in 1970, where a bacterial strain exhibited slow loss of viability without lysis during penicillin exposure [2]. The clinical relevance solidified when Gary Best identified the first genotypically tolerant clinical isolate of S. aureus (strain Evans) in 1974 [2].

Modern Resurgence of Interest

A significant turning point in persister research came in the early 2000s, when Kim Lewis and colleagues established a crucial link between bacterial persistence and biofilm infections [2]. They discovered that biofilms harbor persister cells, identifying these phenotypic variants as the primary culprit behind the recalcitrance of biofilm-associated and other chronic persistent infections to antibiotic therapy [2]. This connection sparked renewed and widespread interest in understanding the molecular mechanisms of persistence.

Discovery of the First hipA Mutant

Original Experimental Approach

The first genetic breakthrough in persistence research came in 1983 from the laboratory of Harris Moyed. The research team employed a classical mutagenesis-and-selection scheme to isolate mutants with enhanced survival under antibiotic pressure [6] [5].

• Mutagenesis: The researchers treated Escherichia coli K-12 with a mutagen to introduce random genetic changes.
• Selection Pressure: The mutated population was then exposed to prolonged inhibition of murein (peptidoglycan) synthesis. This was achieved using antibiotics that target different steps of cell wall biosynthesis, including phosphomycin, cycloserine, and ampicillin, or by creating a metabolic block through starvation for diaminopimelic acid [6].
• Isolation of Mutants: After 24 independent selection attempts, they identified four mutants exhibiting a "high persistence" (Hip) phenotype. Genetic mapping revealed that two of these mutations resided in the same previously unrecognized gene, which they named hipA (high persistence) [6] [5].

Phenotypic Characterization of hipA Mutants

Moyed and Bertrand conducted meticulous phenotypic characterization of their hipA mutants, with key findings summarized in the table below [6]:

Table 2: Phenotypic Characterization of the Original hipA Mutant

Characteristic	Wild-type E. coli	hipA Mutant	Experimental Evidence
Persister Fraction	10⁻⁶ to 10⁻⁵	Up to 10⁻² (100- to 1000-fold increase)	Survival counts after prolonged antibiotic exposure
Killing Kinetics	Biphasic: rapid killing followed by slower death	Rapid initial killing phase, then viability remains constant after ~30 min	Time-kill curves with multiple murein synthesis inhibitors
MIC to Antibiotics	Unchanged in mutants	Unchanged	Standard MIC determination
Genetic Stability	N/A	Phenotype was stable and heritable	Progeny of persisters showed same high-persistence phenotype
Growth Rate	Normal	Normal in absence of antibiotic	Growth curves in rich media

The critical finding was that the hipA mutation did not confer antibiotic resistance—the MIC remained unchanged—but instead dramatically increased the fraction of persister cells able to survive antibiotic treatment [6]. This established hipA as the first genetically defined locus specifically affecting bacterial persistence.

Molecular Function and Evolution of the hipBA System

hipBA as a Toxin-Antitoxin Module

Subsequent research revealed that hipA is part of a type II toxin-antitoxin (TA) module [4] [3]. The hipBA operon consists of:

• HipA: A protein kinase that acts as the toxin.
• HipB: A DNA-binding transcriptional regulator that acts as the antitoxin.

Under normal conditions, HipB forms a complex with HipA and binds to the hipBA promoter, repressing its transcription and neutralizing HipA's toxic activity [4]. This keeps the persister formation in check.

Molecular Mechanism of hipA7

The original hipA7 allele contains two mutations, G22S and D291A, with the G22S mutation being primarily responsible for the high-persistence phenotype [4]. Structural studies have illuminated how these mutations lead to increased persistence.

The wild-type HipA protein can form dimers in the higher-order HipA-HipB-promoter complex. This dimerization, which occurs via interactions between the N-subdomain-1 regions of two HipA molecules, occludes the active sites and thereby inhibits HipA's kinase activity [4]. The G22S mutation in hipA7 weakens this HipA-HipA dimerization. With dimerization disrupted, HipA is more readily released from the complex, unleashing its kinase activity even in the presence of HipB and leading to a higher frequency of persister formation [4].

HipA's Biochemical Activity and Cellular Impact

HipA is a serine/threonine protein kinase. Its primary cellular target is glutamyl-tRNA synthetase (GltX) [4]. HipA phosphorylates GltX, inhibiting its activity. This disruption in tRNA charging leads to the accumulation of uncharged tRNA in the cell, which then activates the stringent response via the RelA enzyme [3]. RelA synthesizes the alarmone (p)ppGpp, a key global regulator that reprograms cellular metabolism, shuts down growth, and induces dormancy—the hallmark of the persister state [3].

Diagram Title: Molecular Mechanism of hipA7-Induced Persistence

Clinical Relevance of hipA Mutants

The clinical significance of hipA mutants has been firmly established. Screening of a library of 477 E. coli isolates from both commensal and urinary tract infection (UTI) patients identified 23 hipA7 mutants and one hipA(P86L) mutant [4]. In a human bladder cell infection model, a clinical UTI isolate carrying the hipA7 allele showed significantly higher persistence to ciprofloxacin treatment compared to an isogenic strain where hipA7 was deleted [4]. This provides direct evidence that hipA mutations are selected for in clinical settings and contribute to recurrent and chronic infections.

Quantitative Analysis of Persister Phenotypes

Quantifying Persister Fractions

A standardized approach for quantifying persisters uses a biphasic killing curve and mathematical modeling. In this model, cells exist in two states: normal (N) and persister (P). Upon antibiotic exposure, normal cells die at rate μ or switch to the persister state at rate α. Persister cells do not grow and can switch back to the normal state at rate β [1]. This model allows researchers to derive reliable, comparable estimates of persister fractions independent of experimental idiosyncrasies like the exact time of measurement.

Variation Across Strains and Antibiotics

Quantitative surveys reveal substantial variation in persister fractions across different bacterial species and in response to different antibiotics. One comprehensive analysis of 36 bacterial species and 54 antibiotics showed that the median percentage of persistent cells spans several orders of magnitude, from as low as 7×10⁻⁴% in Pseudomonas putida to 100% in Enterococcus faecium [7]. For species with sufficient data, the range was narrower, with the lowest persistence starting at 0.01% in Acinetobacter baumannii [7].

Notably, the fraction of persisters surviving treatment with one antibiotic is often uncorrelated with the fraction surviving another, even for drugs with nearly identical modes of action (e.g., ciprofloxacin and nalidixic acid) [1]. This supports the hypothesis that persistence is not governed by a single physiological switch but involves multiple mechanisms specific to different stressors.

Table 3: Persister Fractions Across Bacterial Species and Antibiotic Classes

Bacterial Species	Number of Antibiotics Tested	Typical Persister Fraction Range	Noteworthy Observations
Escherichia coli	32	0.001% - 10% (varies by strain and condition)	Most extensively studied; hipA7 mutant can increase fraction to ~1%
Staphylococcus aureus	18	0.01% - 5%	MRSA strains found with ~5% persister incidence
Pseudomonas aeruginosa	16	0.001% - 1%	Clinical isolates from chronic infections show 100-fold increased persistence
Acinetobacter baumannii	Data from multiple studies	Median starts at 0.01%	Known for high levels of antibiotic tolerance
Mycobacterium tuberculosis	Multiple	Varies by strain and metabolic state	Natural persisters underlie need for long-course therapy

Experimental Approaches and Research Tools

Core Methodologies for Persister Research

• Time-Kill Assays: The gold standard for detecting and quantifying persisters. A bacterial culture is exposed to a lethal concentration of a bactericidal antibiotic, and viable cell counts are determined over time, typically by plating and colony counting after drug removal or inactivation. The resulting biphasic killing curve indicates persister presence [7].
• Mutant Selection/Screening: Following Moyed's approach, researchers subject mutagenized populations to cyclic antibiotic killing to enrich for high-persister mutants, which are then isolated and characterized genetically [6].
• Fluorescence-Activated Cell Sorting (FACS) with Reporter Systems: Using promoter-GFP fusions (e.g., P_hipBA-gfp) to isolate subpopulations with varying expression levels of persistence-related genes. These subpopulations can then be tested for their persister frequency, linking gene expression heterogeneity to the phenotype [4].
• Molecular Genetics: Gene knockout/complementation studies to confirm the role of specific genes. For example, deleting the hipA7 allele from a clinical UTI isolate and demonstrating a sharp decline in antibiotic tolerance confirms its functional role [4].

The Scientist's Toolkit: Key Research Reagents

Table 4: Essential Research Reagents for Investigating hipA and Persistence

Reagent / Tool	Function/Description	Application in Persister Research
hipA7 Allele	Mutant allele of hipA (G22S, D291A) from E. coli	Reference high-persister mutant for genetic and mechanistic studies [4]
P_hipBA-GFP Reporter	Plasmid with hipBA promoter fused to GFP	Visualizing and sorting cells based on native hipBA operon expression levels in single cells [4]
Antibiotics for Selection	Ampicillin, Ciprofloxacin, Ofloxacin	Applying lethal selection pressure to kill non-persisters and enumerate surviving persister fractions [1] [4]
Expression Vectors for Ectopic Overexpression	Plasmids allowing inducible expression of hipA, hipB, or mutants	Studying the effects of toxin/antitoxin imbalance on macromolecular synthesis and persistence [8]
Anti-HipA Antibodies	Specific antibodies against HipA protein	Detecting HipA expression levels and cellular localization via Western blot or immunofluorescence
ATP Assay Kits	Luminescence-based kits for quantifying cellular ATP	Measuring metabolic activity and dormancy depth in persister subpopulations [3]

Diagram Title: Experimental Workflow for hipA Persister Research

The discovery of bacterial persisters by Bigger in 1944 and the subsequent identification of the hipA gene by Moyed in 1983 were pivotal moments that laid the foundation for understanding the non-genetic, phenotypic basis of antibiotic treatment failure. The hipA7 mutant provided the first genetic evidence that persistence is a programmable cellular state, moving the field from phenomenological observation toward mechanistic dissection.

Subsequent research has firmly established hipA as a central player in a sophisticated regulatory network. The HipA-HipB TA module integrates environmental and internal signals to control bacterial dormancy through phosphorylation events and the stringent response. The clinical isolation of hipA mutants from persistent UTIs underscores the real-world significance of this mechanism. Future research will likely focus on translating this molecular understanding into novel therapeutic strategies that either prevent persister formation or eradicate existing persister cells, thereby addressing a critical vulnerability in our antimicrobial arsenal.

In the ongoing battle against bacterial infections, the phenomenon of treatment failure extends beyond the well-characterized realm of genetic antibiotic resistance. A more insidious challenge arises from bacterial populations that, despite being genetically susceptible to antibiotics, survive therapeutic treatment through non-inherited, phenotypic mechanisms. This technical guide examines the critical distinction between phenotypic tolerance and genetic resistance, with specific focus on the role of the hipA gene in high-persistence (HIP) mutants. Understanding this distinction is paramount for researchers and drug development professionals aiming to develop more effective therapeutic strategies against chronic and relapsing infections. Bacterial persistence represents a significant clinical challenge, underlying chronic infections in tuberculosis, recurrent urinary tract infections, and biofilm-associated infections on medical devices [2]. These phenotypically tolerant cells, known as persisters, contribute to relapse after antibiotic treatment and can serve as a reservoir for the eventual emergence of genetic resistance [2] [9].

Defining the Concepts: Tolerance Versus Resistance

Core Conceptual Distinctions

The following table summarizes the fundamental differences between phenotypic tolerance (persistence) and genetic resistance:

Characteristic	Phenotypic Tolerance (Persistence)	Genetic Resistance
Definition	Non-inherited survival of a bacterial subpopulation without genetic change [9] [10]	Heritable ability to grow in the presence of antibiotics due to genetic alterations [10] [11]
Prevalence in Population	Affects a small subpopulation (e.g., ~0.001%-1%) [2] [10]	Affects the entire population
Growth State	Non-growing or slow-growing (dormant) [2]	Actively growing
Minimum Inhibitory Concentration (MIC)	Unchanged [2]	Increased
Stability	Transient; reversible after stress removal [2] [9]	Stable and inherited by daughter cells
Underlying Mechanism	Dormancy, toxin-antitoxin systems, reduced metabolic activity [2] [8]	Genetic mutations, acquisition of resistance genes (e.g., β-lactamases, efflux pumps) [10] [11]
Detection Method	Time-kill assays, persistence cell counts [2]	Standard MIC tests, genetic assays [10]

Relationship to Other Phenomena

Phenotypic tolerance manifests in several related forms. Drug indifference describes the reduced susceptibility of resting or stationary-phase cells to antibiotics like ampicillin and tetracycline [9]. Biofilm-associated tolerance arises from the complex structure and heterogeneous metabolic states of biofilm-embedded bacteria, which limit antibiotic penetration and create protective microenvironments [9]. Crucially, persistence represents an extreme form of phenotypic tolerance characterized by a biphasic killing pattern in time-kill assays: a rapid initial decline in viable cells followed by a plateau where a small subpopulation (persisters) survives [2] [12].

The Molecular Basis of Persistence: Focus on thehipAGene

1hipAand High-Persistence (HIP) Mutants

The hipA gene encodes the toxin component of the HipBA toxin-antitoxin (TA) module in Escherichia coli and represents one of the most thoroughly studied molecular mechanisms of bacterial persistence [8] [13]. The landmark discovery of the hipA7 mutant allele, which confers a high-persistence (HIP) phenotype without changing the minimum inhibitory concentration (MIC) to antibiotics, provided critical genetic evidence that persistence is a genetically selectable trait [2] [8].

Molecular Mechanism of HipA-Induced Persistence

The molecular mechanism by which HipA induces dormancy involves a sophisticated phosphorylation cascade that ultimately triggers the bacterial stringent response:

Figure 1: Molecular mechanism of HipA-induced bacterial persistence. The HipA toxin triggers a cascade from glutamate tRNA synthetase inhibition to ribosomal stalling and the stringent response, leading to cellular dormancy.

As illustrated in Figure 1, HipA induces persistence through the following molecular events:

• Activation: HipA is normally bound and inhibited by its antitoxin, HipB. Upon proteolytic release from the HipBA complex, HipA becomes active [8] [14].
• Target Phosphorylation: The activated HipA toxin specifically phosphorylates glutamyl-tRNA synthetase (GltX) at a conserved serine residue (Ser239) when GltX is bound to its cognate tRNAᴹᵃˢ. This phosphorylation inhibits GltX's aminoacylation activity, preventing it from charging tRNAᴹᵃˢ with glutamate [13].
• Ribosomal Stalling: The resulting accumulation of uncharged tRNAᴹᵃˢ leads to stalling of ribosomes at glutamate codons, creating "hungry" codons at the ribosomal A-site [13].
• Stringent Response Activation: Ribosomal stalling activates the RelA enzyme, which synthesizes the alarmone (p)ppGpp, triggering the stringent response [13].
• Cellular Dormancy: Elevated (p)ppGpp levels lead to widespread transcriptional reprogramming, ultimately inducing a state of cellular dormancy characterized by halted growth and multidrug tolerance [8] [13].

This mechanism is distinct from the hipA7 mutant allele, which confers high persistence through different means, as it does not markedly inhibit overall protein synthesis like the wild-type hipA gene yet still confers a high frequency of persister cells [8].

Experimental Methodologies for Studying Persistence

Standardized Persistence Assays

Research on bacterial persistence relies on specific methodologies to distinguish persister cells from resistant mutants:

Figure 2: Core experimental workflow for isolating and quantifying bacterial persister cells using a standard antibiotic killing assay.

Advanced Single-Cell and Molecular Techniques

Contemporary research utilizes sophisticated approaches to dissect persistence mechanisms:

• Controlled hipA Induction: Ectopic overexpression of wild-type hipA or mutant alleles (e.g., hipA7) using inducible promoters (e.g., Pᴮᴬᴰ with arabinose) to quantitatively study persistence formation and its effects on macromolecular synthesis [8] [14]. This system allows dose- and time-dependent analysis of dormancy.
• Single-Cell Tracking: Time-lapse microscopy and microfluidics to track growth and death of individual bacteria and their descendants under antibiotic exposure, revealing lineage-dependent inheritance of survival traits [15].
• Flow Cytometry and Viability Staining: Using fluorescent dyes (e.g., SYTO 9 and propidium iodide from LIVE/DEAD BacLight kits) to distinguish viable, dormant, and dead subpopulations at single-cell resolution [16].
• Raman Spectroscopy: Single-cell Raman spectroscopy (SCRS) to obtain biomolecular fingerprints of persister cells, revealing changes in cytochrome, lipid, and other macromolecules associated with the persistent state [16].

The Scientist's Toolkit: Essential Research Reagents

The following table details key reagents and methodologies employed in persistence research, particularly in studies involving the hipA gene:

Research Reagent / Method	Specific Function in Persistence Research	Example Application / Note
Inducible Expression System	Controlled overexpression of hipA toxin gene	Arabinose-inducible Pᴮᴬᴰ promoter for dose- and time-dependent persistence induction [14]
Fluoroquinolone Antibiotics	Primary antibiotic for persister selection and killing assays	Ciprofloxacin at 10-20× MIC used to kill growing cells and isolate persisters [12]
Viability Staining Kit	Differentiation of live, dormant, and dead cells at single-cell level	LIVE/DEAD BacLight bacterial viability kit (SYTO 9/PI) for flow cytometry [16]
(p)ppGpp Detection Assays	Measurement of stringent response activation	Monitor alarmone levels as readout of HipA activity via RelA activation [13]
RNA Sequencing	Transcriptomic profiling of persister cells	Identify gene expression signatures of the persistent state [2]
Microfluidic Devices	Single-cell tracking under controlled environments	Study lineage correlations in survival and heritable phenotypic resistance [15]

Therapeutic Implications and Future Directions

The distinction between phenotypic tolerance and genetic resistance has profound implications for antimicrobial drug development. Traditional antibiotics primarily target metabolically active cells, making them largely ineffective against dormant persisters [2] [9]. Novel therapeutic strategies are emerging to overcome this challenge:

Anti-Persister Compounds and Approaches:

• Membrane-Targeting Synergy: Combinations of membrane-disrupting agents show promise against persisters. For example, aminoglycoside-polymyxin combinations can rapidly sterilize cultures of E. coli persister mutants (hipA7, metG2) and wild-type persisters through ROS-independent, synergistic membrane disruption [12].
• Metabolic Stimulation: "Awakening" persisters from dormancy by providing specific nutrients or metabolic intermediates to sensitize them to conventional antibiotics [9].
• Toxin-Antitoxin System Disruption: Targeting the HipBA and other TA systems to prevent entry into or promote exit from the persistent state [2].

Research Priorities: Future research should prioritize identifying novel drug targets within persistence pathways, developing standardized persistence diagnostics for clinical microbiology, and exploring combination therapies that simultaneously target both growing and dormant bacterial subpopulations [2]. A deeper understanding of the hipA-mediated molecular cascade and its relationship to other persistence mechanisms will be crucial for developing more effective treatments for persistent bacterial infections.

The hipBA toxin-antitoxin (TA) module is a pivotal bacterial genetic element implicated in the formation of persister cells, a subpopulation of bacteria that exhibit multidrug tolerance without genetic resistance. This module was first identified in Escherichia coli through mutations (such as hipA7) that led to a high incidence of persistence [6]. Persister cells are a significant clinical concern as they underlie chronic and recurrent infections and contribute to treatment failures [2]. The hipBA module is a type II TA system, comprising a stable toxin (HipA) and a labile antitoxin (HipB) that complexes with and neutralizes the toxin [17] [18]. Under normal growth conditions, the HipB antitoxin binds and inhibits the HipA toxin. However, under stress, proteolytic degradation of HipB leads to HipA-mediated growth arrest, enabling the bacterial population to survive adverse conditions, including antibiotic exposure [19] [20]. This whitepaper delves into the structure, regulatory dynamics, and experimental methodologies pertinent to the hipBA module, framing it within the broader context of HipA function in bacterial persistence.

Molecular Architecture of the hipBA System

Genetic Organization and Protein Components

The hipBA operon is characterized by its autoregulatory genetic layout. The antitoxin gene, hipB, typically precedes the toxin gene, hipA. The HipB antitoxin protein possesses a structured N-terminal domain that facilitates DNA binding and an unstructured C-terminal stretch that is critical for its regulatory fate [20]. This unstructured region is the primary recognition site for proteolytic degradation. HipB functions as a dimer, binding to operator sites within the hipBA promoter region to repress transcription [20].

The HipA toxin is a eukaryote-like serine-threonine kinase [13] [20]. Its structure features a conserved kinase fold with critical active site residues, including aspartate residues involved in catalytic activity and magnesium binding [21]. A key feature of HipA is its ability to autophosphorylate, which is believed to be a mechanism for controlling its activity and facilitating the resuscitation of persister cells once the stress has subsided [21].

Table 1: Core Components of the hipBA Toxin-Antitoxin Module

Component	Type	Key Features	Primary Function
HipA	Toxin (Protein)	Serine-threonine kinase; conserved active site (e.g., D332, D309 in E. coli); undergoes autophosphorylation.	Phosphorylates cellular targets (e.g., GltX) to inhibit growth and induce persistence.
HipB	Antitoxin (Protein)	Contains structured DNA-binding domain and unstructured C-terminus; forms dimers.	Neutralizes HipA toxin; represses hipBA operon transcription; degraded by Lon protease.
hipBA Operon	Genetic Locus	Autoregulated promoter with multiple HipB binding sites.	Encodes the HipB antitoxin and HipA toxin.

Structural Variations: The Unusual Case of Haemophilus influenzae

While the classic hipBA system is a two-component system, notable variations exist. In Haemophilus influenzae, the system is split into an unusual three-component regulatory mechanism [22]. The hipA gene is divided into two separate genes: hipAN (encoding the N-terminal part of HipA) and hipAC (encoding the C-terminal, toxic part). In this configuration, HipAN functions as the primary antitoxin to inactivate HipAC, while the canonical HipB protein appears to augment HipAN's antitoxin activity rather than directly neutralizing the toxin itself [22]. This divergence suggests evolutionary flexibility in the organization and regulation of this critical TA system.

Regulatory Mechanisms and Signaling Pathways

The activity of the hipBA module is tightly controlled through a multi-layered regulatory network that integrates transcriptional, post-translational, and proteolytic mechanisms.

Transcriptional Autorepression and Proteolytic Regulation

The HipB antitoxin, alone or in complex with HipA, binds to the promoter of the hipBA operon, repressing its own transcription. A critical regulatory step is the controlled degradation of the HipB antitoxin, which is primarily carried out by the ATP-dependent Lon protease [19] [20]. The unstructured C-terminal end of HipB, particularly a conserved tryptophan residue at the terminus, serves as a recognition signal for Lon-mediated proteolysis [19] [20]. Under stress conditions, accelerated degradation of HipB tilts the balance, freeing HipA to exert its toxic effects on the cell.

Diagram 1: hipBA Regulatory Pathway. The pathway illustrates the activation of HipA toxin under stress via Lon-mediated HipB degradation, leading to persistence, and subsequent inactivation via autophosphorylation for resuscitation.

HipA's Molecular Targets and the Link to Persistence

The mechanism by which free HipA induces dormancy has been elucidated. HipA does not target EF-Tu as initially proposed. Instead, it phosphorylates glutamyl-tRNA synthetase (GltX) on a conserved serine residue (Ser239 in E. coli) [13]. This phosphorylation inhibits GltX's aminoacylation activity, preventing the charging of tRNA^Glu^ with glutamate. This results in the accumulation of uncharged tRNA^Glu^ in the cell, which is sensed by the ribosome-associated RelA protein. RelA then synthesizes the alarmone (p)ppGpp, triggering the stringent response [13] [2]. This global stress response reprograms cellular metabolism, downregulates macromolecular synthesis, and promotes a dormant, persistent state.

This mechanism is conserved in other bacteria, though with variations. In Caulobacter crescentus, which possesses three HipBA systems, HipA1 and HipA2 phosphorylate GltX and tryptophanyl-tRNA synthetase (TrpS), respectively, indicating that different HipA toxins within a single organism can target distinct aminoacyl-tRNA synthetases to promote persistence [21].

Table 2: Experimentally Determined HipA Targets and Consequences

HipA Source	Identified Target	Target Function	Consequence of HipA Action	Experimental Evidence
E. coli	Glutamyl-tRNA synthetase (GltX)	Charges tRNA^Glu^ with glutamate	Inhibition of aminoacylation; uncharged tRNA accumulation; (p)ppGpp synthesis & stringent response [13].	Genetic suppression; in vitro phosphorylation assays.
C. crescentus (HipA1)	Glutamyl-tRNA synthetase (GltX)	Charges tRNA^Glu^ with glutamate	Induction of persistence in stationary phase [21].	Phos-tag assays; persistence phenotyping.
C. crescentus (HipA2)	Tryptophanyl-tRNA synthetase (TrpS)	Charges tRNA^Trp^ with tryptophan	Induction of persistence in stationary phase [21].	Phos-tag assays; persistence phenotyping.

Experimental Analysis of hipBA

Key Methodologies and Workflows

Research into the hipBA system relies on a combination of genetic, biochemical, and structural techniques.

Genetic Analysis: A common approach involves the ectopic expression of HipA from an inducible plasmid to observe growth inhibition and measure the resulting persister frequency [21]. The function of the antitoxin is tested by co-expressing HipB and assessing the rescue of growth [22] [21]. Furthermore, the construction of kinase-dead HipA mutants (e.g., by substituting a critical aspartate with glutamine, D→Q) is essential to confirm that toxicity is dependent on phosphorylation activity [21].

Protein-Protein Interaction Studies: The formation of complexes between HipA, HipB, and their targets is validated using techniques like co-purification and electrophoretic mobility shift assays (EMSAs). For instance, the H. influenzae three-component system was confirmed by co-expressing HipB, HipAN, and HipAC and analyzing their interactions [22].

Phosphorylation Detection: The kinase activity of HipA is directly demonstrated using Phos-tag SDS-PAGE, which causes a mobility shift for phosphorylated proteins. This method can be used to monitor HipA autophosphorylation and the phosphorylation of its targets like GltX [21].

Diagram 2: Experimental Workflow. A generalized workflow for the biochemical and functional characterization of hipBA components.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for hipBA Studies

Reagent / Tool	Function / Application	Example from Literature
Lon Protease-Deficient Strain	To demonstrate the role of Lon in HipB antitoxin turnover and stabilize HipB for study.	E. coli KLE902 (Δlon) used to show HipB stabilization [20].
Kinase-Dead HipA Mutant	Serves as a negative control to confirm that phenotypic effects are due to HipA kinase activity.	Aspartate-to-glutamine (D-Q) mutants in C. crescentus HipA toxins [21].
Inducible Expression Plasmids	For controlled, high-level expression of hipA or hipB to study toxicity and rescue.	pET vectors (e.g., pET28a) used for IPTG-induced expression in E. coli [22] [21].
Phos-tag SDS-PAGE	A specialized gel system to detect phosphorylated proteins based on reduced electrophoretic mobility.	Used to confirm autophosphorylation of C. crescentus HipA toxins [21].
Polyclonal Anti-HipB Antibody	To detect and quantify HipB protein levels in degradation assays via Western blotting.	Used to monitor HipB half-life in different protease backgrounds [20].

Detailed Experimental Protocol: HipB Degradation Assay

The following protocol is adapted from studies investigating the proteolytic regulation of the HipB antitoxin in E. coli [19] [20].

Objective: To determine the in vivo half-life of the HipB antitoxin and identify the protease responsible for its degradation.

Materials:

• Bacterial Strains: Wild-type E. coli and isogenic protease-deficient mutants (e.g., Δlon, ΔclpP, ΔhslVU).
• Plasmid: pBRhipB or similar, carrying hipB under an inducible promoter (e.g., PIPTG).
• Antibodies: Primary antibody specific for HipB (e.g., polyclonal anti-HipB).
• Growth Media: LB broth with appropriate antibiotics.
• Inducer: Isopropyl β-D-1-thiogalactopyranoside (IPTG).
• Protein Synthesis Inhibitor: Chloramphenicol.
• Equipment: Western blot apparatus, incubator.

Procedure:

• Transformation: Transform the pBRhipB plasmid into wild-type and protease-deficient E. coli strains.
• Culture and Induction: Grow transformed cultures to mid-exponential phase (OD600 ≈ 0.5) and induce HipB expression with a suitable concentration of IPTG (e.g., 1 mM) for 60 minutes.
• Block Protein Synthesis: Add chloramphenicol (200 µg/mL) to the cultures to halt further protein synthesis. This marks time zero (t = 0).
• Sample Collection: Collect 1 mL aliquots of the culture at regular time intervals post-chloramphenicol addition (e.g., 0, 10, 20, 40, 60, 90, 120 minutes).
• Sample Preparation: Immediately pellet the cells by centrifugation, lyse them, and prepare samples for SDS-PAGE.
• Western Blotting: Separate proteins by SDS-PAGE, transfer to a membrane, and probe with the anti-HipB antibody to detect HipB levels.
• Data Analysis: Quantify the band intensity of HipB at each time point using densitometry. Plot the relative intensity (log scale) against time. The half-life (t~1/2~) of HipB is the time at which the signal is 50% of the t=0 value.

Expected Outcome: HipB will be rapidly degraded in wild-type cells (t~1/2~ ≈ 17 min) but will be significantly stabilized in a Lon protease-deficient strain (t~1/2~ > 200 min), identifying Lon as the primary protease for HipB turnover [20].

The hipBA toxin-antitoxin module represents a sophisticated bacterial adaptation for survival in fluctuating and stressful environments. Its core mechanism—involving transcriptional autorepression, Lon-mediated antitoxin degradation, and toxin-induced disruption of translation leading to a stringent response—is elegantly complex. While the fundamental principles are shared, discoveries of divergent systems, such as the three-component module in H. influenzae and the multiple, non-redundant HipA toxins with distinct targets in C. crescentus, underscore the evolutionary versatility of this system [22] [21]. A deep understanding of the structure and regulatory dynamics of hipBA is paramount for developing novel therapeutic strategies that target bacterial persistence, a major hurdle in treating chronic infections. Future research will continue to unravel the intricacies of this system across different pathogens, potentially revealing new avenues for anti-persister drug development.

Bacterial persistence represents a significant challenge in treating recalcitrant infections, contributing to antibiotic treatment failure. This whitepaper examines the molecular mechanism by which the HipA toxin induces bacterial persistence through targeted phosphorylation of glutamyl-tRNA synthetase (GltX) and subsequent activation of the stringent response. Within the broader context of hipA gene function in high-persistence bacterial mutants, we delineate the precise signaling pathway from HipA-mediated phosphorylation through (p)ppGpp synthesis to multidrug tolerance. The experimental data and methodologies presented provide researchers and drug development professionals with critical insights for designing novel therapeutic strategies targeting bacterial persistence.

Bacterial persistence describes a phenomenon where a small subpopulation of genetically identical bacteria enters a transient, dormant state that exhibits multidrug tolerance without genetic resistance. First observed by Joseph W. Bigger in 1944, persisters survive lethal antibiotic treatments that effectively kill the majority of the population, subsequently regrowing once antibiotic pressure is removed [23]. This phenotypic heterogeneity serves as a bet-hedging strategy, ensuring population survival against catastrophic events like antibiotic exposure. The hipA (high persistence) gene was among the first genetic elements linked to this phenotype, with the hipA7 mutant allele demonstrating a 10,000-fold increase in persistence frequency compared to wild-type Escherichia coli [23].

HipA functions as a eukaryote-like serine-threonine kinase that inhibits cell growth and induces persistence when its cellular concentration exceeds that of its cognate antitoxin, HipB [24] [25]. The hipBA locus constitutes a type II toxin-antitoxin (TA) module, with HipB acting as both an antitoxin that neutralizes HipA toxicity and a transcriptional repressor of the hipBA operon [25] [26]. Early research suggested HipA inhibited cell growth through phosphorylation of the essential translation factor EF-Tu, but recent evidence has revealed a more sophisticated mechanism involving targeted inhibition of protein synthesis via glutamyl-tRNA synthetase phosphorylation, ultimately triggering the stringent response [24] [27] [13].

The Core Mechanism: From HipA Phosphorylation to Stringent Response

HipA Phosphorylation of GltX

The pivotal discovery that glutamyl-tRNA synthetase (GltX) serves as the primary target of HipA kinase activity fundamentally advanced understanding of persistence mechanisms. Genetic screens revealed that overexpression of GltX suppresses HipA toxicity and prevents persister formation, directly implicating this aminoacyl-tRNA synthetase in the persistence pathway [24] [25]. Subsequent biochemical analyses demonstrated that HipA specifically phosphorylates GltX at conserved Serine 239 (Ser239), a residue located near the enzyme's active center within its ATP-binding site [24] [27] [13].

This phosphorylation event exhibits a unique substrate recognition requirement: HipA only phosphorylates tRNA-bound GltX, indicating the kinase specifically targets the enzymatically active form of the synthetase [24] [13]. The Ser239 phosphorylation site lies within the KKLSKR motif of GltX's ATP-binding domain, and phosphorylation at this site is predicted to alter the conformation of the ATP-binding pocket, thereby inhibiting the enzyme's catalytic activity [25]. This represents a unique example of an aminoacyl-tRNA synthetase being regulated by phosphorylation through a toxin-antitoxin system [24].

Downstream Signaling and Stringent Response Activation

Phosphorylation of GltX at Ser239 inhibits its aminoacylation function, leading to accumulation of uncharged tRNA^Glu^ in the cell [25]. This accumulation of uncharged tRNA creates "hungry" codons at the ribosomal A-site, which in turn activates the RelA enzyme [24] [28]. Activated RelA synthesizes the alarmones (p)ppGpp (guanosine tetraphosphate and guanosine pentaphosphate), which serve as central signaling molecules in the bacterial stringent response [24] [28] [25].

The elevated (p)ppGpp levels trigger comprehensive transcriptional and physiological reprogramming, resulting in growth arrest and metabolic dormancy that characterizes persistent cells [28] [25]. This connection explains the long-observed relationship between persistence and the stringent response, providing a mechanistic pathway from HipA kinase activity through tRNA charging status to global physiological changes that confer multidrug tolerance [27] [25].

Diagram Title: HipA-GltX Stringent Response Pathway

Experimental Evidence and Key Data

Genetic Suppression Studies

The connection between HipA and GltX was initially established through genetic suppression screens. Researchers transformed MG1655A7 cells (carrying the hipA7 allele) with a genomic E. coli library and selected for clones that overcame the cold-sensitive phenotype associated with hipA7. This approach identified two classes of suppressing plasmids: those containing the hipAB operon and those carrying the gltX gene. Subsequent experiments confirmed that GltX overexpression alone could suppress both HipA-mediated growth arrest and persistence [25].

Phosphorylation and Biochemical Validation

Direct evidence of HipA-mediated GltX phosphorylation came from multiple experimental approaches. Radioactive labeling experiments using ^32^P demonstrated increased phosphorylation of a 56 kDa protein (corresponding to GltX's molecular weight) upon HipA overexpression [25]. Mass spectrometry analysis precisely identified the phosphorylation site as Ser239 within the KKLSKR motif of GltX's ATP-binding domain [25]. Additional biochemical assays confirmed that phosphorylation at Ser239 inhibits GltX's aminoacylation activity, leading to accumulation of uncharged tRNA^Glu^ [24] [25].

Stringent Response Connection

The critical link to stringent response activation was established by monitoring (p)ppGpp levels following HipA induction. Researchers demonstrated clear (p)ppGpp synthesis within 30 minutes of HipA overexpression, which was completely abolished when GltX was co-overexpressed [25]. This provided direct evidence that HipA activates the stringent response through GltX inhibition, rather than through previously proposed mechanisms involving EF-Tu phosphorylation [24] [25].

Table 1: Quantitative Effects of Genetic Manipulations on Persistence Frequency

Strain/Modification	Persistence Frequency (Relative to Wild-type)	Key Experimental Condition	Citation
hipA7 mutant	10,000-fold increase	Ampicillin exposure	[23]
metG::Tn (C-terminal disruption)	10,000-fold increase	Ampicillin exposure	[23]
GltX overexpression + HipA	Complete suppression of HipA-induced persistence	Norfloxacin treatment	[25]
ΔrelA strain	Reduced resistance development	Amoxicillin evolution experiment	[28]
Transposon mutant library	~10-fold increase	Initial ampicillin enrichment	[23]

Table 2: Key Molecular Interactions in HipA-GltX Stringent Response Pathway

Molecular Component	Function/Interaction	Effect of Perturbation	Experimental Validation
HipA (Ser/Thr kinase)	Phosphorylates GltX at Ser239	Overexpression induces persistence; knockout reduces persistence in some conditions	Genetic screens; phosphorylation assays	[24] [25]
GltX (Glu-tRNA synthetase)	Charges tRNA^Glu^ with glutamate	Ser239Ala mutation prevents phosphorylation; overexpression suppresses HipA toxicity	Mass spectrometry; aminoacylation assays	[24] [27] [25]
RelA	(p)ppGpp synthetase	Knockout reduces persistence and resistance development	(p)ppGpp measurement; resistance evolution experiments	[28] [25]
Uncharged tRNA^Glu^	Activates RelA	Accumulation triggers stringent response	tRNA charging assays	[24] [25]
(p)ppGpp	Stringent response alarmone	Elevated levels induce growth arrest and persistence	HPLC measurement; genetic manipulation	[28] [25]

Detailed Experimental Protocols

Genetic Screening for HipA Suppressors

Objective: Identify genetic elements that suppress HipA-mediated growth arrest and persistence.

Methodology:

• Transform E. coli MG1655A7 (hipA7 mutant) with a genomic library cloned into an expression vector.
• Plate transformed cells at the restrictive temperature (20°C) to select for clones that overcome HipA7-mediated cold sensitivity.
• Isolate resistant colonies and purify plasmids for sequencing.
• Verify suppressor activity by retransforming purified plasmids into fresh MG1655A7 cells.
• Test confirmed suppressors for their ability to prevent persistence using antibiotic kill curves [25].

Key Reagents:

• E. coli genomic library in expression vector (e.g., pBR322 derivatives)
• MG1655A7 strain (or other hipA7-containing strains)
• Selective media with appropriate antibiotics
• Temperature-controlled incubators (20°C and 37°C)

Detection of GltX Phosphorylation

Objective: Confirm HipA-mediated phosphorylation of GltX at Ser239.

Methodology: Radioactive Labeling Approach:

• Culture cells expressing HipA and His-tagged GltX in presence of ^32^P-orthophosphate.
• Induce HipA expression with anhydrotetracycline (aTc).
• Harvest cells and purify His-GltX under denaturing conditions.
• Separate proteins by SDS-PAGE and visualize phosphorylation by autoradiography.
• Confirm equal protein loading by Western blotting [25].

Mass Spectrometry Approach:

• Induce HipA overexpression in cells expressing GltX.
• Immunoprecipitate GltX from cell lysates.
• Digest purified GltX with trypsin.
• Analyze phosphopeptides by LC-MS/MS.
• Identify phosphorylation sites by database searching and manual verification of MS/MS spectra [25].

Key Reagents:

• ^32^P-orthophosphate or anti-phosphoserine antibodies
• His-tagged GltX expression plasmid
• Inducible HipA expression system (e.g., pTet-hipA-mcherry)
• Ni-NTA resin for His-tag purification
• Mass spectrometry facilities

Measuring Persistence Frequencies

Objective: Quantify persistence frequencies under various genetic and chemical conditions.

Methodology: Agar-Based Method:

• Grow cultures to stationary phase in appropriate media.
• Dilute and plate on LB agar containing lethal antibiotic concentrations (e.g., ampicillin).
• Incubate plates at 37°C for 24 hours.
• Spray plates with penicillinase to inactivate ampicillin.
• Incubate plates for additional 24-48 hours to allow survivor growth.
• Count colonies and calculate persistence frequency relative to initial viable count [23].

Liquid Culture Kill Curves:

• Grow test strains to mid-exponential or stationary phase.
• Add bactericidal antibiotic (e.g., norfloxacin, ampicillin) at appropriate concentrations.
• Take samples at timed intervals (0, 1, 2, 4, 6, 24 hours).
• Dilute and plate samples on antibiotic-free media.
• Count colonies after overnight incubation.
• Plot survival fraction versus time [25].

Key Reagents:

• Bactericidal antibiotics (ampicillin, norfloxacin, etc.)
• Antibiotic-inactivating enzymes (penicillinase for β-lactams)
• Rich and minimal media for various growth conditions

(p)ppGpp Quantification

Objective: Measure cellular (p)ppGpp levels following HipA induction.

Methodology:

• Grow cells expressing HipA under inducible control to mid-exponential phase.
• Induce HipA expression with aTc.
• At timed intervals (0, 30, 60, 120 minutes), extract nucleotides using formic acid.
• Separate nucleotides by thin-layer chromatography (TLC) or HPLC.
• Visualize and quantify (p)ppGpp spots using phosphoimager or appropriate detectors.
• Normalize (p)ppGpp levels to GTP or ATP pools [25].

Key Reagents:

• Inducible HipA expression system
• ^32^P-orthophosphate for labeling or cold nucleotides with UV detection
• Polyethyleneimine-cellulose TLC plates
• Formic acid for nucleotide extraction
• Appropriate standards (GTP, ATP, ppGpp, pppGpp)

Diagram Title: Experimental Approaches for HipA Research

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for Investigating HipA-GltX Persistence Mechanisms

Reagent/Tool	Function/Application	Example Use Case	Critical Features
hipA7 mutant strains	High-persistence model system	Studying persistence frequency and suppressor genes	Cold-sensitive phenotype for selection	[23] [25]
Inducible HipA expression systems	Controlled toxin expression	Studying direct effects of HipA without genetic compensation	Tight regulation (e.g., tet promoter)	[25]
GltX expression plasmids	Suppressor validation	Testing reversal of HipA-mediated persistence	Compatible promoter systems with HipA expression	[24] [25]
His-tagged GltX constructs	Protein purification and phosphorylation studies	In vitro kinase assays and phosphorylation site mapping	Affinity purification tags; native activity	[25]
RelA knockout strains	Stringent response pathway dissection	Determining RelA-dependence of HipA effects	Clean deletion mutants; complemented strains	[28]
Radioactive ^32^P-orthophosphate	Phosphorylation detection	Confirming HipA-mediated phosphorylation of targets	High-specific activity; appropriate safety protocols	[25]
Antibiotic-inactivating enzymes	Persistence assays on solid media	Selective killing and regrowth for persistence quantification	Specific activity against test antibiotics	[23]

Research Implications and Future Directions

The elucidation of the HipA-GltX-stringent response pathway provides a mechanistic framework for understanding bacterial persistence that extends beyond the specific hipAB system. The discovery that inhibition of a specific aminoacyl-tRNA synthetase can trigger persistence suggests that other metabolic bottlenecks might similarly induce dormancy programs. This paradigm offers novel targets for anti-persister therapies, potentially including small molecule inhibitors of HipA kinase activity or compounds that prevent GltX phosphorylation [24] [13].

From a drug development perspective, the HipA-GltX interaction interface represents a promising target for anti-persistence compounds. Small molecules that stabilize the GltX-HipA interaction or prevent HipA access to Ser239 could potentially block persistence induction without affecting bacterial growth, thereby complementating conventional antibiotics [24]. Additionally, the central role of (p)ppGpp in this pathway suggests that inhibitors of RelA or SpoT synthetases could broadly target multiple persistence mechanisms [28] [29].

Future research should focus on structural characterization of the HipA-GltX complex to identify precise interaction interfaces, development of high-throughput screens for inhibitors of this interaction, and exploration of potential connections between metabolic regulation and persistence induction in clinical isolates. The integration of this molecular understanding with systems-level approaches will be essential for developing effective strategies against persistent infections.

HipA Homologs and Phylogenetic Diversity Across Bacterial Species

Bacterial persistence represents a significant challenge in treating infectious diseases. Persisters are a sub-population of genetically drug-susceptible, quiescent (non-growing or slow-growing) bacteria that survive exposure to antibiotics and other stresses, only to resume growth once the stress is removed, potentially leading to relapsing infections [2]. This phenotypic tolerance is distinct from genetic antibiotic resistance and is a major contributor to chronic and biofilm-associated infections.

The hipA gene (high persister gene A) was the first bacterial gene linked to this persistence phenotype. Discovered in Escherichia coli K-12, gain-of-function mutations in hipA (such as hipA7) result in a dramatic 100 to 1000-fold increase in the frequency of persister cells following antibiotic treatment [30] [6]. HipA functions as a bacterial serine/threonine kinase toxin. Together with its antitoxin, HipB, it forms a canonical type II toxin-antitoxin (TA) module [30]. These modules are widespread in bacterial and archaeal chromosomes and are debated to function in genetic stability, antiphage defense, and antibiotic tolerance [30]. The HipA toxin inhibits cell growth and induces persistence, while the HipB antitoxin neutralizes the toxin and regulates operon transcription [30].

Understanding the phylogenetic diversity of HipA homologs is crucial for elucidating the evolution of bacterial persistence mechanisms and for developing novel therapeutic strategies aimed at eradicating persistent infections. This guide provides a comprehensive technical overview of HipA homologs, their molecular mechanisms, and the experimental approaches used to study them.

Molecular Mechanisms of HipA-Mediated Persistence

Core Signaling Pathway: From HipA to Growth Arrest

HipA mediates persistence through a specific molecular pathway that culminates in bacterial growth arrest. The core mechanism involves the phosphorylation of a key aminoacyl-tRNA synthetase, leading to the activation of the stringent response. The following diagram illustrates this signaling cascade.

Key Mechanistic Insights

• Primary Cellular Target: A key breakthrough was the identification of glutamyl-tRNA synthetase (GltX) as a primary target of HipA [25]. HipA phosphorylates GltX at a conserved serine residue (Ser239) located within its ATP-binding site (KKLSKR motif). This phosphorylation inactivates GltX, preventing it from charging tRNA^Glu with glutamate [25].
• Activation of the Stringent Response: The accumulation of uncharged tRNA^Glu is sensed by the RelA enzyme on the ribosome. Activated RelA then synthesizes the alarmone (p)ppGpp, which triggers the stringent response [30] [25]. This fundamental stress response leads to a dramatic reprogramming of cellular metabolism, including a shutdown of ribosomal RNA synthesis and growth arrest, thereby rendering the cell tolerant to antibiotics [25].
• Functional Diversification of Homologs: While the canonical HipA of E. coli K-12 targets GltX, subsequent research has revealed functional diversification among HipA homologs. For instance, HipT from pathogenic E. coli O127 phosphorylates and inactivates a different aminoacyl-tRNA synthetase, tryptophanyl-tRNA synthetase (TrpS) [30]. Furthermore, in Caulobacter crescentus, the HipA homolog HipA2 has been reported to target TrpS, and potentially LysS and GltX, indicating that some homologs may have multiple targets or different specificities [30].

Phylogenetic Analysis of HipA Homologs

Evolutionary Relationships and Novel Families

Initial knowledge of Hip kinases was largely based on a few model systems. However, a comprehensive phylogenetic analysis has revealed a much wider and diverse family of HipA-homologous kinases across bacteria and archaea [30]. This analysis, initiated with seed sequences from E. coli K-12 HipA and YjjJ, as well as E. coli O127 HipT, uncovered seven novel Hip kinase families, significantly expanding the known diversity beyond the classic HipA, HipT, and YjjJ [30].

The phylogenetic tree of HipA-homologous kinases is bifurcated, suggesting an early evolutionary divergence into two major clades. This analysis has also illuminated the diverse genetic contexts in which these kinases are found, leading to a classification based on operon structure [30].

Classification Based on Operon Structure and Domain Architecture

The phylogenetic diversity is reflected in the varying genetic architectures of the operons encoding Hip kinases and their associated antitoxins. The table below summarizes the characteristic features of the major types of Hip kinase operons.

Table: Diversity of Hip Kinase Operon Structures and Domain Architectures

Operon Type	Representative	Gene Organization	Key Kinase Domains/Features	Putative Antitoxin Domains/Features
Bicistronic	E. coli K-12 HipBA	hipB - hipA	Core kinase domain	HipB with HTH DNA-binding domain
Tricistronic	E. coli O127 HipBST	hipB - hipS - hipT	C-terminal kinase domain (similar to HipT)	HipS (neutralizes HipT); HipB (HTH, augments HipS)
Monocistronic	E. coli K-12 YjjJ	yjjJ	Core kinase domain; N-terminal HTH domain	No dedicated antitoxin; auto-regulation via HTH?
Novel Monocistronic	Newly identified families	kinase	N-terminal core kinase, HipS-like domain, HIRAN domain	No dedicated antitoxin [30]
Novel Bicistronic	Newly identified families	antitoxin - kinase	Various kinase domains	Putative antitoxins with HIRAN, HipS, γδ-resolvase, or Stl repressor-like domains [30]

The discovery of HIRAN domains in several novel Hip kinases and their putative antitoxins is particularly noteworthy. The HIRAN domain is a putative DNA-binding module that recognizes single- or double-stranded DNA ends, suggesting that some of these novel TA systems may be involved in DNA repair processes or in the genetic stabilization of chromosomal segments [30].

Experimental Protocols for Studying HipA Homologs

Key Methodologies for Molecular Mechanism Elucidation

Research into HipA and its homologs relies on a combination of genetic, biochemical, and molecular biology techniques. The following workflow outlines a standard pipeline for identifying and characterizing a novel HipA homolog.

Detailed Protocol Description:

• Bioinformatic Identification: HipA homologs can be identified using sequence homology search tools like BLASTP and HMMER against public databases, using known HipA (e.g., from E. coli K-12) or HipT sequences as queries [30].
• Genetic Complementation and Toxicity Assay: The putative toxin gene is cloned into an inducible expression vector (e.g., pTet, pBad) and transformed into a susceptible host like E. coli. Induction of expression with an agent like anhydrotetracycline (aTc) or IPTG is used to assess growth inhibition via spot assays or growth curve measurements [30] [25]. Suppression of toxicity, as seen in the reversal of the hipA7 cold-sensitive phenotype by GltX overexpression, can identify cellular targets or suppressors [25].
• Biochemical Validation of Kinase Activity:
  • In Vitro Kinase Assay: The purified putative kinase is incubated with ATP (including [γ-³²P]ATP for radiolabeling) and a potential substrate (e.g., purified GltX or TrpS). Phosphorylation is detected by autoradiography after SDS-PAGE or by phospho-staining [25].
  • Mass Spectrometry (MS): To identify the specific phosphorylation site, the phosphorylated substrate is digested with trypsin and analyzed by MS/MS. This method confirmed the phosphorylation of GltX at Ser239 by HipA [25].
• Target Identification:
  • Genomic Library Screening: A genomic expression library from the host organism is introduced into a strain expressing the toxic kinase. Plasmids that suppress toxicity are sequenced to identify the suppressor gene, which may be the direct target or a pathway component [25].
  • Measurement of Uncharged tRNA: The accumulation of uncharged tRNA following kinase induction can be measured to confirm the functional inhibition of a tRNA synthetase [25].
• Phenotypic Confirmation (Persistence Assays): The contribution of the homolog to the persistent phenotype is tested by comparing persister levels between wild-type and knockout strains after antibiotic exposure.
  • Protocol: Cultures are grown to mid-log or stationary phase and treated with a high concentration of a bactericidal antibiotic (e.g., fluoroquinolones like Norfloxacin, or β-lactams like ampicillin). Aliquots are taken at intervals, washed to remove the antibiotic, serially diluted, and plated on solid media to count Colony Forming Units (CFUs) after incubation. The subpopulation that survives prolonged exposure is quantified as persisters [2] [25].

The Scientist's Toolkit: Essential Research Reagents

Table: Key Reagents and Solutions for HipA Homolog Research

Reagent / Material	Function / Application	Specific Examples / Notes
Bacterial Strains	Host for genetic experiments; source of genomic DNA	E. coli K-12 MG1655; MG1655A7 (hipA7 mutant); Clinical isolates (e.g., UPEC) [30] [6] [25]
Expression Vectors	Controlled expression of toxin/antitoxin genes	pTet vectors (aTc-inducible); pBad vectors (arabinose-inducible); pTac vectors (IPTG-inducible) [25]
Genomic Library	Screening for toxin suppressors or targets	Plasmid-based library from the organism of interest [25]
Antibiotics	Selective pressure; persister assays	Ampicillin, Norfloxacin, Phosphomycin, Cycloserine [6] [25]
Radiolabeled ATP	Detecting phosphorylation in kinase assays	[γ-³²P]ATP [25]
Chromatography Systems	Protein purification for biochemical studies	Affinity chromatography (e.g., His-tag purification of His-GltX) [25]
Mass Spectrometer	Identifying post-translational modifications	LC-MS/MS for phosphorylation site mapping [25]

Implications for Therapeutic Development

The study of HipA homologs and bacterial persistence has direct translational potential. As the understanding of persistence mechanisms deepens, novel strategies are being explored to develop anti-persister therapies.

• Targeting Persister Mechanisms: Directly targeting the molecular pathways that induce dormancy, such as the (p)ppGpp-mediated stringent response or specific TA modules, represents a promising avenue to sensitize persisters to conventional antibiotics [2].
• Exploiting Metabolic Dependencies: The methylerythritol phosphate (MEP) pathway is an essential metabolic pathway in many pathogens (e.g., Pseudomonas aeruginosa) but absent in humans, making it an attractive drug target. Fragment-based screening and structure-guided design have yielded inhibitors targeting the IspD enzyme in this pathway, showing promise as novel antibiotics [31].
• Leveraging Natural Products: Innovative approaches like the ACTIMOT (Advanced Cas9-mediaTed In vivo MObilization and mulTiplication of BGCs) technology can activate silent biosynthetic gene clusters in bacteria, leading to the discovery of new natural products with anti-infective properties [32]. This has already enabled the discovery of 39 new natural products from four previously unknown classes [32]. Engineered derivatives of natural products, such as the darobactin derivative D22, have shown excellent in vivo efficacy against critical Gram-negative pathogens like E. coli and Acinetobacter baumannii in animal models, highlighting their potential as resistance-breaking antibiotics [33] [34].

The phylogenetic landscape of HipA is far more complex and diverse than previously appreciated. The discovery of seven novel families, along with a wide array of associated operon structures and putative antitoxin domains, underscores the evolutionary success and functional adaptability of this kinase family in mediating bacterial survival. Continued research into the molecular mechanisms and physiological roles of these diverse HipA homologs, facilitated by the experimental frameworks outlined in this guide, is essential to fully understand bacterial persistence. This knowledge is a critical foundation for developing the next generation of therapeutic interventions aimed at eradicating persistent and relapsing bacterial infections.

Techniques and Models: Investigating hipA-Mediated Persistence in the Lab and Clinic

Bacterial persistence describes the phenomenon where a subpopulation of genetically drug-susceptible cells survives exposure to high concentrations of bactericidal antibiotics. These persister cells are not resistant; they are typically non-growing or slow-growing (dormant) cells that tolerate the antibiotic and can regrow once the treatment is removed, often leading to relapsing infections [2]. This phenotypic tolerance is a major contributor to chronic and biofilm-associated infections, presenting a significant challenge in clinical practice [2] [5].

The hipA gene (high persister protein A) was the first genetic element identified to be involved in the persistence phenomenon. The original hipA7 mutant allele (containing two amino acid changes) was isolated in 1983 and caused a dramatic 100 to 1000-fold increase in persister frequency in Escherichia coli without changing the minimum inhibitory concentration (MIC) [5]. HipA is a serine/threonine kinase that functions as the toxin in the hipBA type II toxin-antitoxin (TA) system. It inhibits cell growth by phosphorylating and inactivating glutamyl-tRNA synthetase (GltX), an essential enzyme for protein synthesis. This inhibition leads to the accumulation of uncharged tRNA^Glu, which in turn activates the stringent response and the production of the alarmone (p)ppGpp, a key regulator of bacterial stress survival and persistence [35].

The Time-Kill Curve Assay: Core Principles and Workflow

The time-kill curve assay (or time-kill assay) is the sector's standard and most widely used method for quantifying antibiotic persistence in vitro [7]. It is a quantitative method that measures the number of viable bacteria remaining in a population over time when exposed to a lethal concentration of an antibiotic.

The core principle involves exposing a bacterial culture to a bactericidal antibiotic and enumerating viable cells (CFUs) at regular intervals. A biphasic killing curve, characterized by an initial rapid decline in viable cells followed by a plateau, is the classic signature of persistence. The initial phase represents the killing of the majority, antibiotic-sensitive population, while the plateau indicates the survival of the non-growing persister subpopulation [7] [2].

The workflow can be broken down into key stages, as illustrated below.

Detailed Experimental Protocol for hipA Studies

This protocol is adapted for investigating high-persistence mutants, such as those involving the hipA gene.

Day 1: Culture Preparation

• Strain Selection: Include the wild-type strain (e.g., E. coli K-12 MG1655) and the isogenic hipA7 mutant. A ΔhipA strain can serve as a negative control.
• Inoculation: Pick single colonies from a fresh agar plate and inoculate them into 3-5 mL of LB broth. For hipA studies, the medium may be supplemented with appropriate antibiotics to maintain plasmids if needed.
• Incubation: Grow the cultures overnight (16-18 hours) at 37°C with shaking (200-250 rpm) to reach stationary phase.

Day 2: Antibiotic Exposure and Sampling

• Sub-culture: Dilute the overnight culture 1:100 or 1:1000 into fresh, pre-warmed LB broth to ensure actively dividing cells. Grow until the culture reaches the mid-exponential phase (OD₆₀₀ ~0.3-0.5).
• Antibiotic Stock: Prepare a concentrated stock solution of the bactericidal antibiotic (e.g., ampicillin, ofloxacin). The working concentration should be a high multiple of the MIC (e.g., 10x, 50x, or 100x MIC) to ensure rapid killing of regular cells.
• Time Zero (t=0) Sample: Just before adding the antibiotic, collect a 1 mL aliquot from the culture. Perform serial dilutions in phosphate-buffered saline (PBS) or saline, and plate 100 µL of appropriate dilutions (e.g., 10^-1 to 10^-5) onto drug-free LB agar plates in duplicate or triplicate.
• Antibiotic Addition: Add the predetermined volume of antibiotic stock to the main culture to achieve the desired final concentration. Mix thoroughly and note this time as t=0.
• Time-Course Sampling: Continue to incubate the culture with antibiotic at 37°C with shaking. Collect 1 mL aliquots at predetermined time points (e.g., 1, 2, 4, 6, and 24 hours). Immediately perform serial dilutions and plate as for the t=0 sample. For high-titer samples, a brief centrifugation and washing step may be included to remove the antibiotic before plating, though this can also reduce persister counts.

Day 3: Data Collection

• Colony Counting: After 16-48 hours of incubation at 37°C, count the colonies on plates that contain between 30 and 300 colonies.
• Data Recording: Record the colony-forming units per milliliter (CFU/mL) for each time point and strain.

Quantification and Data Analysis

Key Metrics for Quantifying Persistence

From the time-kill data, several quantitative metrics can be derived to characterize persistence.

Table 1: Key Quantitative Metrics for Persistence Assays

Metric	Description	Formula/Interpretation	Application
Persister Fraction [7]	The proportion of surviving cells after a defined period of antibiotic exposure.	(CFU/mL at time t) / (CFU/mL at t=0)	A simple, widely used measure for cross-study comparison. Often reported at 24 hours.
MDK99 (Minimum Duration for killing 99%) [36]	The time required to kill 99% of the bacterial population.	Determined from the time-kill curve.	A direct measure of tolerance; independent of population size. Higher MDK99 indicates higher tolerance.
Persistence Level [37]	The absolute number of surviving cells after the initial rapid killing phase.	CFU/mL measured after 2-5 hours of exposure.	Useful for evaluating the burden of persisters that can lead to relapse.

Factors Influencing Persistence Levels in Assays

The measured persistence level is highly dependent on experimental conditions. When compiling data from studies with 36 bacterial species and 54 antibiotics, several key factors were identified [7]:

Table 2: Factors Affecting Persister Levels in Kill-Curve Assays

Factor	Impact on Persistence	Notes
Antibiotic Class	Membrane-active antibiotics admit the fewest persisters.	Cell wall synthesis inhibitors (e.g., ampicillin) and protein synthesis inhibitors (e.g., aminoglycosides) often show higher persister fractions.
Growth Phase	Persistence is less common in exponential phase and more common in stationary phase.	Stationary phase cultures can have persister fractions several orders of magnitude higher than exponential phase cultures.
Culture Medium	Persistence is less common in rich media compared to nutrient-limited media.
Gram Staining	Persistence is more common in Gram-positive bacteria than in Gram-negative bacteria.	Median persister fractions can vary by up to 5 orders of magnitude across species [7].

Molecular Mechanisms of hipA-Mediated Persistence

The molecular pathway by which HipA induces persistence is complex and involves a cascade of interactions with other cellular systems. The mechanism is not autonomous but relies on cross-activation of other toxin-antitoxin systems.

Key Steps in the Pathway:

• HipA Activation: Stochastic expression or mutation (e.g., hipA7) leads to free HipA toxin.
• Translation Inhibition: HipA phosphorylates GltX, preventing it from charging tRNA^Glu with glutamate. This halts translation and causes uncharged tRNA^Glu to accumulate in the cell.
• Stringent Response Activation: Uncharged tRNA^Glu binds to and activates the ribosome-associated RelA synthetase, triggering a sharp increase in the synthesis of (p)ppGpp.
• Polyphosphate Accumulation: The high level of (p)ppGpp competitively inhibits the exopolyphosphatase PPX, leading to a buildup of inorganic polyphosphate [Poly(P)].
• Antitoxin Degradation: Poly(P) activates the Lon protease, which subsequently degrades the labile antitoxin components of multiple type II TA modules.
• mRNase Toxin Activation: With the antitoxins degraded, the TA-encoded toxins (eRNases like RelE and MazF) are freed. These enzymes catalytically degrade cellular mRNA, further reinforcing the state of growth arrest.
• Persistence Establishment: This multi-layered inhibition of translation and cellular growth renders the cell dormant and tolerant to multiple antibiotic classes.

Critically, HipA-induced persistence depends entirely on this cascade. Even though HipA activation can halt cell growth in a strain lacking the 10 mRNase TA modules, it fails to induce persistence in such a strain. This demonstrates that slow growth alone is insufficient for tolerance and that the TA-encoded mRNases are central effectors of the persistent state [35].

The Scientist's Toolkit: Essential Reagents and Materials

Table 3: Key Research Reagent Solutions for Persistence Assays

Reagent / Material	Function / Application	Specific Examples / Notes
Bacterial Strains	Study of genetic mechanisms.	E. coli BW25113 (wild-type), isogenic hipA7 mutant, ΔhipA knockout, ΔrelA mutant (to confirm (p)ppGpp dependence) [35].
Antibiotics	Selective pressure in kill-curve assays.	Bactericidal antibiotics: Ampicillin (cell wall), Ofloxacin/Ciprofloxacin (DNA), Tobramycin (protein). Use at 10-100x MIC [7] [37].
Culture Media	Supporting bacterial growth under defined conditions.	LB broth (rich medium), M9 minimal medium (defined, nutrient-limited). The choice affects persister frequency [7].
Antibiotic Neutralizers	Preventing carryover effect during plating.	Include in dilution blanks or plating media. e.g., Penicillinase for β-lactams, Mg2+ for aminoglycosides.
Polyphosphate & Lon Assay Kits	Quantifying key molecules in the HipA pathway.	Measure intracellular poly-P levels and Lon protease activity to validate mechanism [35].
(p)ppGpp Detection	Confirming activation of the stringent response.	Thin-layer chromatography (TLC) or HPLC to measure (p)ppGpp accumulation upon HipA expression [35].

Concluding Remarks

The time-kill curve assay remains the gold standard for in vitro quantification of bacterial persistence. Its quantitative nature is an invaluable asset for global and cross-species analyses [7]. When studying specific genetic determinants like hipA, the assay provides a robust framework for comparing persistence levels between mutant and wild-type strains. The molecular insights gained from hipA research—showing the central role of (p)ppGpp and cross-talk between TA modules—highlight the complexity of the persistence phenotype. Furthermore, the correlation between in vitro persistence levels and survival in animal models of infection [37] validates the use of these assays to predict treatment outcomes and screen for novel anti-persister therapies. A comprehensive understanding of both the experimental methodology and the underlying molecular mechanisms is essential for advancing research aimed at eradicating persistent bacterial infections.

The hipA (high persistence) gene encodes a bacterial toxin that is a central component of the hipBA toxin-antitoxin (TA) system in Escherichia coli and other bacteria. Research into high persistence bacterial mutants has established that far from being a simple genetic switch, the hipBA system generates a phenotypically heterogeneous population through an elegant threshold-based mechanism [38]. This technical guide details the methodologies for monitoring hipBA expression and its functional consequences at single-cell resolution, providing the tools necessary to investigate the formation of antibiotic-tolerant persister cells—a major clinical challenge in treating persistent infections.

The hipBA Toxin-Antitoxin System: Mechanism and Function

Core System Components and Regulation

The hipBA TA module consists of two core components:

• HipA toxin: A serine/threonine protein kinase that inhibits cell growth by targeting essential cellular processes [21] [39].
• HipB antitoxin: A DNA-binding protein that neutralizes HipA toxicity and represses transcription of the hipBA operon [39].

The system exhibits autoregulation where HipB alone or the HipBA complex binds the operator region to repress transcription. Under normal conditions, the antitoxin HipB sequesters the HipA toxin. However, in response to stress or stochastic fluctuations, proteolytic degradation of HipB can free HipA to exert its toxic effects [21].

Molecular Targets and Persistence Induction

HipA induces bacterial persistence through targeted phosphorylation of essential cellular components:

• Primary target: Glutamyl-tRNA synthetase (GltX) – Phosphorylation by HipA inhibits GltX activity, leading to accumulation of uncharged tRNA^Glu [40] [21].
• Stringent response activation: Uncharged tRNA^Glu triggers the RelA/SpoT-mediated stringent response, increasing (p)ppGpp levels [40].
• Cellular dormancy: Elevated (p)ppGpp reprograms cellular metabolism, inhibits DNA replication, transcription, and translation, ultimately inducing a dormant state that protects cells from antibiotics [40] [21].

Table 1: Key Components of the hipBA-Mediated Persistence Pathway

Component	Type	Primary Function in Persistence
HipA	Toxin kinase	Phosphorylates GltX and other targets to inhibit growth
HipB	Antitoxin/repressor	Neutralizes HipA and represses hipBA transcription
GltX	Aminoacyl-tRNA synthetase	Essential tRNA charging enzyme; inhibition triggers stringent response
RelA/SpoT	(p)ppGpp synthetases	Mediate stringent response to nutrient stress
(p)ppGpp	Alarmone	Global regulator that reprograms cell for dormancy

Key Experimental Models and Reagent Solutions

Bacterial Strains and Expression Systems

Essential genetic tools for hipBA research include:

• E. coli BW25113: Common wild-type background for persistence studies [40].
• hipA7 mutant: Gain-of-function allele (G22S) that increases persistence frequency [21].
• ΔhipBA strains: Chromosomal deletion mutants to study ectopically expressed hipBA [40] [38].
• Inducible expression systems: Arabinose (pBAD) or tetracycline (Ptet) promoters for controlled HipA expression [40] [38].

Monitoring and Detection Reagents

Table 2: Essential Research Reagents for hipBA Single-Cell Analysis

Reagent/Category	Specific Examples	Research Application
Fluorescent Reporters	HipA-mCherry transcriptional fusions [38]	Single-cell quantification of HipA expression levels
Induction Systems	Arabinose-inducible pBAD33_hipA [40]	Controlled toxin expression with temporal precision
Growth Media	M9 + 0.5% glycerol + 0.9% casamino acids [40]	Defined medium for reproducible growth and persistence assays
Antibiotic Selection	Chloramphenicol (30 μg/mL) [40]	Plasmid maintenance for expression constructs
Viability Stains	Not specified in results	Differentiation of dormant vs. dead cells (commonly used: propidium iodide, SYTO dyes)

Single-Cell Methodologies for hipBA Expression Monitoring

Time-Lapse Microscopy with Fluorescent Reporters

Protocol: Single-cell measurement of HipA expression and growth arrest

• Genetic construct: Implement a HipA-mCherry transcriptional fusion to monitor protein expression dynamics [38].
• Image acquisition: Capture time-lapse images of individual cells under controlled growth conditions (37°C, appropriate magnification).
• Data extraction:
  • Quantify fluorescence intensity (HipA expression level) for each cell
  • Measure division times or growth cessation (arrest duration)
  • Correlate expression levels with phenotypic outcomes [38]

Key finding: HipA exhibits a threshold effect where toxicity only manifests when cellular concentration exceeds a critical level, explaining the bimodal response in isogenic populations [38].

Flow Cytometry for Population Heterogeneity

Protocol: Population-level analysis of hipBA expression distribution

• Sample preparation: Grow cultures to early exponential phase (OD600 ≈ 0.1-0.2) [40].
• HipA induction: Add 0.2% arabinose for 15 minutes for pBAD-driven expression [40].
• Fixation/Washing: Process cells for fluorescence-activated cell sorting (FACS).
• Data analysis: Measure fluorescence distribution across 10,000+ cells to quantify population heterogeneity.

Quantitative Assessment of Persister Formation

Growth Arrest and Recovery Profiling

Protocol: Population growth dynamics during hipA induction

• Culture conditions: Grow E. coli in Erlenmeyer flasks or microplates at 37°C with agitation [40].
• Induction timing: Induce HipA expression with 0.2% arabinose at OD600 ≈ 0.05-0.15 [40].
• Monitoring: Measure OD600 continuously using plate readers or periodic spectrophotometry.
• Data analysis: Calculate growth arrest duration by intersecting linear regression lines of exponential growth, arrest, and recovery phases [40].

Key finding: Repeated hipA induction leads to progressively shorter growth arrest durations, suggesting a cellular memory of previous stress exposure [40].

Colony Formation and Appearance Timing

Protocol: Quantitative persistence frequency measurement

• HipA induction: Express HipA for 3 hours in hipB+ strains [38].
• Plating: Plate serial dilutions on non-inducing media to allow recovery.
• Monitoring: Automatically image plates every 30-60 minutes using commercial scanners [38].
• Analysis: Use automated image analysis to determine colony appearance times across thousands of colonies simultaneously [38].

Key finding: HipA expression generates extremely broad distributions of growth-arrest times (hours to days), with distinct subpopulations exhibiting fundamentally different time scales [38].

Signaling Pathway and Experimental Workflows

hipBA-Mediated Persister Formation Pathway

Diagram 1: HipBA Signaling Pathway in Persister Formation

Single-Cell Experimental Workflow

Diagram 2: Single-Chip Analysis Workflow for hipBA

Advanced Technical Applications and Integration

Single-Cell RNA Sequencing and Multi-Omics

Emerging technologies enable unprecedented resolution in persistence research:

• Single-cell RNA-seq: Resolve transcriptional heterogeneity in isogenic populations during HipA-induced dormancy [41] [42].
• Spatial transcriptomics: Map persister formation in structured environments and biofilms [42].
• Multi-omics integration: Combine scRNA-seq with protein abundance (CITE-seq) or chromatin accessibility (scATAC-seq) [42].

Platform recommendation: ezSingleCell provides an integrated analysis suite for single-cell and spatial omics without requiring programming expertise [42].

Computational Analysis Framework

Quantitative metrics for single-cell data:

• Global structure preservation: Evaluate dimensionality reduction techniques using Pearson correlation of cell-cell distances [41].
• Local neighborhood preservation: Assess K-nearest neighbor (Knn) graph conservation after data transformation [41].
• Distance distribution analysis: Apply Earth-Mover's Distance (EMD) to quantify structural alterations in high-dimensional data [41].

Table 3: Quantitative Analysis of HipA-Induced Growth Arrest Dynamics

Experimental Condition	Arrest Duration (First Induction)	Arrest Duration (Second Induction)	Key Interpretation
Early stationary inoculum	3-5 hours [40]	Significantly shorter [40]	Cellular memory effect strongest with robust starting culture
Late stationary inoculum	Extended duration	Variable reduction	Growth phase influences stress response memory
Microplate vs. flask	Varies by vessel [40]	Differential memory effect	Aeration and growth conditions impact persistence
hipA7 mutant	Constitutively high persistence [21]	N/A	Genetic mutation bypasses regulation
Threshold exceedance	Proportional to exceedance level [38]	N/A	Supra-threshold HipA determines arrest duration

Single-cell analysis of hipBA expression and persister formation reveals a sophisticated cellular strategy for managing stress survival in bacterial populations. The threshold-based response mechanism, cellular memory of previous stress exposures, and integration with global regulatory networks position the hipBA system as a key mediator of phenotypic heterogeneity. The methodologies detailed in this technical guide—from single-cell fluorescence microscopy to advanced omics approaches—provide researchers with the tools necessary to dissect this clinically significant phenomenon at unprecedented resolution, ultimately informing strategies to combat persistent bacterial infections.

The study of bacterial persistence, a phenomenon where a sub-population of bacteria survives antibiotic treatment without genetic resistance, is crucial for addressing chronic and relapsing infections. The hipA gene (high persistence) was one of the first genetic elements identified as central to this phenotype. Initial research in 1983 isolated Escherichia coli K-12 mutants in which a significantly larger fraction of cells, approximately 10-2, persisted after inhibition of murein synthesis by antibiotics like ampicillin, compared to 10-6 to 10-5 in the parent strain [6]. These mutations mapped to 33.8 minutes on the E. coli chromosome, defining hipA as a newly recognized gene and providing the first genetic handle on the persistence phenomenon [6]. The isolation of these original hipA mutants demonstrated that persistence was a manipulatable genetic trait, opening the door for the development of sophisticated genetic tools like transposon mutant libraries and transposon sequencing (Tn-seq) to systematically uncover the full genetic network underlying this clinically important phenotype.

Key Genetic Tools for Persistence Research

Transposon Mutant Libraries

Transposon mutagenesis is a powerful forward-genetics approach for creating comprehensive collections of random insertion mutants within a bacterial genome.

• Principle: A transposon, a mobile DNA sequence carrying a selectable marker (e.g., an antibiotic resistance gene), is randomly inserted into the target genome. This disrupts the coding sequence or expression of the gene at the insertion site, creating a knockout mutant.
• Library Generation: A saturating library, where insertions are represented in a large proportion of non-essential genes, is generated and the mutants are pooled. In a reported protocol for Acinetobacter baumannii, a library of over 400,000 mutants was created, equating to a transposon insertion approximately every 10 base pairs [43].
• Screening: The pooled mutant library can be subjected to a selective pressure, such as antibiotic treatment. Mutants with insertions in genes important for persistence (e.g., hipA) will be depleted from the pool, while those with insertions in non-essential genes will survive.

Table 1: Core Components for Generating a Transposon Mutant Library

Component	Function	Example
Transposon Donor Strain	Delivers the transposon DNA into the recipient cell via conjugation.	E. coli MFD ΔdapA pir+ pJNW68 [43]
Transposon Vector	Carries the transposon with a selectable marker and requires a conditional origin of replication (e.g., R6K).	pJNW68 [43]
Recipient Strain	The target bacterium in which the mutant library is to be generated.	Acinetobacter baumannii ATCC 17978 [43]
Selectable Marker	Allows for selection of successful transposon insertion mutants.	Kanamycin resistance gene [43]
Transposase	Enzyme that catalyzes the excision and integration of the transposon.	Himar1 C9 mariner transposase [43]

Transposon Sequencing (Tn-seq)

Tn-seq is a high-throughput method that combines transposon mutagenesis with next-generation sequencing to quantitatively map insertion sites and fitness defects on a genome-wide scale [43].

• Workflow: After creating a transposon mutant library and exposing it to a condition of interest (e.g., an antibiotic), genomic DNA is isolated from the pre- and post-selection pools. The transposon-genome junctions are amplified and sequenced.
• Data Analysis: The number of sequence reads for each insertion site is counted. A significant depletion of reads for a specific gene after antibiotic treatment indicates that mutants with insertions in that gene have a fitness defect, implying the gene is important for persistence.
• Application to Persistence: This approach allows for the unbiased discovery of all genes involved in persistence, beyond known loci like hipA. For example, Tn-seq has been used to identify molecular determinants that contribute to A. baumannii fitness when challenged with colistin, a last-resort antibiotic [43].

Experimental Protocols for Key Experiments

Protocol: Generating a Saturating Transposon Mutant Library

This protocol, adapted for Gram-negative bacteria like A. baumannii and E. coli, streamlines library construction by eliminating the need for restriction enzymes and adapter ligation [43].

1. Bacterial Strain Preparation:

• Streak the donor strain (e.g., E. coli MFD DAP- pJNW68) on LB agar supplemented with 600 µM diaminopimelic acid (DAP), 100 mg/L ampicillin, and 25 mg/L kanamycin.
• Streak the recipient strain (e.g., A. baumannii ATCC 17978) on LB agar.
• Inoculate separate liquid cultures and incubate overnight at 37°C.

2. Conjugation:

• Mix donor and recipient cells at an optimized ratio (e.g., 1:1) and pellet by centrifugation.
• Resuspend the cell mixture in a small volume of LB and spot onto a pre-warmed LB agar plate without antibiotics. Incubate for 4-6 hours at 37°C.
• Harvest the cell mixture from the plate and resuspend in LB. Plate serial dilutions onto selective plates containing kanamycin (to select for transposon insertions) but no DAP (to counterselect against the donor strain). Incubate for 24-48 hours at 37°C.

3. Library Pooling and Storage:

• Scrape all colonies from the selection plates and pool into a single suspension in LB with 15-25% glycerol.
• Aliquot the library and store at -80°C. Determine the library's complexity by plating serial dilutions and counting CFUs. A high-quality library should contain at least 100,000-400,000 unique mutants.

Protocol: Tn-seq for Persister Gene Discovery

1. Selection and DNA Extraction:

• Thaw the mutant library and grow it to mid-log phase.
• Divide the culture and treat one portion with a lethal dose of an antibiotic (e.g., ampicillin) for a defined period. Keep an untreated portion as the "input" control.
• Pellet the cells from both treated and untreated cultures. Extract genomic DNA using a method that yields high-molecular-weight DNA.

2. Library Preparation and Sequencing:

• Fragment the gDNA using sonication or enzymatic digestion.
• Use a PCR-based method with primers specific to the transposon ends to amplify the transposon-genome junctions.
• Purify the amplified fragments and use a next-generation sequencing platform (e.g., Illumina) to sequence the amplicons.

3. Data Analysis:

• Map the sequenced reads to the reference genome of the bacterium to identify the exact location of each transposon insertion.
• Count the number of reads for each insertion site in the input (T0) and treated (T1) samples.
• Use specialized software (e.g., TRANSIT, Bio-Tradis) to identify genes that show a statistically significant reduction in transposon insertions following antibiotic treatment. These genes are putative persistence genes.

The Molecular Function of hipA and Integrated Pathways

The molecular function of HipA has been elucidated, revealing its role as a central kinase in a toxin-antitoxin system. HipA is a eukaryote-like serine-threonine kinase that phosphorylates a conserved serine residue (Ser239) on glutamyl-tRNA synthetase (GltX) [13]. This phosphorylation event inhibits the aminoacylation activity of GltX, preventing it from charging tRNA^Glu^ with glutamate. This disruption in translation leads to the accumulation of uncharged tRNA^Glu^ at the ribosomal A-site, which in turn triggers the stringent response [13]. The stringent response is mediated by the alarmone (p)ppGpp, synthesized by RelA. Elevated (p)ppGpp levels lead to widespread transcriptional reprogramming, downregulating energy-intensive processes like DNA replication and ribosome synthesis, and promoting a dormant, multidrug-tolerant state characteristic of persister cells [13].

Table 2: Key Reagents for Investigating hipA and Persistence Pathways

Research Reagent	Function in Research
pJNW68 Vector	A mariner-based transposon delivery vector used for generating high-complexity mutant libraries in Gram-negative bacteria [43].
HipA-specific Antibodies	Used to detect and quantify HipA protein expression levels in wild-type versus mutant strains via Western blotting.
Anti-GltX (phospho-S239) Antibodies	Critical for verifying the phosphorylation and functional inhibition of the HipA target, GltX, in vivo [13].
(p)ppGpp Detection Kits	(e.g., HPLC, ELISA) Used to measure the cellular levels of the alarmone ppGpp, a key downstream effector of HipA-induced persistence [13].
Luxury Bacterial Cultivation Systems	(e.g., chemostats, microfluidic devices) Enable precise control of growth conditions and single-cell analysis to study persister formation and resuscitation dynamics.

HipA Molecular Signaling Pathway

Data Presentation and Analysis

Table 3: Quantitative Comparison of Persistence Frequencies in Key Studies

Bacterial Strain / Condition	Persistence Frequency	Inducing Condition	Key Finding
E. coli K-12 (Parent)	10⁻⁶ to 10⁻⁵	Inhibition of murein synthesis [6]	Established baseline persistence level.
E. coli K-12 (hipA mutant)	~10⁻²	Inhibition of murein synthesis [6]	First genetic evidence of a "high-persistence" (Hip) mutant.
Transposon Library Size	>400,000 mutants	N/A [43]	Enables saturating genome coverage for Tn-seq.
P. aeruginosa (CF isolates)	High (Hip mutants)	Chronic antibiotic exposure in patients [2]	Correlation between clinical antibiotic use and hip mutant selection.

Tn-seq Experimental Workflow

This technical guide provides a framework for modeling complex clinical infection scenarios, with a specific focus on the role of high-persistence bacterial mutants in chronic and biofilm-associated infections. The hipA gene serves as a central model for understanding the molecular mechanisms of bacterial persistence, a phenomenon directly contributing to treatment failure and infection relapse. HipA, a bacterial serine-threonine kinase, was one of the first genes specifically linked to a high-persistence (Hip) phenotype, where mutations cause a substantial increase (up to 10^(-2)) in the fraction of bacterial cells surviving antibiotic exposure [6]. This guide synthesizes current research and methodologies to equip researchers and drug development professionals with the tools to model these clinically critical scenarios.

The hipA Gene: A Molecular Model for Bacterial Persistence

Historical Context and Phenotypic Characterization

The hipA gene was first identified in Escherichia coli K-12 through the isolation of mutants exhibiting a high-persistence (Hip) phenotype. In wild-type populations, persisters represent a very small subpopulation (10^(-6) to 10^(-5)) of cells that survive prolonged exposure to antibiotics without being genetically resistant. In contrast, Hip mutants display a dramatically increased fraction of persister cells, up to 10^(-2), following inhibition of murein synthesis by various antibiotics or metabolic blocks [6]. Initial genetic mapping placed hipA at 33.8 minutes on the E. coli chromosome, a region with few other recognized functions at the time [6].

Molecular Mechanism of HipA-Induced Persistence

The molecular function of HipA has been elucidated as a key mediator of bacterial multidrug tolerance. HipA is a eukaryote-like serine-threonine kinase that functions as a toxin in a bacterial toxin-antitoxin system.

• Primary Cellular Target: HipA specifically phosphorylates glutamyl-tRNA synthetase (GltX) at a conserved serine residue (Ser239) located near its active center. This phosphorylation event occurs only when GltX is bound to its cognate tRNA^(Glu), and it effectively inhibits the aminoacylation activity of GltX [13].
• Triggering the Stringent Response: The inactivation of GltX leads to the accumulation of uncharged tRNA in the cell. This mimics amino acid starvation and serves as the signal for RelA to synthesize the alarmone (p)ppGpp [13].
• Induction of Dormancy: The elevated levels of (p)ppGpp trigger a comprehensive cellular shutdown, slowing down or halting metabolic processes and leading to a dormant, antibiotic-tolerant state. This state is reversible upon cessation of stress, allowing persister cells to resume growth once the antibiotic pressure is removed [13].

Table 1: Key Characteristics of hipA-Mediated Persistence

Feature	Wild-Type E. coli	hipA Mutant E. coli
Persistence Frequency	10^(-6) to 10^(-5) [6]	Up to 10^(-2) [6]
Genetic Basis	Not applicable (phenotypic state)	Mutation in the hipA gene [6]
Primary Molecular Target	Not applicable	Glutamyl-tRNA synthetase (GltX) [13]
Key Signaling Molecule	Basal (p)ppGpp levels	High (p)ppGpp levels [13]
Cellular State	Transient dormancy in a small subpopulation	Increased subpopulation in a dormant state [6] [2]
Antibiotic Susceptibility	Killed by prolonged exposure	Tolerant to prolonged exposure [6]

The following diagram illustrates the molecular pathway through which HipA induces persistence.

Biofilms as a Paradigm for Persistent Infections

Biofilm Architecture and the Persister Niche

Biofilms are structured microbial communities encased in a self-produced extracellular polymeric substance (EPS) matrix. This matrix is composed of polysaccharides, lipids, proteins, and extracellular DNA (eDNA) [44]. This structured environment is critical for the survival of persister cells.

• Physical Protection: The EPS matrix acts as a physical barrier, hindering the penetration of antibiotics into the deeper layers of the biofilm. Some antibiotics may bind to or be degraded by matrix components [44].
• Metabolic Heterogeneity: Biofilms exhibit profound gradients of nutrients and metabolic waste products. This creates microenvironments within the biofilm where cells exhibit vastly different metabolic activities. Cells in the inner core or deeper layers often experience nutrient limitation and become slow-growing or dormant, a state that mimics and can enrich for the persister phenotype [44] [2].
• A Reservoir for Recurrence: Biofilms are a primary reservoir for chronic and recurrent infections. They are associated with 70% of all microorganism-induced infections and are a significant contributor to healthcare-associated infections (HAIs) [45]. The dormant persister cells within a biofilm can survive antibiotic treatment and, upon cessation, lead to a relapse of the infection.

Table 2: Quantitative Analysis of Biofilm Biovolume in Mycoplasma fermentans

M. fermentans Strain	Median Biovolume at 3 days (µm³ × 10³)	Median Biovolume at 7 days (µm³ × 10³)
ATCC19989 (Type Strain)	76	97
M67910 (Clinical)	4.9	5.8
MF1 (Clinical)	7.7	40
M67195 (Clinical)	1.9	2.0

Source: Adapted from [46]. Data demonstrates variability in biofilm-forming capacity between strains and a general increase in biovolume over time.

The Biofilm Lifecycle in Clinical Context

The formation of a biofilm is a cyclic process with critical implications for infection and treatment. The lifecycle can be broadly described in five main steps [45] [44]:

• Initial Attachment: Planktonic (free-floating) cells reversibly attach to a biotic (e.g., host tissue) or abiotic (e.g., medical implant) surface.
• Irreversible Attachment: Cells become permanently affixed using surface adhesins like pili and MSCRAMMs (Microbial Surface Components Recognizing Adhesive Matrix Molecules).
• Microcolony Formation: Attached cells proliferate and begin to form clusters, initiating the production of the EPS matrix.
• Maturation: The biofilm develops a complex 3D architecture with characteristic structures like towers and water channels. Gradients of nutrients and waste products are established.
• Dispersion: Cells detach from the biofilm, either as single cells or clumps, to colonize new niches. This step is crucial for the dissemination of infection and can be triggered by environmental cues or therapeutic interventions.

Experimental Modeling and Analysis Protocols

In Vitro Biofilm Cultivation and Visualization

Protocol: Biofilm Growth on Abiotic Surfaces (Adapted from [46])

This protocol is suitable for studying biofilm formation on medical devices like catheters or implants.

• Material Preparation: Place sterile glass coverslips (22 mm²) vertically into culture tubes (e.g., 50 ml Falcon tubes).
• Inoculation: Add pre-warmed culture medium (e.g., Eaton's broth for mycoplasmas, LB for E. coli) to the tubes. Inoculate with a 1:100 dilution of a mid-logarithmic phase planktonic culture.
• Incubation: Incubate at the optimal growth temperature (e.g., 37°C for human pathogens) in a 5% CO₂ atmosphere without agitation for 3-7 days. Static incubation promotes surface attachment.
• Sample Processing:
  • Fixation: Carefully remove coverslips, wash gently with phosphate-buffered saline (PBS) to remove non-adherent cells, and fix with 4% formaldehyde in PBS for 10 minutes at room temperature.
  • Staining: Stain with an appropriate fluorescent dye. For total biomass, use propidium iodide (15 minutes) or SYTO dyes. For matrix components, use specific fluorescently-labeled lectins or antibodies.
  • Mounting: Mount coverslips on slides using an anti-fade mounting medium (e.g., 90% glycerol in PBS).

Protocol: Confocal Laser Scanning Microscopy (CLSM) and 3D Analysis [46]

• Imaging: Image the stained biofilms using a CLSM with appropriate laser lines and emission filters for your fluorophores. Use a high-numerical-aperture oil immersion objective (e.g., 63x).
• Z-stack Acquisition: Collect a series of optical sections (Z-stacks) through the entire depth of the biofilm. Set the Z-step size to 0.1-0.5 µm to ensure sufficient resolution for 3D reconstruction.
• 3D Reconstruction and Quantification:
  • Import Z-stack image files into 3D analysis software (e.g., Amira, BiofilmQ, ImageJ).
  • Apply a median filter to each slice to reduce noise.
  • Apply a global threshold to segment the biofilm biomass from the background.
  • Use the software's quantification tools to measure key parameters, including:
    • Total Biovolume (µm³): The total volume of the biofilm.
    • Average Thickness (µm): The mean height of the biofilm.
    • Surface Area and Roughness: Descriptors of the biofilm's topography.

Quantifying Persister Cells

Protocol: Isolation and Enumeration of Persisters [2]

This protocol allows for the quantification of the persister subpopulation within a culture or biofilm.

• Challenge with a High Concentration of Bactericidal Antibiotic: Treat a stationary-phase culture or a harvested, homogenized biofilm with a high concentration of a bactericidal antibiotic (e.g., 10x MIC of a fluoroquinolone or an aminoglycoside). Ensure the antibiotic is dissolved in the appropriate buffer or medium.
• Incubate and Sample: Incubate the culture under normal growth conditions. At predetermined time points (e.g., 0, 2, 4, 8, 24 hours), remove aliquots.
• Wash and Remove Antibiotic: Centrifuge the aliquots, discard the supernatant containing the antibiotic, and wash the pellet with fresh, sterile medium or PBS. This step is critical to remove the antibiotic that would inhibit the outgrowth of persisters.
• Viable Cell Count (CFU): Serially dilute the washed cells and plate them onto antibiotic-free solid medium. Incubate the plates until colonies appear.
• Calculation: The number of colony-forming units (CFUs) that appear after the antibiotic exposure and washing represents the persister population. The persistence frequency can be calculated as CFUperml post-treatment / CFUperml pre-treatment.

Advanced Image Cytometry with BiofilmQ

For high-throughput, quantitative analysis of 3D biofilm images, the software tool BiofilmQ is indispensable [47]. Its workflow and capabilities can be visualized as follows.

BiofilmQ enables the quantification of hundreds of parameters, which can be categorized as follows [47]:

• Global Parameters: Describe the whole biofilm (e.g., total biovolume, mean thickness, surface area, roughness).
• Internal Parameters: Describe the spatial heterogeneity within the biofilm. The software divides the biofilm volume into a cubical grid and for each cube, it calculates:
  • Spatial Context: Distance to substratum, distance to biofilm surface.
  • Fluorescence Intensity: Reporter gene expression, immunostaining signals.
  • Structural Properties: Local biovolume density, texture.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents and Tools for Persistence and Biofilm Research

Reagent / Tool	Function / Application	Example Use-Case
HipA Expression Plasmids	Genetically induce high-persistence phenotype in wild-type strains.	Study the direct effects of HipA expression on antibiotic tolerance and physiology [6].
Transposons (Tn5, Tn10)	Generate mutant libraries for genetic screening; map genes.	Identify genes linked to persistence by screening for altered Hip phenotypes [6].
Fluorescent Protein Reporters (e.g., GFP, mCherry)	Visualize and quantify gene expression in space and time.	Fuse to promoter of interest (e.g., relA for stringent response) to monitor activity in biofilms [47].
Anti-Matrix Antibodies	Specific detection and localization of EPS components (e.g., PNAG, alginate).	Immunofluorescence staining to correlate matrix production with persister cell niches [47] [44].
Glycoside Hydrolases & Dispersin B	Enzymatically degrade specific polysaccharides in the biofilm matrix.	Induce biofilm dispersal; study the effect of matrix disruption on antibiotic efficacy against persisters [44].
Confocal Laser Scanning Microscope (CLSM)	Acquire high-resolution 3D images of live or fixed biofilms.	Non-destructively visualize the 3D architecture of biofilms and spatial localization of cells [45] [46].
BiofilmQ Software	Automated image cytometry for 3D microbial communities.	Quantify spatiotemporal heterogeneity in gene expression and structure within biofilms [47].

Integrated Clinical Scenario: Modeling a Chronic Airway Infection

To effectively model a complex clinical scenario like a chronic Pseudomonas aeruginosa infection in a cystic fibrosis (CF) lung, an integrated approach combining the elements above is required.

• Establish the Biofilm Model: Grow a P. aeruginosa biofilm, potentially a co-culture with other CF-relevant pathogens like S. aureus, in a flow cell system that mimics the shear forces and nutrient conditions of the airway.
• Incorporate the Persistence Element: Utilize a clinical P. aeruginosa isolate or a laboratory strain with a defined hipA homolog or other persistence mechanism.
• Simulate Antibiotic Fluctuation: Treat the mature biofilm with a regimen of tobramycin (a common CF treatment) in a pulsed manner, mimicking the pharmacokinetic profile in a patient (peak and trough concentrations).
• Analyze the Outcome:
  • Use CLSM and BiofilmQ to quantify the reduction in overall biofilm biovolume and, crucially, the spatial distribution of the remaining persister cells post-treatment.
  • Harvest biofilm cells, perform the persister enumeration protocol, and compare persister frequencies before, during, and after antibiotic pulses.
  • Use fluorescent reporters to track the activation of the stringent response ((p)ppGpp) in real-time during antibiotic stress.

This integrated model directly tests how the physical barrier of the biofilm, the physiological state of the cells (induced by HipA-mediated pathways), and the fluctuating antibiotic concentration interact to produce a treatment-resistant chronic infection. The insights gained from such a model are critical for developing novel anti-persister therapies that can be added to existing antibiotic regimens to finally eradicate these stubborn infections.

Bacterial multidrug tolerance (MDT) is a significant obstacle in effectively treating chronic and recurrent infections, largely driven by a small, dormant subpopulation of cells known as persisters [2]. The hipA (high persistence) gene represents the first and one of the most critically studied genetic loci linked to this phenomenon [6] [4]. Originally identified in Escherichia coli K-12, gain-of-function mutations in hipA, such as the classic hipA7 allele, can increase the frequency of persister cell formation by 100 to 1000-fold, enabling populations to survive prolonged exposure to lethal antibiotic concentrations without genetically acquired resistance [6] [48]. The pressing clinical relevance of this mechanism is underscored by the discovery of hipA mutants, including hipA7, in uropathogenic E. coli (UPEC) isolates from patients with recurrent urinary tract infections, establishing a direct link between laboratory models and human disease [4].

The translation of hipA research into diagnostic applications is imperative for improving patient outcomes. Persisters are now recognized as key contributors to chronic and biofilm-associated infections, facilitating relapse after treatment and acting as a potential precursor to full genetic resistance [2]. Detecting these mutants in clinical isolates provides valuable prognostic information, potentially guiding more aggressive or alternative therapeutic strategies for infected patients. This technical guide details the transition from foundational research on hipA function to the development of robust diagnostic protocols, providing researchers and drug development professionals with the methodologies and frameworks needed to identify and characterize these critical genetic determinants of treatment failure.

Molecular Mechanisms of HipA-Mediated Persistence

The HipBA Toxin-Antitoxin System

HipA is a serine-threonine protein kinase that functions as the toxin component of the HipBA type II toxin-antitoxin (TA) module [30]. The antitoxin, HipB, is a DNA-binding protein that forms a complex with HipA, neutralizing its toxicity and repressing the transcription of the hipBA operon [4]. Under normal conditions, this complex maintains HipA in an inactive state. However, stochastic fluctuations or environmental stress can lead to HipB degradation, freeing HipA to exert its toxic effects and induce a dormant, persistent state [2].

Signaling Pathway and Key Molecular Interactions

The core mechanism by which HipA induces dormancy involves a targeted attack on essential cellular metabolism. The following diagram illustrates the sequence of molecular events triggered by HipA activation.

HipA specifically phosphorylates glutamyl-tRNA synthetase (GltX) at a conserved serine residue (Ser239) located near its active site [13]. This phosphorylation event occurs exclusively when GltX is bound to its cognate tRNAGlu, leading to inhibition of the enzyme's aminoacylation function [13]. The resulting accumulation of uncharged tRNAGlu is recognized as a starvation signal by the ribosome-associated enzyme RelA, which subsequently synthesizes the alarmone (p)ppGpp [13]. This triggers the stringent response, a global physiological shift that dramatically reduces metabolic activity and growth, thereby rendering the cell dormant and tolerant to multiple antibiotic classes [30] [13].

High-Persistence Mutations and Their Structural Basis

The high-persistence (hip) phenotype of certain hipA mutants, such as hipA7 (carrying G22S and D291A substitutions) and hipA (P86L), stems from a failure to properly regulate kinase activity within the HipA-HipB-promoter complex [4]. These mutations map to the N-subdomain-1 of HipA, a region distant from the kinase active site [4]. Structural analyses reveal that in the wild-type complex, HipA molecules form dimers via interactions through their N-subdomain-1, which effectively occludes their active sites and suppresses kinase function [4]. The hip mutations diminish HipA-HipA dimerization, thereby "unleashing" the kinase to more readily phosphorylate GltX and induce persistence, even under conditions that would normally suppress its activity [4].

Key hipA Mutations and Their Phenotypic Impact

Since the initial discovery of the hipA7 allele, several other mutations have been identified that confer a high-persistence phenotype. These mutations provide critical targets for diagnostic assays.

Table 1: Characterized High-Persistence hipA Mutants

Mutant Allele	Amino Acid Substitution(s)	Phenotypic Impact on Persistence	Isolation Source
hipA7	G22S, D291A	100 to 1000-fold increase in persister frequency [6] [48]	Laboratory selection [6], Uropathogenic E. coli (UPEC) [4]
hipA (P86L)	P86L	Similar high-persister phenotype to hipA7 [4]	Laboratory selection and clinical screen [4]
hipA (D88N)	D88N	Increased persister formation [4]	Laboratory screen [4]

Experimental Protocols for Detection and Characterization

Workflow for hipA Mutant Analysis

A comprehensive approach to identifying and characterizing hipA mutants in clinical or laboratory samples involves a multi-stage process, from isolation to mechanistic validation.

Protocol 1: Selection and Enrichment of High-Persister Isolates

This protocol is designed to isolate bacterial subpopulations with elevated multidrug tolerance from a mixed culture, a critical first step in identifying potential hipA mutants [48].

Materials:

• Bacterial Strains: Clinical isolates or laboratory strains grown to mid-logarithmic or stationary phase.
• Culture Media: Appropriate liquid and solid media (e.g., LB, M9).
• Antibiotics: High-concentration stocks of bactericidal antibiotics (e.g., ampicillin, ciprofloxacin, ofloxacin).

Procedure:

• Culture Standardization: Grow bacterial cultures to the desired optical density (e.g., OD600 ~0.5 for exponential phase, or ~1.2+ for stationary phase).
• Antibiotic Challenge: Expose cultures to a high concentration of a selected bactericidal antibiotic (e.g., 10x MIC) for a prolonged period (e.g., 5-24 hours, depending on the antibiotic and species).
• Survivor Harvesting: After antibiotic exposure, wash the cells by centrifugation (e.g., 5,000 x g for 10 min) to remove the antibiotic. Resuspend the pellet in fresh, antibiotic-free medium.
• Outgrowth and Repetition: Allow the surviving cells to recover and grow in fresh medium. Repeat steps 2-4 for 2-3 cycles to enrich the culture for high-persister mutants.
• Plating and Isolation: Plate the enriched culture on non-selective solid media to obtain single colonies. These individual clones can be screened further.

Protocol 2: PCR Amplification and Sequencing of the hipA Locus

This protocol details the genotypic identification of hipA mutations, which is necessary for confirming the presence of known or novel alleles.

Materials:

• Genomic DNA Template: Purified from candidate bacterial isolates.
• PCR Reagents: Thermostable DNA polymerase (e.g., Taq polymerase), dNTPs, reaction buffer.
• Oligonucleotide Primers: Designed to flank the entire hipA coding sequence.
• Sequencing Facility/Platform: Access to Sanger sequencing or next-generation sequencing services.

Procedure:

• Primer Design: Design primers to amplify the hipA gene. For E. coli K-12, the hipA gene is located at 33.8 minutes on the genetic map [6].
• PCR Amplification: Set up a standard PCR reaction. A typical 50 µL reaction might contain 1x polymerase buffer, 200 µM dNTPs, 0.5 µM each primer, 50-100 ng genomic DNA, and 1-2 units of DNA polymerase.
• Thermocycling Conditions: Use a standard protocol: initial denaturation at 95°C for 5 min; 30 cycles of 95°C for 30s, 55-60°C (primer-specific) for 30s, 72°C for 1-2 min/kb; final extension at 72°C for 5-10 min.
• Amplicon Purification: Purify the PCR product using a commercial kit to remove primers, enzymes, and dNTPs.
• DNA Sequencing: Submit the purified amplicon for bidirectional Sanger sequencing using the same PCR primers or internal primers for adequate coverage.
• Sequence Analysis: Align the obtained sequence to a reference hipA sequence using bioinformatics software (e.g., BLAST, Geneious) to identify nucleotide changes and their corresponding amino acid substitutions.

Protocol 3: Phenotypic Validation via Time-Dependent Persister Assays

This gold-standard assay quantifies the persister frequency of a confirmed hipA mutant compared to a wild-type control [48].

Materials:

• Test and Control Strains: Confirmed hipA mutant and isogenic wild-type strain.
• Antibiotics: Multiple classes of bactericidal antibiotics not used in the initial enrichment.

Procedure:

• Culture Growth: Grow test and control strains in biological triplicate to the same growth phase.
• Antibiotic Exposure: Treat cultures with a lethal dose of an antibiotic (e.g., 100 µg/mL ampicillin or 10 µg/mL ciprofloxacin).
• Viability Sampling: At predetermined time points (e.g., 0, 3, 6, 24 hours), remove aliquots from the culture.
• Washing and Plating: Wash the samples to remove the antibiotic, perform serial dilutions in buffer or medium, and plate on non-selective solid media.
• Colony Counting and Calculation: After 24-48 hours of incubation, count the colony-forming units (CFU). The persister frequency is calculated as (CFU at time T / CFU at time 0).

Expected Outcome: A genuine hipA hip mutant will show a significantly higher survival rate (e.g., 100-1000x) after prolonged antibiotic exposure compared to the wild-type strain, without a change in the minimum inhibitory concentration (MIC) [48].

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for hipA Mutant Research

Reagent / Material	Function / Application	Specific Examples / Notes
hipA Mutant Strains	Positive controls for persistence assays	E. coli strains with hipA7 (G22S, D291A) or P86L alleles [4]
Anti-HipA Antibodies	Immunoblotting, protein expression level analysis	Custom polyclonal or monoclonal antibodies
Cloning Plasmids	Ectopic expression of hipA alleles	Overexpression vectors (e.g., pBAD, pET) for toxicity and suppression studies [13]
GltX & tRNAGlu	In vitro kinase activity assays	Purified GltX and tRNAGlu substrates for HipA phosphorylation assays [13]
[γ-32P]ATP	Radioactive detection of phosphorylation	Used in in vitro kinase assays to measure HipA-mediated phosphorylation of GltX [13]
Specific Antibiotics	Selective pressure and persister assays	Ampicillin, Ciprofloxacin, Ofloxacin for killing curves [6] [4]

Transition to Clinical Diagnostics: Challenges and Future Directions

The movement from research-based detection of hipA mutants to routine clinical diagnostics presents several challenges and opportunities. A primary hurdle is the low frequency of persisters in a population, which can make direct detection from patient samples difficult without an initial enrichment culture [2]. Furthermore, persistence is a polygenic and multifactorial phenomenon; while hipA is a key player, other mechanisms can confer identical phenotypes, necessitating that a hipA-focused diagnostic be part of a broader panel [48] [2].

Future diagnostic platforms may leverage next-generation sequencing (NGS) for high-throughput screening of hipA and other persistence-linked genes from clinical isolates [49]. The development of rapid PCR-based assays (e.g., qPCR with melting curve analysis for specific mutations) could provide a faster, more cost-effective method for surveillance in high-risk patient populations, such as those with recurrent UTIs. Furthermore, the integration of artificial intelligence (AI) and predictive bioinformatics models could eventually allow for the prediction of persister phenotypes based on genomic signatures, guiding personalized antibiotic regimens [50] [49]. The ultimate goal is to provide clinicians with timely information about not just which antibiotic a pathogen is resistant to, but also which therapies may fail due to tolerance, enabling more effective and tailored treatment strategies for persistent infections.

Challenges and Solutions: Navigating the Complexities of Persister Research

Distinguishing True Persistence from Resistance and VBNC States

Within bacterial populations, several distinct survival states enable bacteria to withstand antibiotic treatment and other environmental stresses. For researchers investigating the hipA gene and its role in high-persistence mutants, clearly differentiating between antibiotic resistance, antibiotic tolerance, persistence, and the viable but non-culturable (VBNC) state is fundamental. These states represent different bacterial strategies for survival under adverse conditions, each with unique molecular mechanisms and phenotypic characteristics [2] [51] [3].

Confusion between these states can significantly hamper research progress and therapeutic development. This guide provides a technical framework for distinguishing these phenomena, with particular emphasis on the mechanisms and experimental approaches relevant to hipA-mediated bacterial persistence.

Conceptual Definitions and Comparative Analysis

Antibiotic Resistance

Antibiotic resistance involves heritable genetic changes that enable bacteria to grow in the presence of an antibiotic. The minimum inhibitory concentration (MIC) for resistant strains is significantly elevated compared to their susceptible counterparts [51] [3]. Resistance mechanisms include: (1) enzymatic inactivation of antibiotics, (2) mutation or modification of antibiotic targets, and (3) reduced intracellular accumulation via efflux pumps or decreased membrane permeability [51] [3]. Resistance is stable and inheritable, allowing resistant clones to propagate under continuous antibiotic selection.

Antibiotic Tolerance

Tolerance describes the ability of a bulk population to survive transient exposure to high concentrations of bactericidal antibiotics without genetic mutation. Tolerant populations exhibit an unchanged MIC but display a significantly slower death rate in time-kill assays [3]. Tolerance is often associated with slow growth or transient metabolic downregulation induced by environmental cues [3]. Unlike persistence, tolerance affects most of the population rather than a small subpopulation.

Bacterial Persistence

Persistence is characterized by a biphasic killing curve in which a small, non-growing subpopulation (typically <1%) survives antibiotic treatment that kills the majority of the population [51] [3]. These persister cells are genetically identical to their susceptible counterparts, do not possess elevated MICs, and resume normal growth once antibiotic pressure is removed [2] [3]. The persister state is transient and non-heritable, representing a phenotypic switch rather than a genetic mutation [2] [51].

Viable but Non-Culturable (VBNC) State

The VBNC state is a survival strategy in which bacteria lose culturability on routine media that normally supports their growth but maintain viability and metabolic activity [52] [53]. VBNC cells require specific resuscitation signals to return to a culturable state, unlike persisters which spontaneously resume growth upon stress removal [53] [3]. Some researchers propose that VBNC represents a deeper state of dormancy compared to persistence, forming a continuum of metabolic activity [52] [53].

Table 1: Comparative Characteristics of Bacterial Survival States

Feature	Antibiotic Resistance	Antibiotic Tolerance	Persistence	VBNC State
MIC Change	Increased	Unchanged	Unchanged	Unchanged (but not measurable)
Genetic Basis	Heritable mutations	Non-heritable	Non-heritable, phenotypic	Non-heritable, phenotypic
Population	Entire population	Entire population	Small subpopulation (<1%)	Variable subpopulation
Culturability	Culturable	Culturable	Culturable	Non-culturable on standard media
Metabolic State	Active	Reduced/Slow-growing	Dormant/Slow-growing	Dormant but metabolically active
Recovery	Continuous growth	Growth upon stress removal	Growth upon stress removal	Requires specific resuscitation signals
Key Feature	Genetic resistance mechanisms	Slower death rate of entire population	Biphasic killing curve	Requires resuscitation to become culturable

The hipA Gene: A Paradigm for Molecular Persistence Mechanisms

Historical Context and Discovery

The hipA gene was the first genetic element identified to directly affect persistence. In 1983, Moyed and Bertrand isolated E. coli mutants with a 1,000-fold increase in persister frequency after mutagenesis and selection for survival against penicillin, naming the responsible gene hipA (high persistence) [6]. This seminal discovery provided the first genetic evidence that persistence was a programmable phenotype, opening molecular investigation into persister formation mechanisms [5] [6].

Molecular Function in Toxin-Antitoxin Systems

HipA functions as a bacterial serine/threonine kinase in a type II toxin-antitoxin (TA) module with its cognate antitoxin HipB [54] [3]. Under normal conditions, HipB binds and inhibits HipA toxicity. However, in the hipA7 mutant variant, elevated HipA levels lead to phosphorylation of specific cellular targets:

• GltX (tRNA^Glu^ synthetase): Phosphorylation inhibits its function, causing accumulation of uncharged tRNA^Glu^ at the ribosomal A-site [54] [3]
• Elongation Factor Tu (EF-Tu): Phosphorylation may inhibit translation elongation [54]

These phosphorylation events ultimately inhibit global translation and arrest cell growth, inducing a dormant state tolerant to multiple antibiotic classes [54] [3].

Connection to Stringent Response

Uncharged tRNA accumulation at the ribosome activates RelA, triggering the synthesis of the alarmone (p)ppGpp [55] [3]. This alarmone mediates the stringent response, a global reprogramming of gene expression that promotes bacterial survival under stress. Elevated (p)ppGpp levels lead to:

• Downregulation of energy-intensive processes (DNA replication, protein synthesis)
• Upregulation of stress response genes
• Potentiation of the persistent state [55]

This establishes HipA as a central regulator connecting TA modules with the stringent response in persistence formation.

Figure 1: Molecular Mechanism of hipA-Mediated Persistence Formation. The diagram illustrates how hipA mutations trigger a cascade leading to multidrug tolerance through toxin-antitoxin systems and stringent response activation.

Experimental Approaches for Differentiation and Study

Core Methodological Framework

Time-Kill Assays for Persistence Detection

Time-kill assays remain the gold standard for identifying and quantifying persister cells [2] [3].

Protocol:

• Grow bacterial culture to mid-log phase (OD~600~ ≈ 0.5)
• Expose to lethal concentration of bactericidal antibiotic (typically 10-100× MIC)
• Remove samples at predetermined time points (e.g., 0, 2, 4, 8, 24 hours)
• Serially dilute and plate on antibiotic-free media
• Count colony-forming units (CFUs) after incubation
• Plot log~10~ CFU/mL versus time

Interpretation: A biphasic killing curve with an initial rapid decline followed by a plateau indicates persister presence. The plateau level represents the persister fraction [3].

Minimum Inhibitory Concentration (MIC) Determinations

MIC testing distinguishes resistance from persistence/tolerance [51] [3].

Broth Microdilution Protocol:

• Prepare two-fold serial antibiotic dilutions in broth
• Inoculate with standardized bacterial suspension (5×10^5^ CFU/mL)
• Incubate for 16-20 hours at appropriate temperature
• Identify the lowest concentration inhibiting visible growth

Interpretation: Persisters and tolerant strains show unchanged MICs compared to susceptible parents, while resistant strains exhibit significantly elevated MICs [51].

Persister Isolation and Characterization

Protocol for Enrichment:

• Treat exponential-phase culture with high antibiotic concentration
• Incubate for 3-5 hours to kill susceptible cells
• Wash cells to remove antibiotic or use antibiotic-deactivating enzymes
• Plate on fresh media to recover surviving persisters

Key Consideration: Always confirm that isolated persisters maintain genetic susceptibility to verify the phenotype is non-heritable [2] [3].

Distinguishing Persisters from VBNC Cells

Culturability Assessment

The fundamental distinction lies in culturability:

• Persisters: Form colonies on standard media after antibiotic removal
• VBNC cells: Fail to grow on standard media but remain metabolically active [52] [53]

VBNC Identification Protocol:

• Assess metabolic activity using CTC (5-cyano-2,3-ditolyl tetrazolium chloride) or similar redox dyes
• Perform membrane integrity staining with propidium monoazide (PMA) combined with qPCR
• Attempt resuscitation using specific conditions (temperature shift, nutrient addition, host passage)

Interpretation: VBNC cells show metabolic activity without culturability and require specific resuscitation signals, unlike persisters [53].

Table 2: Key Experimental Differentiators Between Survival States

Experimental Method	Antibiotic Resistance	Persistence	VBNC State
MIC Testing	Elevated MIC	Normal MIC	Not applicable (non-culturable)
Time-Kill Kinetics	Growth at MIC concentrations	Biphasic killing curve	Not applicable (non-culturable)
Population Dynamics	Uniform population response	Small surviving subpopulation	Variable subpopulation
Genetic Analysis	Resistance-conferring mutations	No resistance mutations; possible hipA mutations	No resistance mutations
Recovery Pattern	Continuous growth on antibiotic media	Growth on antibiotic-free media after stress removal	Requires specific resuscitation conditions
Viability Staining	Culturable and metabolically active	Culturable after stress removal	Metabolically active but non-culturable

Figure 2: Experimental Workflow for Differentiating Bacterial Survival States. The decision tree guides researchers through key assays to distinguish resistance, persistence, tolerance, and VBNC states based on MIC, killing kinetics, and culturability.

The Scientist's Toolkit: Essential Research Reagents and Solutions

Table 3: Key Research Reagents for Studying hipA-Mediated Persistence

Reagent/Category	Specific Examples	Research Application	Technical Function
Bacterial Strains	E. coli hipA7 mutant, ΔhipA knockout strain, BW25113 wild-type	Comparative persistence studies, Genetic validation	Provide isogenic backgrounds to study hipA-specific effects [54] [6]
Antibiotics	Ampicillin (100 μg/mL), Kanamycin (50 μg/mL), Ciprofloxacin	Persister selection and time-kill assays	Apply selective pressure to eliminate susceptible populations [54] [3]
Molecular Biology Tools	HipA expression plasmids, Anti-HipA antibodies, SPR chips with immobilized HipA	Mechanistic studies, Protein interaction analysis	Enable overexpression, detection, and binding studies of HipA protein [54]
Biochemical Assays	ATP detection kits, (p)ppGpp quantification, Surface Plasmon Resonance (SPR)	Metabolic activity measurement, Alarmone quantification, Binding affinity studies	Characterize metabolic state and molecular interactions [54] [3]
Inhibitors/Modulators	PKUMDL-LTQ compounds (HipA inhibitors), ppGpp analogs	Targeted persistence disruption, Pathway manipulation	Probe specific mechanisms and potential therapeutic interventions [54]
Viability Stains	Propidium Monoazide (PMA), CTC, SYTO dyes	Differentiation of viable/non-viable cells, Metabolic activity assessment	Distinguish between different physiological states without culturability [53]

Advanced Techniques and Research Applications

HipA-Targeted Therapeutic Development

The discovery of HipA inhibitors represents a promising strategy for combating persistent infections. In a 2016 study, structure-based virtual screening identified compound PKUMDL-LTQ-301, which:

• Binds HipA with high affinity (K~D~ = 270 ± 90 nM)
• Reduces E. coli persistence 5-fold (EC~50~ = 46 ± 2 μM with ampicillin)
• Shows no activity in ΔhipA strains, confirming target specificity [54]

This approach demonstrates the potential of targeting persistence mechanisms directly rather than relying solely on conventional antibiotics.

Single-Cell Analysis Technologies

Advanced techniques enable persister study at single-cell resolution:

• Microfluidics: Allows observation of individual persister cell formation and resuscitation
• Flow cytometry: Enables sorting of persister subpopulations based on dye retention or reporter expression
• Time-lapse microscopy: Visualizes heterogeneous responses within bacterial populations [51] [3]

These approaches help overcome challenges posed by the low abundance and transient nature of persisters in bulk cultures.

Distinguishing between bacterial resistance, persistence, tolerance, and VBNC states requires integrated methodological approaches centered on MIC determination, killing kinetics, and culturability assessment. The hipA gene serves as a key molecular paradigm connecting toxin-antitoxin systems with stringent response activation in persistence formation. As research advances, targeted inhibition of persistence mechanisms combined with traditional antibiotics represents a promising therapeutic strategy against recalcitrant bacterial infections.

Within the field of bacterial persistence research, the hipA gene stands as a landmark discovery, representing the first genetically identified determinant of high-persistence phenotypes [6]. Investigations into hipA function and related persistence mechanisms necessitate rigorous experimental control, as technical variables such as growth phase, inoculum size, and bacterial culturability significantly influence observed outcomes. This technical guide examines these critical pitfalls and provides methodologies to account for them, ensuring reliable and reproducible research on bacterial persisters.

The Inoculum Effect: Mechanisms and Experimental Control

The inoculum effect (IE) describes the phenomenon where antibiotic efficacy decreases as the initial density of a bacterial population increases [56]. This effect has profound implications for persistence studies, as it can be easily confounded with genuine genetic persistence mechanisms, such as those conferred by hipA mutations.

Mechanism: Growth Productivity

Recent evidence suggests that growth productivity—the combined effect of bacterial growth rate and metabolic state—serves as a key mechanism underlying IE for multiple bactericidal antibiotics [56]. Growth productivity measures the relationship between the maximum growth rate and intracellular ATP concentration during log-phase growth. The accompanying diagram illustrates this central mechanism and its relationship to experimental variables.

Quantitative Evidence for Growth Productivity

The relationship between growth productivity and IE strength has been quantitatively demonstrated in Escherichia coli. The following table summarizes key experimental findings that illustrate how manipulating growth medium composition affects IE for kanamycin.

Table 1: Growth Productivity and Inoculum Effect Strength in E. coli BW25113 [56]

Glucose Concentration (%)	Growth Productivity (μM ATP/h⁻¹)	ΔMICₖₐₙ (Inoculum Effect Strength)
0.00004	Highest observed	Lowest observed
0.04	Lowest observed	Highest observed
Varies with casamino acids	Biphasic relationship	Inversely correlated with growth productivity

Experimental Protocol: Controlling for the Inoculum Effect

To isolate genuine persistence mechanisms from IE-related artifacts, implement the following protocol:

• Standardize Inoculum Preparation

  • Prepare two distinct inocula from an overnight stationary-phase culture: a high-density (e.g., 1:5000 dilution, ~1.13×10⁶ CFU/mL) and a low-density (e.g., 1:50000 dilution) suspension [56].
  • Verify initial densities using optical density (OD₆₀₀) and plate counting.

• Manipulate Growth Medium

  • Utilize a defined minimal medium (e.g., M9).
  • Systematically vary the concentration of the carbon source (e.g., glucose from 0.00004% to 0.04%) and a nitrogen source (e.g., casamino acids from 0% to 0.8%) to create environments with differing growth productivities [56].

• Quantify Key Parameters

  • Maximum Growth Rate: Measure cell density (OD₆₀₀) over time and fit data to a logistic growth equation.
  • ATP Concentration: During mid-log phase, harvest cells and use a bioluminescent assay to determine intracellular ATP concentration.
  • Growth Productivity: For each carbon source percentage, plot ATP concentration versus maximum growth rate and calculate the slope of a linear regression. A positive slope indicates high growth productivity [56].

• Determine Minimum Inhibitory Concentration (MIC)

  • Expose both high- and low-density populations to a concentration gradient of the target antibiotic.
  • Incubate for 24 hours and measure final cell density.
  • Define MIC as the lowest antibiotic concentration that inhibits visible growth.
  • Calculate ΔMIC as the average difference in MIC between high- and low-density populations [56].

Growth Phase Heterogeneity in Persister Populations

Bacterial persisters are not a uniform population but exhibit significant phenotypic heterogeneity based on their metabolic state and growth phase [2].

Classification of Persister Types

• Type I Persisters: Non-growing, metabolically quiescent cells induced by external environmental factors, such as stationary phase cultivation [2].
• Type II Persisters: Slow-growing, slow-metabolizing cells that arise spontaneously without external induction and can revert to normal growth [2].
• Persistence Continuum: A hierarchy exists where some persisters exhibit "deep" persistence (strong tolerance) while others show "shallow" persistence (weak tolerance) [2].

Experimental Protocol: Distinguishing Growth Phase-Dependent Persistence

To characterize persistence across growth phases, particularly when investigating hipA mutants:

• Culture Synchronization

  • For Type I persisters: Grow cultures to stationary phase (typically 24-48 hours) to maximize population heterogeneity.
  • For Type II persisters: Use exponentially growing cultures from diluted overnight cultures (OD₆₀₀ ~0.2-0.4) to capture spontaneously arising persisters.

• Antibiotic Challenge

  • Apply a lethal concentration of an appropriate antibiotic (e.g., ampicillin for hipA studies [6]).
  • Sample at regular intervals over 3-8 hours to monitor biphasic killing kinetics.

• Regrowth Assessment

  • After antibiotic removal (via washing or dilution), monitor culture regrowth.
  • Confirm persistent phenotype by demonstrating that progeny of survivors remain susceptible to the same antibiotic [2].

Culturability and the Viable But Non-Culturable State

A significant challenge in persistence research involves bacteria that remain viable but resist standard laboratory cultivation, potentially leading to underestimation of persister populations.

The Culturability Gap

Standard microbiological media often fail to support the growth of many bacterial types, with typically only about 1% of soil bacteria forming colonies on conventional media [57]. This issue extends to clinical isolates and persister populations, including those of hipA mutants.

Experimental Protocol: Enhancing Culturability Recovery

To improve the recovery of persisters, particularly those in a viable but non-culturable (VBNC) state:

• Media Selection

  • Employ newly developed, nutrient-rich media instead of traditional minimal media.
  • Consider supplementation with specific growth factors or catalase to neutralize reactive oxygen species [57].

• Inoculum Size Optimization

  • Use lower inoculum sizes (e.g., 10²-10⁴ cells per plate) rather than dense suspensions, as this can significantly increase viable counts [57].

• Extended Incubation

  • Incubate plates for extended periods (up to 3 months) to allow slow-growing persisters to form visible colonies [57].
  • Maintain proper humidity to prevent desiccation during prolonged incubation.

• Culture Verification

  • Once isolated, characterize growth rates of pure cultures, as members of rarely isolated groups often take longer to form visible colonies [57].
  • Confirm identity through 16S rRNA sequencing.

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for Bacterial Persistence Research [57] [56]

Reagent/Condition	Function in Persistence Research
Defined Minimal Medium (e.g., M9)	Serves as a base for precise manipulation of carbon and nitrogen sources to control growth productivity.
Carbon Sources (e.g., Glucose)	Variation in concentration (0.00004% - 0.04%) allows experimental modulation of bacterial metabolic state and ATP production.
Nitrogen Sources (e.g., Casamino Acids)	Used in conjunction with carbon sources to create growth environments with differing relationships between growth rate and ATP.
Bioluminescent ATP Assay	Quantifies intracellular ATP concentration as a key indicator of metabolic state and growth productivity.
Extended Incubation Systems	Environmental chambers that maintain stable conditions for prolonged periods (up to 3 months) enable recovery of slow-growing persisters.
Alternative Culture Media	Specially formulated media support the growth of diverse bacterial types that fail to grow on standard laboratory media.

Methodological Integration forhipAResearch

When investigating hipA gene function, integrate these considerations into a unified experimental workflow, as depicted below.

Research on bacterial persistence, particularly studies investigating the hipA gene, demands meticulous attention to technical variables. The inoculum effect, largely driven by growth productivity; growth phase-dependent heterogeneity; and limitations in culturability represent interconnected pitfalls that can compromise experimental validity. By implementing the standardized protocols, quantification methods, and control strategies outlined in this guide, researchers can advance our understanding of persistence mechanisms with greater accuracy and reproducibility, ultimately contributing to improved therapeutic strategies against persistent bacterial infections.

Bacterial persistence represents a significant challenge in clinical medicine, underlying the relapse of chronic and persistent infections following antibiotic treatment. Persisters are defined as genetically drug-susceptible subpopulations of bacteria that can survive antibiotic exposure by entering a transient state of dormancy or reduced metabolic activity, only to resume growth once the antibiotic pressure is removed [2] [58]. This phenomenon was first identified by Gladys Hobby in 1942 and later named "persisters" by Joseph Bigger in 1944 when he observed that a small fraction of staphylococci survived penicillin treatment [2]. Unlike antibiotic resistance, which involves genetic mutations that increase the minimum inhibitory concentration (MIC), persistence is a non-heritable phenotypic variant characterized by unchanged MIC but enhanced survival against bactericidal antibiotics [58] [59].

The concept of a "persistence continuum" has emerged to describe the spectrum of dormant states bacteria can occupy. This continuum ranges from shallow persistence, where bacteria exhibit minimal metabolic reduction and can quickly resume growth, to deep persistence, characterized by profound metabolic arrest and extended lag times before regrowth [2]. This framework is crucial for understanding treatment failures and developing more effective therapeutic strategies against persistent infections. The hipA gene, discovered in 1983 through its mutation (hipA7) in Escherichia coli, represents the first genetically identified molecular determinant of high persistence and serves as a cornerstone for understanding the molecular mechanisms driving bacterial dormancy [2] [6].

Molecular Mechanisms of the hipA System

hipAB Toxin-Antitoxin Module Structure and Function

The hipA gene is part of the hipAB toxin-antitoxin (TA) module, a type II TA system where HipA functions as the toxin and HipB as the antitoxin [58]. In this system, HipB forms a tight complex with HipA, neutralizing its toxic effects under normal growth conditions. However, under stress conditions or through stochastic fluctuations, HipA can be released and exert its toxic effects on the bacterial cell [58]. The hipA7 mutant allele, containing two point mutations, produces a 100 to 1000-fold increase in persister frequency compared to wild-type strains when exposed to antibiotics such as ampicillin [2] [6]. This established hipAB as the prototype TA system linked to bacterial persistence and provided the first genetic evidence for the molecular basis of this phenotype.

HipA-Mediated Persistence Through GltX Phosphorylation

The molecular mechanism by which HipA induces dormancy was elucidated through a series of elegant experiments demonstrating that HipA, a serine-threonine kinase, specifically targets glutamyl-tRNA synthetase (GltX) [24] [25]. This phosphorylation event occurs at Ser239 within the ATP-binding site of GltX, inhibiting its aminoacylation activity and consequently leading to the accumulation of uncharged tRNA^Glu^ in the cell [24] [25]. The accumulation of uncharged tRNA then triggers the stringent response via RelA activation, resulting in increased synthesis of the alarmone (p)ppGpp, which globally reprograms bacterial metabolism toward dormancy [25].

This mechanism represents a sophisticated bacterial survival strategy: by modulating tRNA charging, HipA artificially creates a nutrient starvation signal that activates the stringent response even in nutrient-replete conditions, thereby inducing a dormant state that protects against antibiotics [25]. The central role of this pathway was confirmed by experiments showing that overexpression of GltX reverses HipA toxicity, prevents (p)ppGpp accumulation upon HipA expression, and significantly reduces persister formation [25].

Table 1: Key Molecular Components in HipA-Mediated Persistence

Component	Type	Function in Persistence
HipA	Toxin kinase	Phosphorylates GltX at Ser239, inhibiting tRNA charging
HipB	Antitoxin	Binds and neutralizes HipA activity
GltX	Glutamyl-tRNA synthetase	Essential for tRNA^Glu^ charging; when phosphorylated by HipA, triggers persistence
tRNA^Glu^	Transfer RNA	When uncharged, activates RelA and stringent response
(p)ppGpp	Alarmone	Global regulator of stringent response, induces dormancy

Figure 1: HipA-Mediated Pathway to Bacterial Persistence. The mechanism begins with environmental stress or stochastic fluctuations disrupting the HipAB complex, freeing HipA to phosphorylate GltX, ultimately leading to dormancy through the stringent response.

The Persistence Continuum: From Shallow to Deep Dormancy

Characterizing Persistence Depths

The persistence continuum concept provides a framework for understanding the heterogeneous nature of bacterial dormancy. This continuum encompasses a spectrum of metabolic states with varying depths of persistence, which directly influence survival rates under antibiotic pressure and recovery times after antibiotic removal [2]. At one end of the spectrum, shallow persisters exhibit minimal metabolic reduction and can quickly resume growth once antibiotics are removed, typically after hours rather than days. These cells might experience partial inhibition of specific metabolic pathways while maintaining relatively active energy metabolism. At the opposite extreme, deep persisters exist in a state of profound metabolic arrest, with dramatically extended lag times before resuming growth, potentially lasting for days or weeks [2].

This continuum model helps explain the biphasic killing patterns observed when bacterial populations are exposed to bactericidal antibiotics. The initial rapid killing phase predominantly eliminates susceptible cells and shallow persisters, while the subsequent plateau phase represents the survival of deeper persisters with substantially reduced killing rates [2] [59]. The position of a bacterial cell along this continuum is influenced by various factors, including the specific molecular mechanism inducing persistence, environmental conditions, and stochastic variations in gene expression.

Relationship to VBNC States and Other Dormant Forms

The deepest end of the persistence continuum may overlap with the viable but non-culturable (VBNC) state observed in various pathogens, including Vibrio cholerae, Legionella pneumophila, and Mycobacterium tuberculosis [2]. Cells in the VBNC state fail to grow on standard laboratory media but maintain metabolic activity and can resuscitate under appropriate conditions. This relationship suggests that the persistence continuum may extend beyond traditionally culturable persisters to include these more extreme dormant states, further complicating eradication efforts [2].

Table 2: Characteristics Across the Persistence Continuum

Parameter	Shallow Persisters	Intermediate Persisters	Deep Persisters
Metabolic Activity	Moderately reduced	Significantly reduced	Profoundly arrested
Recovery Time	Hours	1-2 days	Days to weeks
Resuscitation Probability	High	Moderate	Low
Antibiotic Survival Rate	Moderate	High	Very high
Relationship to VBNC	Distinct	Potential overlap	Strong overlap

Experimental Implications and Methodologies

Assessing Persistence Depth Through Lag Time Distribution

The ScanLag method represents a powerful approach for quantifying persistence depth by measuring the distribution of lag times across individual bacterial cells following antibiotic treatment [25]. This method involves monitoring the appearance of colonies after plating antibiotic-treated cultures, where extended lag times correlate with deeper persistence states. Research using this technique has demonstrated that HipA expression above a specific threshold produces a broad distribution of colony appearance times, with a pronounced "tail" representing the persister subpopulation [25]. This heterogeneity in lag time distribution directly reflects the persistence continuum, with deeper persisters taking substantially longer to resume growth and form visible colonies.

Experimental evidence confirms that the depth of persistence is directly modulated by HipA expression levels. At low to medium HipA expression levels, GltX overexpression can prevent extended lag times, but at very high HipA concentrations, the growth arrest persists despite additional GltX, indicating a threshold mechanism governing persistence depth [25]. This relationship between toxin concentration and persistence depth provides experimental support for the continuum model, with higher HipA levels driving cells deeper into dormancy.

Quantifying Persistence in Laboratory Evolution Experiments

Laboratory evolution experiments have been instrumental in studying how bacterial populations adapt to repetitive antibiotic treatments by increasing their persistence levels. These experiments typically involve cyclic antibiotic exposures followed by outgrowth periods, mimicking clinical treatment regimens [59]. The development of tolerance is quantified using parameters such as the minimum duration of killing (MDK), which measures the time required to reduce a bacterial population by a certain percentage (e.g., 99%) at a specific antibiotic concentration [59].

Through such evolution experiments, researchers have observed that bacterial populations can optimize their lag times to match the duration of antibiotic exposure, effectively tuning their position along the persistence continuum in response to treatment pressures [59]. Genomic analysis of evolved high-persistence mutants has identified mutations in genes involved in TA modules (e.g., vapB), aminoacyl-tRNA synthetases (e.g., metG), and metabolic pathways (e.g., prsA), highlighting the multiple genetic routes to enhanced persistence along the continuum [59].

Figure 2: Experimental Workflow for Evolution of Persistence. Laboratory evolution experiments involve cyclic antibiotic treatment and regrowth to select for increased persistence, with assessment methods quantifying changes along the persistence continuum.

Research Toolkit: Essential Reagents and Methodologies

Table 3: Essential Research Reagents and Methods for hipA/Persistence Studies

Reagent/Method	Specific Example	Application/Function
Bacterial Strains	E. coli MG1655 hipA7 mutant	High-persistence model strain for mechanistic studies
Expression Systems	pTet-hipA-mcherry plasmid	Controlled HipA expression for persistence induction
Antibiotics	Ampicillin, Norfloxacin	Selection pressure for persister formation and assessment
Genetic Tools	pTac-gltX plasmid	GltX overexpression to reverse HipA-mediated persistence
Detection Methods	(p)ppGpp quantification	Measurement of stringent response activation via TLC
Analytical Techniques	ScanLag method	High-throughput measurement of lag time distributions
Evolution Protocols	Cyclic antibiotic treatment	Laboratory evolution of persistence under drug pressure

Therapeutic Implications and Future Directions

The persistence continuum model has profound implications for antimicrobial therapy development. Traditional MIC-based antibiotic susceptibility testing fails to detect persisters, as they exhibit normal MIC values despite their enhanced survival during treatment [2] [58]. This limitation necessitates the development of complementary diagnostic approaches that assess time-dependent killing kinetics rather than just growth inhibition thresholds. The MDK (minimum duration of killing) has been proposed as a valuable additional parameter for evaluating antibiotic efficacy against persistent populations [59].

Understanding the hipA-mediated persistence mechanism reveals potential therapeutic targets for anti-persister strategies. These include:

• Inhibitors of HipA kinase activity that prevent GltX phosphorylation and subsequent stringent response activation.
• GltX stabilizers that maintain tRNA charging functionality despite HipA expression.
• * (p)ppGpp antagonists* that interfere with the stringent response signaling cascade.
• Resuscitation-promoting factors that could help eradicate deep persisters by forcing them out of dormancy into a metabolically active state where they become susceptible to antibiotics.

The continuum model suggests that successful anti-persister therapies may need to be tailored to specific depths of persistence, with combination approaches potentially required to address the heterogeneous nature of persistent subpopulations. As research continues to unravel the complexities of the persistence continuum, new opportunities will emerge for developing more effective treatments against chronic and recurrent bacterial infections that have long plagued clinical practice.

Antibiotic persistence represents a formidable challenge in treating bacterial infections, distinct from conventional genetic resistance. Persisters are a small, transient, and phenotypically variant subpopulation of bacteria that can survive exposure to lethal concentrations of antibiotics without undergoing genetic mutation [21] [7]. These dormant cells can resuscitate once antibiotic pressure is removed, leading to relapsing infections and contributing to the development of genetic resistance [21] [60]. The hipA (high persistence) gene was the first genetic element linked to this phenomenon, establishing toxin-antitoxin (TA) systems as crucial molecular players in bacterial persistence [21] [61].

TA systems are small, bicistronic operons encoding a stable toxin that inhibits vital cellular processes and a labile antitoxin that neutralizes the toxin [21]. Under stress conditions, proteases degrade the antitoxin, freeing the toxin to induce a state of growth arrest and dormancy [62]. The hipBA module is a canonical type II TA system where HipA functions as a serine/threonine protein kinase and HipB acts as its antitoxin and transcriptional repressor [21] [61]. HipA's kinase activity is essential for its function, as mutations in its active site (e.g., D309Q, D332Q, S150A) abolish its ability to cause growth arrest and confer multidrug tolerance [61].

While early research focused on single TA systems, modern studies reveal that bacterial genomes typically encode multiple, often redundant, TA modules. Escherichia coli K-12 possesses at least 36 TA systems, while Mycobacterium tuberculosis boasts a remarkable 88 such systems [63] [62]. This apparent redundancy raises critical questions about why bacteria maintain multiple TA systems and how these systems coordinate to influence bacterial persistence—questions central to developing effective antipersister therapies.

Mechanisms of Functional Redundancy and Cooperation Between TA Systems

Distinct Molecular Targets and Signaling Pathways

Research in Caulobacter crescentus, which possesses three hipBA operons, demonstrates that different HipA toxins can phosphorylate distinct substrates despite their structural similarities. HipA1 and HipA2 contribute to antibiotic persistence in stationary phase by phosphorylating different aminoacyl-tRNA synthetases (GltX and TrpS, respectively) [21]. This target specialization suggests that redundant TA systems provide a broader surveillance network, allowing bacteria to respond to diverse environmental stresses through different signaling pathways.

The stringent response, mediated by the alarmone (p)ppGpp, serves as a common downstream pathway for multiple TA systems. In C. crescentus, HipA-mediated persistence requires the stringent response regulator SpoT [21]. However, persister cells can still form in the absence of all hipBA operons or spoT, indicating that multiple parallel pathways can lead to the same phenotypic outcome [21]. This network architecture ensures robustness in the bacterial stress response system.

Theoretical Framework for Bistability and Cooperation

Computational modeling reveals that the generic architecture of TA systems provides the potential for bistability—the ability to exist in one of two stable states under the same environmental conditions [63] [62]. Even when individual TA systems do not exhibit bistability alone, they can couple through the shared cellular growth rate to create a strongly bistable, hysteretic switch between normal (fast-growing) and persistent (slow-growing) states [62].

Table 1: Key Parameters Enabling Cooperation Between Diverse TA Systems

Parameter	Impact on System Cooperation	Experimental Evidence
Relative Switching Thresholds	Primary determinant of bistability; systems with proximal thresholds cooperate more effectively	Modeling shows different kinetic parameters can produce similar toxic switching thresholds [62]
Stochastic Fluctuations	Can spontaneously switch all TA systems in a cell simultaneously, creating heterogeneity	Stochastic models explain persister formation without external induction [63] [62]
Growth Rate Coupling	Dilution serves as the coordinating signal between unrelated TA systems	Models show growth rate links toxin concentration across systems [63]
Kinetic Diversity	Systems with varying parameters can still cooperate if thresholds are aligned	Study of unrelated TA systems with dramatically different kinetics [62]

This cooperative bistability explains the observed correlation between persister frequency and the number of TA system genes in a bacterium [63] [62]. When stochastic fluctuations trigger one TA system, the resulting decrease in growth rate reduces dilution of all toxins in the cell, potentially pushing other systems past their activation thresholds in a positive feedback loop that reinforces the persistent state.

Cross-Talk Between TA Modules

Evidence from C. crescentus demonstrates potential interaction between different hipBA modules. The toxicity of HipA1 or HipA2 can be counteracted by coexpression of HipB2 or HipB1, respectively, indicating that hipBA1 and hipBA2 modules can influence each other's phenotypic effects [21]. This cross-talk suggests that overexpression of one HipA toxin in a wild-type strain could coactivate other HipA kinases by binding to and titrating away the cellular supply of shared antitoxins [21].

Experimental Approaches for Dissecting Multiple TA Systems

Single-Cell Transcriptomics of Persister States

Recent advances in single-cell RNA sequencing (scRNA-seq) have enabled unprecedented resolution in characterizing persister cell states. A 2024 study generated a high-resolution single-cell RNA atlas of E. coli growth transitions, revealing that persisters from diverse genetic and physiological models converge to transcriptional states distinct from standard growth phases [64]. These persister states exhibit a dominant signature of translational deficiency, providing a unified view of the persistent phenotype despite originating from different TA systems and triggers.

The experimental workflow for persister characterization typically involves:

• Strain Engineering: Construction of mutants in key TA genes (e.g., metG*, hipA7) and deletion of multiple TA operons [21] [64]
• Controlled Cultivation: Use of chemostats to establish uniform exponential populations before inducing persistence [64]
• Persister Isolation: Antibicide treatment (e.g., ampicillin, ciprofloxacin) to kill non-persisters while preserving persisters [64]
• Single-Cell Analysis: Application of scRNA-seq (e.g., PETRI-seq) to capture transcriptional states of rare persister cells [64]
• Validation: Use of transcriptional fusions and mutant analysis to confirm marker gene expression [64]

Table 2: Quantitative Persistence Levels Across Bacterial Species and Conditions

Bacterial Species	Growth Phase	Antibiotic Challenge	Persistence Frequency	Key TA Systems Involved
Escherichia coli (wild-type)	Stationary	Ampicillin	0.01-0.02%	Multiple, including hipBA [64]
Escherichia coli (metG*)	Lag phase	Ampicillin	30-60%	metG mutation [64]
Escherichia coli (hipA7)	Lag phase	Ampicillin	~10%	hipA7 mutation [64]
Caulobacter crescentus	Stationary	Not specified	Significant reduction in ΔhipBA1,2,3	hipBA1, hipBA2 [21]
Pseudomonas putida	Not specified	Not specified	53x increase in ΔmqsA	mqsRA [65]
Burkholderia pseudomallei	Stationary	Various	10-64%	Multiple predicted systems [60]

Systematic Genetic Screening

Ultra-dense CRISPR interference (CRISPRi) screening enables comprehensive assessment of how every gene in a bacterium contributes to persister formation. A recent genome-wide CRISPRi screen in E. coli across three genetic models identified several critical genes with large effects on persistence, including lon protease and the previously uncharacterized yqgE [64]. This approach can identify which transcriptional markers of persisters are causal to their formation rather than merely correlative.

Computational Prediction and Data Mining

For organisms with numerous TA systems like Burkholderia pseudomallei (103 predicted toxin-like proteins), computational approaches enable prioritization of targets for experimental validation [60]. Methods include:

• PSI-BLAST searches against known toxin families
• Hidden Markov Model platforms like TASmania
• Transcriptional data repurposing to identify host-induced toxins
• Conservation analysis across strains to identify core persistence factors [60]

These computational methods have revealed that putative toxins with the strongest transcriptional response to host conditions often have low conservation between strains, while constitutively expressed toxins tend to be highly conserved [60].

Research Toolkit: Essential Reagents and Methodologies

Table 3: Key Research Reagent Solutions for TA System and Persistence Studies

Reagent/Method	Function/Application	Example Use Case
Kinase-dead Mutants (e.g., HipA D309Q)	Determining kinase-dependent effects; negative controls	Confirming HipA kinase activity is essential for persistence [21] [61]
Phos-tag Mobility Shift Assays	Detecting protein autophosphorylation	Validating HipA kinase activity in C. crescentus [21]
PETRI-seq	Prokaryotic single-cell RNA sequencing	Defining persister transcriptional states in E. coli [64]
CRISPRi Library	Genome-wide functional screening	Identifying novel persistence genes (lon, yqgE) [64]
Ectopic Expression Systems (e.g., arabinose-inducible)	Controlled toxin overexpression	Assessing toxicity and persistence induction [21] [61]
Bacterial Cytological Profiling	Visualizing morphological changes	Detecting filamentation in HipA3-expressing cells [21]

Visualization of TA System Interactions and Experimental Workflows

Cooperative Bistability in Multiple TA Systems

Integrated Experimental Workflow for Persister Research

Therapeutic Implications and Future Perspectives

The redundancy and cooperation between multiple TA systems present both challenges and opportunities for therapeutic development. Traditional antibiotic discovery has focused on killing rapidly growing cells, leaving persisters largely unaffected. New strategies that specifically target persistence mechanisms are needed to combat chronic and relapsing infections.

Promising approaches include:

• Combination therapies that simultaneously target multiple TA systems or their downstream effectors
• Anti-persister compounds that disrupt the cooperative bistability of TA networks
• Membrane-active agents that demonstrate superior activity against persisters [7]
• CRISPR-based technologies that could selectively eliminate persister cells [66]

The development of such therapies requires a systems-level understanding of how multiple TA systems interact and coordinate their activities. Future research should focus on mapping the complete network of TA interactions in clinically relevant pathogens, identifying master regulators that coordinate multiple systems, and developing quantitative models that predict how perturbations to one system affect the entire network.

Overcoming the functional redundancy of multiple TA systems represents a critical frontier in the battle against persistent bacterial infections. By leveraging advanced single-cell technologies, computational modeling, and systematic genetic approaches, researchers are beginning to decode the complex logic underlying bacterial persistence—paving the way for a new generation of antimicrobial therapies that can effectively target even the most recalcitrant bacterial cells.

Bacterial persistence describes a phenomenon in which a small subpopulation of genetically susceptible cells enters a transient, non-growing or slow-growing state, allowing them to survive exposure to high doses of antibiotics [2]. These bacterial persisters are increasingly recognized as a critical factor in treatment failure and recurrent infections. Research on high-persistence (hip) mutants, particularly those involving the hipA gene, has been fundamental to our understanding of this phenotype [23]. The hipA7 allele, for instance, increases persistence frequency by up to 10,000-fold compared to wild-type strains [23]. However, a significant challenge in comparing findings across studies is the lack of standardized methodologies for quantifying and characterizing persisters. Variations in experimental parameters such as antibiotic treatment duration, growth phase at the time of treatment, and the specific techniques used for persister enumeration can dramatically influence results [67]. This article provides a technical guide toward standardized, reproducible assays for studying bacterial persistence, with a specific focus on the context of hipA gene function research.

Core Concepts and Definitions: Establishing a Common Framework

A persistent cell is defined by its ability to survive lethal antibiotic exposure despite being genetically identical to and as drug-susceptible as its killed counterparts. After antibiotic removal, persisters can resume growth and give rise to a new population with the same antibiotic susceptibility profile as the original [2]. It is crucial to distinguish between antibiotic resistance and antibiotic tolerance. Resistance is the ability to grow in the presence of an antibiotic, typically measured by the Minimal Inhibitory Concentration (MIC), and is a stable, heritable genetic trait. In contrast, tolerance or persistence is the ability to survive antibiotic treatment without growing and is a non-genetic, transient phenotypic variant [2].

Two general types of persisters have been described [2]:

• Type I persisters are induced by external environmental cues, such as transition into stationary phase or nutrient starvation.
• Type II persisters are spontaneously generated during balanced growth through stochastic phenotypic switching.

The complex nature of persistence necessitates precise and consistent experimental design to ensure that data from different laboratories are directly comparable and reproducible.

Standardized Experimental Protocols for Persister Assays

Determining the Minimal Inhibitory Concentration (MIC)

The MIC must be determined for each bacterial strain and antibiotic combination to ensure appropriate treatment concentrations are used in persistence assays [68].

• Key Reagents: Cation-adjusted Mueller-Hinton broth, sterile saline (e.g., 0.85% NaCl or 10 mM MgSO4), antibiotic stock solution.
• Procedure:
  • Prepare a standardized inoculum from a fresh overnight culture, adjusting to a turbidity of 0.08-0.1 at OD625, equivalent to a 0.5 McFarland standard (~1.5 x 10^8 CFU/mL) [68].
  • Perform a 1:200 dilution of this suspension in growth medium to achieve a final density of approximately 5 x 10^5 CFU/mL.
  • Dispense 150 µL of the inoculum into wells of a 96-well plate.
  • Create a two-fold serial dilution series of the antibiotic in the inoculated wells.
  • Include growth control (no antibiotic) and sterility control (no inoculum) wells.
  • Incubate the plate for 16-20 hours at the appropriate temperature.
  • The MIC is defined as the lowest antibiotic concentration that completely inhibits visible growth, which can be quantified as an OD595 reading below 10% of the growth control well [68].

Time-Kill Assays for Establishing the Persister Plateau

The persister fraction is optimally quantified after antibiotic treatment has lasted long enough to eliminate the majority of the population and a survival plateau is observed [68].

• Procedure:
  • Grow cultures to the desired physiological state (e.g., mid-exponential or stationary phase).
  • Treat with an antibiotic concentration significantly above the MIC (typically 10x to 100x MIC) to ensure rapid killing of non-persister cells [68].
  • At predetermined time points, remove samples, wash to eliminate the antibiotic, perform serial dilutions, and plate on antibiotic-free solid media.
  • Count colony-forming units (CFUs) after incubation.
  • Plot the log of the surviving fraction against time. The point where the kill curve flattens, indicating a subpopulation dying at a much slower rate, defines the persister plateau [68].

Table 1: Key Parameters for Time-Kill Assays with Model Strains

Bacterial Strain	Antibiotic (Example)	Typical Treatment Concentration	Critical Experimental Consideration
E. coli BW25113	Amikacin	100 µg/mL (12.5x MIC)	A 24-hour incubation typically does not yield VBNC cells, simplifying persister counts [68].
E. coli MG1655	Ampicillin	200 µg/mL	Confirm absence of resistance by verifying unchanged MIC [23] [69].
E. coli MG1655 hipA7	Ampicillin/Ofloxacin	200 µg/mL / 5 µg/mL	Use as a high-persistence control; exhibits ~10,000-fold higher survival [23].

Quantifying Persister Fractions Using a Two-State Model

To enable robust comparisons across studies, persister fractions can be quantified using a mathematical model that treats the population as existing in two states: normal cells (N) and persister cells (P) [67]. In this model, normal cells die at a rate μ and switch to the persister state at a rate α upon antibiotic exposure. Persister cells are assumed not to die and can switch back to the normal state at a rate β. Fitting time-kill data to this model allows for the estimation of the initial persister fraction and the switching rates, providing a more reliable and characteristic measure of a strain's persistence level that is less dependent on arbitrary timepoint selection [67].

Specialized Techniques for hipA Mutant Research

Molecular Mechanism of HipA

A standardized understanding of HipA function is essential for interpreting assays involving hipA mutants. HipA is a serine-threonine kinase that phosphorylates a specific target, glutamyl-tRNA synthetase (GltX), at a conserved serine residue (Ser239) [13]. This phosphorylation event inhibits GltX's aminoacylation activity. The resulting accumulation of uncharged tRNA^Glu then triggers the stringent response via RelA, leading to the synthesis of the alarmone (p)ppGpp. Elevated (p)ppGpp levels mediate multidrug tolerance by downregulating cellular metabolism and growth, thereby inducing the persister state [13].

Diagram 1: HipA-induced persistence pathway.

Controlling for Artifacts in hipA Studies

When working with hipA mutants, particularly the common hipA7 allele, specific controls are necessary:

• Confirm Genotype: The hipA7 allele can be transferred between strains using P1 phage transduction, leveraging a linked selectable marker and a cold-sensitive growth phenotype for selection [23].
• Rule Out Resistance: Verify that the increased survival is due to tolerance and not resistance by confirming that the MIC of the hipA7 mutant is unchanged from the wild-type parent strain [23].
• Monitor Growth Defects: Some high-persistence mutants, including certain hipA alleles or transposon insertions in genes like metG, may exhibit extended lag phases or slightly reduced growth rates, which could indirectly influence survival in time-kill assays. These growth parameters should be characterized [23].

Advanced Methodologies for Mechanistic Insights

Advanced techniques allow for the monitoring of persister cell awakening and physiological changes at the single-cell level.

• Flow Cytometry with Protein Dilution: A method using an inducible fluorescent protein (e.g., mCherry) can track persister resuscitation. After induction and antibiotic treatment (e.g., with ampicillin), only non-growing, intact persister and VBNC cells retain high fluorescence. Upon transfer to fresh media without inducer, the dilution of fluorescence in dividing persisters can be tracked by flow cytometry, allowing calculation of resuscitation times and doubling times [70]. Studies using this method show that persisters resuscitate with the same doubling time as normal cells and can begin division within 1 hour of antibiotic removal [70].
• Metabolic Assays: Persister metabolism can be probed by exploiting the finding that metabolite-enabled killing by aminoglycosides requires metabolic activity to generate a proton motive force (PMF). By exposing persisters to various carbon sources in the presence of an aminoglycoside like kanamycin, the metabolic capabilities of different persister populations can be characterized in a high-throughput manner using phenotype microarrays [69]. This approach has identified glycerol and glucose as commonly used carbon sources by E. coli persisters [69].

Table 2: Essential Research Reagent Solutions for Persister Assays

Reagent / Material	Function / Application	Key Considerations
Antibiotic Inactivators (e.g., Penicillinase)	Neutralizes β-lactam antibiotics after treatment to allow persister outgrowth during plating [23].	Critical for accurate CFU enumeration after ampicillin treatment.
Metabolic Inhibitors (e.g., Sodium Arsenate)	Induces ATP depletion and enriches for persister cells by inhibiting growing populations [70].	Treatment can increase persister levels; removal may be required for effective lysis by ampicillin [70].
Viability Stains (e.g., SYTO9/PI)	Differentiates live from dead cells based on membrane integrity via fluorescence [69].	Does not distinguish between persisters and VBNC cells; must be coupled with culturability assays.
Inducible Fluorescent Reporters (e.g., P_{T5/lac}-mCherry)	Enables tracking of cell division and resuscitation at single-cell level via protein dilution [70].	Requires careful control of inducer (IPTG) concentration and timing.
Phenotype Microarrays (Biolog Plates)	High-throughput profiling of metabolic activity in persister cell populations [69].	Assay is based on aminoglycoside-potentiated killing linked to metabolism of specific carbon sources.

Diagram 2: Single-cell persister resuscitation workflow.

Standardized methodologies are the cornerstone of reproducible and meaningful research into bacterial persistence. The adoption of consistent protocols for determining MICs, performing time-kill assays, and quantifying persister fractions using mathematical models will significantly enhance the comparability of data across different laboratories. Furthermore, integrating mechanistic insights from hipA research with advanced single-cell techniques provides a powerful framework for elucidating the complex physiology of persister cells. As the field moves forward, a commitment to these standardized practices will accelerate the discovery of novel therapeutic strategies targeting persisters to improve the treatment of chronic and recurrent bacterial infections.

Clinical Evidence and System Comparisons: Validating hipA's Role in Infection

The hipA gene, a central component of the HipBA toxin-antitoxin (TA) system, represents a critical molecular determinant in the pathogenesis of persistent and recurrent urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC). This whitepaper synthesizes current evidence detailing the mechanisms by which HipA induces a multidrug-tolerant persister state, enabling bacterial survival during antibiotic chemotherapy and contributing to chronic infections. We provide a comprehensive analysis of HipA's molecular function, its regulation within TA modules, and the downstream cellular events that lead to dormancy. Furthermore, this guide consolidates experimental protocols for investigating hipA-mediated persistence and presents key reagent solutions to accelerate therapeutic development targeting bacterial persisters in clinical settings.

Urinary tract infections (UTIs) rank among the most common healthcare-associated infections, with a global pooled incidence of 1.6% according to a recent systematic review, and incidence rates can be as high as 3.6% in some regions such as Africa [71]. A significant clinical problem is the recurrent and relapsing nature of these infections, which are frequently caused by UPEC. A key bacterial strategy contributing to this recalcitrance is the formation of persister cells—dormant, metabolically quiescent bacterial subpopulations that exhibit remarkable tolerance to lethal concentrations of antibiotics without undergoing genetic resistance [2].

The hipA gene (high persister gene A) was the first bacterial gene identified to be associated with the persistence phenotype. The gain-of-function hipA7 allele was discovered in a clinical isolate of uropathogenic E. coli and found to increase persistence frequency by 100 to 1,000-fold [30] [23]. HipA functions as a serine-threonine kinase toxin in the type II HipBA TA system, where it is transcriptionally regulated by its antitoxin partner, HipB [30] [72]. Under normal conditions, HipA and HipB form a stable complex that represses the hipBA operon. Under stress conditions, degradation of the labile HipB antitoxin releases HipA, allowing it to exert its toxic effects and induce bacterial dormancy [73]. This molecular switch represents a sophisticated bacterial adaptation that facilitates survival during antibiotic exposure, making it a critical research focus in understanding and combating chronic UTIs.

Molecular Mechanisms of HipA-Mediated Persistence

Core Signaling Pathway and Cellular Targets

HipA orchestrates persistence through a precisely regulated molecular pathway that ultimately activates the bacterial stringent response. The diagram below illustrates this sequential process.

The core mechanism involves HipA's phosphorylation of glutamyl-tRNA synthetase (GltX) at a conserved serine residue (Ser239), which inhibits its aminoacylation activity and prevents the charging of tRNA^Glu^ with glutamate [13]. This results in the accumulation of uncharged tRNA^Glu^, which stimulates the ribosome-associated RelA to synthesize the alarmone (p)ppGpp [30] [13]. Elevated (p)ppGpp levels trigger the stringent response, a comprehensive physiological reprogramming that leads to growth arrest and dormancy, thereby rendering the cell tolerant to multiple antibiotic classes [2] [13].

Recent phylogenetic analyses have revealed substantial diversity in HipA homologues, with at least seven distinct kinase families identified across bacteria and archaea [30]. Some HipA homologues, such as HipT in pathogenic E. coli O127, target different aminoacyl-tRNA synthetases; HipT specifically phosphorylates and inhibits tryptophanyl-tRNA synthetase (TrpS) [30]. This suggests evolutionary diversification of the core persistence mechanism while maintaining the fundamental principle of disrupting translation and inducing the stringent response.

Transcriptional Signature of HipA-Induced Persisters

Single-cell RNA sequencing has recently enabled precise characterization of the persister state. Studies reveal that cells entering the HipA-mediated persister state converge to a transcriptional profile distinct from standard growth phases, exhibiting a dominant signature of translational deficiency [64]. This persister cluster is characterized by upregulation of specific markers including:

• rmf: Encoding a ribosome modulation factor associated with translational suppression
• mdtK: Encoding a putative drug efflux pump
• yhaM: Involved in cysteine detoxification
• cysK: Involved in cysteine biosynthesis [64]

Notably, this transcriptional state is consistent across different persistence models, including hipA7 mutants and metG mutants (affecting methionyl-tRNA synthetase), indicating a convergent physiological response to tRNA synthetase disruption [64].

Quantitative Data on HipA-Mediated Persistence Phenotypes

Survival Rates Under Antibiotic Exposure

Table 1: Persistence Frequencies in E. coli Strains Under Antibiotic Stress

Strain / Genotype	Persistence Frequency	Antibiotic Challenge	Reference
Wild-type E. coli	0.01-0.02%	Ampicillin / Ciprofloxacin	[64]
hipA7 mutant (gain-of-function)	30-60% survival	Ampicillin / Ciprofloxacin	[64]
metG mutant (C-terminal disruption)	~10,000-fold increase vs. wild-type	Ampicillin	[23]
E. coli with induced hipA expression	Strong tolerance, dose-dependent	Ofloxacin	[14]

Impact of HipA Induction on Bacterial Culturability and Dormancy

Table 2: Effects of Controlled hipA Expression on E. coli Physiological States

Induction Level (Arabinose)	Culturability	VBNC Formation	Persistence Level	Cellular Activity
Uninduced (control)	Normal growth	Minimal	Baseline (stationary phase increase)	High
Low (0.0002%)	Moderate reduction	Delayed (after 4h)	Increased	Moderately reduced
High (0.002%-0.02%)	Significantly reduced	Rapid (within 2h)	Strong tolerance to ofloxacin	Markedly decreased

Controlled induction of hipA using an arabinose-promoter system demonstrates that high-level expression rapidly decreases culturability within 2 hours and generates substantial populations of viable but non-culturable (VBNC) cells, suggesting a continuum of dormancy states where persisters may represent a shallow dormancy state and VBNCs constitute a deeper dormancy state [14].

Experimental Protocols for HipA Research

Protocol: Validating HipBA as a Functional TA System

The experimental workflow below outlines key steps for establishing a functional HipBA system in bacterial pathogens, adapted from methodology used in Acidovorax citrulli [73].

Detailed Methodology:

• Bioinformatic Identification: Search target bacterial genomes for hipA and hipB homologs using known sequences (e.g., E. coli K-12 HipA, UniProt P23874). Identify conserved domains: CouplehipA and HipAC domains in HipA; HTH_XRE DNA-binding domain in HipB [73].

• Co-transcription Assay: Extract total RNA from bacterial cultures and treat with DNase. Perform reverse transcription using random hexamers. Conduct PCR with primers spanning the intergenic region between hipB and hipA. Use genomic DNA as positive control and water as negative control. A successful amplification from cDNA confirms operon structure [73].

• Promoter Binding Assay: Express and purify recombinant HipB protein. Label DNA fragments containing the putative hipBA promoter region. Perform electrophoretic mobility shift assays (EMSAs) by incubating purified HipB with labeled promoter DNA. A mobility shift indicates specific binding and supports autoregulatory function [73].

• Toxin Toxicity and Neutralization: Clone hipA alone and hipA with hipB into inducible expression vectors. Transform into appropriate bacterial strains. Induce expression and monitor growth by OD~600~. Toxicity is demonstrated by growth inhibition upon hipA induction alone; neutralization is demonstrated by restored growth when both genes are induced [73].

• Stress Response Profiling: Grow bacterial cultures to mid-log phase and expose to stressors relevant to infection (e.g., antibiotic challenge, pH stress). Extract RNA at multiple time points and quantify hipA and hipB transcription using qPCR with appropriate housekeeping controls. Fold changes indicate stress-responsive regulation [73].

Protocol: Measuring Persistence Frequency via Kill Curves

This standardized method determines the proportion of cells surviving antibiotic exposure [23] [14].

• Culture Preparation: Grow bacterial strains to stationary phase under conditions relevant to the research question (e.g., in rich media like LB for basic studies, or in urine-mimicking media for UTI-focused research).

• Antibiotic Exposure: Dilute cultures and plate on solid agar media containing lethal concentrations of the antibiotic of interest (e.g., 100μg/mL ampicillin). Include appropriate controls.

• Time-Course Sampling: At designated time points (e.g., 0, 3, 6, 9, 12, 24 hours), spray plates with a neutralizing agent (e.g., penicillinase for ampicillin) to inactivate the antibiotic.

• Viability Assessment: Incubate plates for an additional period to allow surviving cells to form colonies. Count colony-forming units (CFUs) at each time point.

• Data Analysis: Calculate survival fraction as (CFU at time t)/(CFU at time 0). Plot survival fraction versus time to generate kill curves. Persistence frequency is typically reported as the survival fraction after 24 hours of exposure.

The Scientist's Toolkit: Key Research Reagents

Table 3: Essential Reagents for Investigating HipA-Mediated Persistence

Reagent / Tool	Specifications & Examples	Research Application	Key Function
hipA7 Mutant Strain	E. coli with S→A mutations in HipA catalytic domain	Persistence mechanism studies	Provides high-persistence phenotype for comparative studies
Inducible hipA Expression System	Plasmid with hipA under PBAD (arabinose-inducible) promoter [14]	Dose-response studies of toxin activity	Controlled induction of persistence; study of dormancy continuum
Anti-GltX (pSer239) Antibody	Phospho-specific antibody	Detection of HipA target engagement	Confirms HipA-mediated phosphorylation of GltX in vivo
(p)ppGpp Detection Kits	HPLC or LC-MS based quantification	Stringent response measurement	Downstream verification of HipA pathway activation
CRISPRi Persister Screening Library	Ultra-dense guide RNA libraries targeting all E. coli genes [64]	Genetic interaction studies	Genome-wide identification of persister-modifying genes
VBNC Detection Reagents	SYTO 9/propidium iodide or CTC/DPI for viability staining [14]	Dormancy depth assessment	Differentiates persisters from viable but non-culturable cells

Discussion and Therapeutic Implications

The molecular dissection of HipA function in UPEC reveals a sophisticated bacterial survival strategy with direct implications for UTI treatment failures. The HipA-mediated persistence pathway represents a compelling target for developing anti-persister therapeutics. Potential strategies include:

• HipA Kinase Inhibitors: Small molecules that block HipA's catalytic activity would prevent initiation of the persistence cascade.
• HipA-HipB Complex Stabilizers: Compounds that reinforce the toxin-antitoxin complex could prevent HipA release under stress.
• GltX-HipA Interaction Disruptors: Agents that interfere with the specific recognition of GltX by HipA.
• Persistence Reversal Agents: Molecules that stimulate resuscitation of persisters could render them susceptible to conventional antibiotics.

Recent genetic screens have identified several host factors that influence HipA-mediated persistence, including the Lon protease (which regulates antitoxin degradation) and YqgE (an uncharacterized protein that modulates dormancy duration) [64]. These represent additional layers of regulation that could be exploited therapeutically.

The continuum between actively growing cells, persisters, and VBNCs suggests that therapeutic strategies must account for different dormancy depths. The development of the Persistence-Culturability (PC) plot [14] provides researchers with an analytical tool to more accurately track these transitions in response to potential anti-persister compounds.

HipA stands as a paradigm for molecular mechanisms underlying bacterial persistence in urinary tract infections. Its function as a kinase that disrupts translation through targeted tRNA synthetase phosphorylation represents a conserved and effective strategy for antibiotic tolerance. Future research should focus on structural characterization of HipA complexes to enable rational drug design, in vivo validation of anti-persister compounds in UTI animal models, and epidemiological studies correlating hipA polymorphism diversity with clinical persistence outcomes. Addressing these priorities will accelerate the development of effective therapies against persistent and recurrent UTIs, ultimately improving patient outcomes in the face of escalating antibiotic challenges.

Bacterial persistence presents a formidable challenge in the treatment of chronic and recurrent infections. This phenomenon describes a scenario where a small, genetically susceptible subpopulation of bacteria survives antibiotic treatment by entering a transient, dormant state, only to resume growth once the treatment ceases [2] [58]. These bacterial persisters are now recognized as a critical factor in treatment failure and are distinct from resistant bacteria, which grow in the presence of antibiotics due to genetic mutations [58] [3]. Among the various molecular mechanisms underlying persistence, the hipA-mediated pathway, stringent response via (p)ppGpp, and biofilm-mediated tolerance represent three of the most significant and well-studied paradigms.

This review provides a comparative analysis of these mechanisms, with a specific focus on the hipA gene function in high-persistence mutants. We will dissect the molecular pathways, regulatory networks, and experimental approaches that define each mechanism, providing researchers with a structured framework for understanding and investigating bacterial persistence.

Molecular Mechanisms and Signaling Pathways

hipA-Mediated Persistence

The hipA (high persistence A) gene was the first persistence gene identified, discovered in E. coli via a mutant allele (hipA7) that increased persistence frequency 1,000 to 10,000-fold [6] [5]. hipA encodes the toxin component of the HipBA type II toxin-antitoxin (TA) module [35] [3].

• Core Mechanism: HipA is a serine/threonine kinase that phosphorylates glutamyl-tRNA synthetase (GltX). This phosphorylation inhibits GltX activity, leading to the accumulation of uncharged tRNA^Glu in the cell [35] [3].
• Downstream Signaling: The uncharged tRNA mimics amino acid starvation, activating the RelA protein, which in turn synthesizes the alarmone (p)ppGpp (guanosine tetra/pentaphosphate) [35]. This is a critical step, as HipA-induced persistence is dependent on (p)ppGpp. The elevated (p)ppGpp level does not induce persistence directly but acts hierarchically to cross-activate other TA-encoded mRNA interferases (mRNases) [35]. This cascade ultimately inhibits translation and induces a dormant, multidrug-tolerant state [35] [74].

The following diagram illustrates this interconnected pathway:

The Stringent Response and (p)ppGpp-Mediated Persistence

The stringent response is a universal bacterial stress adaptation mechanism centrally controlled by (p)ppGpp. This alarmone serves as a master regulator of persistence, integrating signals from various stressors [2] [75].

• Induction Pathways: (p)ppGpp synthesis is primarily triggered by nutrient starvation (e.g., amino acid, carbon, fatty acid). In E. coli, RelA responds to uncharged tRNAs, while SpoT synthesizes (p)ppGpp in response to other stresses like carbon starvation [75].
• Mechanism of Action: (p)ppGpp extensively reprograms transcription by binding to RNA polymerase. It downregulates genes for replication, transcription, and translation, and upregulates stress response and survival genes [75]. This reallocation of cellular resources leads to growth arrest and dormancy. Furthermore, (p)ppGpp can activate type II TA modules by a pathway proposed to involve polyphosphate and Lon protease, leading to antitoxin degradation and subsequent toxin-mediated growth inhibition [35] [75]. It is important to note that persistence can still form in the absence of ppGpp, but at significantly reduced levels, indicating that while it is a central hub, it is not the sole pathway [74].

Biofilm-Mediated Persistence

Biofilms are structured communities of bacteria encased in an extracellular matrix. They represent a protected growth mode that inherently fosters high levels of persistence [2] [58].

• Multifactorial Protection: The biofilm's extracellular matrix acts as a physical barrier, hindering the penetration of antibiotics and immune molecules [58].
• Microenvironment-Induced Dormancy: Critically, biofilms exhibit profound physiological heterogeneity. Gradients of nutrients and oxygen create microenvironments where bacteria in the inner core of the biofilm enter a dormant, slow-growing state [76] [58]. This dormancy is the primary driver of tolerance.
• Metabolic Adaptations: Bacteria in biofilms often show downregulated metabolic pathways, such as the tricarboxylic acid (TCA) cycle, which helps reduce the production of reactive oxygen species (ROS), a common mediator of antibiotic lethality [12] [58]. The biofilm environment also activates other persistence mechanisms, including the stringent response and TA systems, creating a multi-layered defense [2].

Quantitative Comparison of Persistence Mechanisms

The table below summarizes and contrasts the key characteristics of the three persistence mechanisms.

Table 1: Comparative Summary of hipA, (p)ppGpp, and Biofilm Persistence Mechanisms

Feature	hipA-Mediated Persistence	(p)ppGpp-Mediated Persistence	Biofilm-Mediated Persistence
Key Inducer/Regulator	HipA toxin (kinase)	(p)ppGpp alarmone	Extracellular matrix & microenvironment
Primary Trigger	Stochastic expression or mutation (e.g., hipA7)	Nutrient starvation, stress signals	Surface attachment, community signaling
Core Action	Inhibits GltX, triggers (p)ppGpp synthesis	Reprograms transcription, inhibits growth	Creates physical barrier & induces dormancy
Persistence Level	Very high (up to 1-10% with hipA7 mutant) [5]	High	High (up to 1% or more) [58]
Dependence on (p)ppGpp	Absolutely required [35]	Core component	Often associated, but not absolute
Relationship with TA Systems	Direct (HipBA is a TA module)	Activates multiple TA modules [35]	Can harbor bacteria with active TA systems
Metabolic State	Dormant, translation inhibited	Dormant, growth arrested	Heterogeneous: dormant core, active periphery

Essential Research Reagents and Methodologies

Studying persisters requires specific tools and assays due to their low abundance and transient phenotype. The following table lists key reagents and their applications in persistence research.

Table 2: Research Reagent Solutions for Investigating Persistence

Research Reagent / Tool	Function/Description	Application Example
hipA7 Mutant Strain	An E. coli mutant with two amino acid substitutions (G22S, D291A) in HipA, leading to high persistence frequency [5].	Model system for studying high-persister mutants and HipA function [12] [74].
ASKA ORF Library	A complete set of E. coli open reading frames (ORFs) cloned into expression plasmids [74].	Genome-wide screening for genes that induce persistence upon overexpression [74].
RelA/SpoT Mutants	Strains deficient in (p)ppGpp synthesis (e.g., ΔrelA ΔspoT).	Elucidating the role of the stringent response in persistence independent of other stresses [74] [75].
Lon Protease Mutant	Strain deficient in ATP-dependent Lon protease.	Investigating the proposed pathway of (p)ppGpp-polyphosphate-Lon mediated antitoxin degradation [35] [74].
Flow Cytometry & Sorting	Technology for analyzing and isolating individual cells based on size, granularity, or fluorescence.	isolating persister cells from a larger population for downstream "omics" analysis [58].
Microfluidic Devices	Chips that allow for environmental control and single-cell imaging over time.	Monitoring the formation and resuscitation of persisters in real-time at the single-cell level [5].

Core Experimental Protocol: hipA Interaction with the Stringent Response

Objective: To validate that HipA-induced persistence depends on (p)ppGpp and cross-activation of other TA modules.

Key Methodology:

• Strain Construction: Generate a set of isogenic E. coli strains:
  • Wild-type (WT)
  • ΔrelA (unable to produce (p)ppGpp in response to HipA)
  • Δ10TA (deleted for 10 mRNase-encoding TA modules) [35]
• hipA Expression: Introduce an inducible plasmid (e.g., pBAD-hipA) into all strains to allow controlled HipA toxin production.
• (p)ppGpp Quantification: Use thin-layer chromatography (TLC) or HPLC to measure intracellular (p)ppGpp levels before and after induction of hipA in the WT and mutant backgrounds [35].
• Persistence Assay:
  • Grow cultures to mid-exponential phase.
  • Induce hipA expression for a set period.
  • Treat cultures with a high concentration of a bactericidal antibiotic (e.g., 100x MIC of ciprofloxacin or ampicillin) for several hours.
  • Determine the number of surviving cells (CFU/mL) by plating serial dilutions onto drug-free LB agar after washing away the antibiotic. The surviving fraction represents persisters [35] [74].
• Expected Outcome: HipA expression in the WT strain should cause a surge in (p)ppGpp and a high persister count. The ΔrelA and Δ10TA strains should show no or significantly reduced persistence upon HipA induction, confirming the hierarchical dependency [35].

The hipA-mediated pathway, the broad stringent response, and the structured biofilm environment represent distinct yet interconnected strategies bacteria employ to survive antibiotic treatment. hipA functions as a specific, potent trigger that hijacks the general stress response network centered on (p)ppGpp, which in turn amplifies the signal through a cascade of TA systems. Biofilms provide a physical and physiological niche where these molecular mechanisms can be optimally induced and maintained.

Understanding these nuanced differences and interactions is paramount for drug development. Targeting the HipA kinase activity or its interaction with GltX could specifically disarm high-persister mutants. Disrupting the (p)ppGpp signaling network represents a broader strategy to sensitize persisters derived from multiple pathways. For biofilm-related infections, combining antibiotics with matrix-degrading enzymes or metabolite adjuvants that reawaken dormant cells ("wake and kill") show significant therapeutic promise [76]. Future research leveraging single-cell technologies and high-throughput screening will continue to unravel the complexity of bacterial persistence, guiding the development of novel therapies to eradicate chronic, relapsing infections.

The hipA gene, encoding the toxin component of the HipBA toxin-antitoxin module, represents a pivotal genetic determinant in bacterial multidrug tolerance. While historically studied through laboratory-derived alleles like hipA7, recent genomic investigations confirm that high-persistence hipA mutants exist in natural and clinical settings. This whitepaper synthesizes current evidence on the distribution, mutational hotspots, and functional consequences of hipA mutations, framing them within the broader thesis of HipA's role in bacterial survival. We provide a detailed analysis for researchers and drug development professionals, consolidating genotypic and phenotypic data into actionable insights and standardized experimental workflows to advance the field.

Bacterial persistence is a phenomenon of phenotypic heterogeneity wherein a small, dormant subpopulation of a genetically susceptible culture survives exposure to lethal concentrations of antibiotics [77] [2]. These persister cells are not resistant; upon antibiotic removal, they resume growth, and their progeny regain susceptibility. This state is a significant contributor to chronic and recurrent infections and a major obstacle in antimicrobial therapy [2].

The hipA (high persistence) gene was the first genetic locus identified to be linked to this phenotype. The HipBA system is a Type II toxin-antitoxin (TA) module where HipB is the antitoxin that sequesters and neutralizes the HipA toxin, a serine/threonine kinase [77] [4]. Under normal conditions, the HipA-HipB complex represses the hipBA operon's transcription. Stochastic fluctuations or stress-induced events can lead to HipA release, triggering a cascade that results in bacterial dormancy [13].

The central thesis of ongoing hipA research posits that this gene is a critical regulator of the entry into a persistent state. Mutations in hipA can disrupt the delicate balance of the TA system, leading to a high-persistence (Hip) phenotype, characterized by a dramatically increased frequency of persister cells in a population [77] [4]. This whitepaper explores the genetic landscape of these mutants beyond laboratory models, focusing on their emergence in clinical and environmental settings.

Mutational Spectrum and Clinical Prevalence of hipA Alleles

The classic laboratory-derived hipA7 allele, containing two point mutations (G22S and D291A), has long been a model for persistence research [77] [4]. Recent sequencing efforts confirm that such high-persistence mutants are not confined to the laboratory but are selected for in natural environments, including human infections.

Key Mutations and Their Frequencies

A targeted screening of a large library of E. coli isolates provides concrete evidence for the clinical relevance of hipA mutants. The table below summarizes identified mutants and their prevalence.

Table 1: Clinically Identified hipA Mutants in E. coli

hipA Allele	Amino Acid Substitution(s)	Prevalence in Clinical Isolates	Phenotype
hipA7	G22S and D291A	23 out of 477 isolates [4]	High Persistence [77]
hipA (P86L)	P86L	1 out of 477 isolates [4]	High Persistence [4]
hipA (D88N)	D88N	Identified in prior laboratory screen [4]	High Persistence [4]

Mapping Mutational Hotspots and Functional Impact

A striking pattern emerges from the mapping of these high-persistence mutations: they predominantly cluster in the N-subdomain-1 of the HipA protein, a region distant from its active kinase site [4]. Structural biology studies have revealed that in the higher-order HipA-HipB-promoter complex, HipA molecules form dimers via interactions through this N-subdomain-1. This dimerization occludes their active sites, thereby inactivating the kinase [4]. The high-persistence mutations (e.g., G22S, P86L, D88N) are proposed to disrupt HipA-HipA dimerization, facilitating the release of active HipA toxin, which then drives cells into dormancy and confers the multidrug-tolerant phenotype [4]. This mechanism explains how mutations far from the active site can profoundly alter the protein's regulatory function.

Furthermore, genome-wide scans of diverse E. coli populations, such as those from wastewater treatment plants, have identified the hipA gene as being under positive selection [78]. This indicates a selective pressure in these environments that favors mutations enhancing persistence, underscoring the adaptive significance of the Hip phenotype.

Core Molecular Mechanisms: From hipA Activation to Dormancy

The primary molecular mechanism by which HipA induces growth arrest and persistence has been elucidated. HipA is a kinase that specifically phosphorylates glutamyl-tRNA synthetase (GltX) at a conserved serine residue (Ser239) [13].

The HipA-GltX-(p)ppGpp Persistence Pathway

The following diagram illustrates the established signaling pathway from HipA activation to persistence.

Diagram Title: HipA Induces Dormancy via GltX and (p)ppGpp

This pathway operates as follows:

• Toxin Activation: Free HipA (not sequestered by HipB) phosphorylates GltX, inhibiting its aminoacylation function [13].
• Signal Generation: Inhibition of GltX leads to an accumulation of uncharged tRNAᴹⁱˢˢᵉᵈ in the ribosomal A-site.
• Alarmone Induction: The presence of uncharged tRNA triggers the stringent response, activating RelA to synthesize the alarmone (p)ppGpp [13].
• Dormancy Entry: The surge in (p)ppGpp levels globally reprograms cellular metabolism, halting growth and leading to a dormant, antibiotic-tolerant state [13].

This mechanism is distinct from the action of other TA toxins like RelE and MazF, which directly cleave mRNA, and underscores HipA's unique role as a meta-regulator of cellular physiology [77].

Essential Methodologies for hipA Phenotype Validation

To establish the high-persistence phenotype of a hipA mutant, researchers must employ a combination of molecular genetics and careful phenotypic assays. The following protocols are foundational to the field.

Protocol: Determination of Persister Frequency via Killing Curves

This protocol quantifies the subpopulation of cells that survive a lethal antibiotic challenge [77] [79].

• Principle: Exposure to a high concentration of a bactericidal antibiotic results in biphasic killing, where the initial rapid kill of the majority population is followed by a plateau of surviving persisters.
• Procedure:
  • Culture Preparation: Grow the bacterial strain of interest (e.g., wild-type and hipA mutant) to the desired growth phase (e.g., mid-exponential or stationary phase).
  • Antibiotic Challenge: Add a lethal concentration of antibiotic (typically 10–100x the MIC) to the culture. For example, 100x MIC of ampicillin or levofloxacin is commonly used [77] [79].
  • Viable Count: At time zero (immediately before antibiotic addition) and at regular intervals thereafter (e.g., 1, 3, 5, 24 hours), remove aliquots. Wash the cells by centrifugation and resuspension in phosphate-buffered saline (PBS) or fresh medium to remove the antibiotic. Serially dilute and plate onto non-selective agar plates [79].
  • Calculation: After incubation, count the colony-forming units (CFU). The persister frequency is calculated as the number of CFU/mL at time t (e.g., 24 hours) divided by the number of CFU/mL at time zero.
• Key Consideration: Confirmation that the surviving cells are persisters, and not resistant mutants, is crucial. This is done by re-streaking survivors and confirming that the new culture exhibits the same antibiotic susceptibility (MIC) and persistence profile as the parent strain [2].

Protocol: Validating the Molecular Impact via Ectopic Overexpression

This assay directly tests the toxicity and persistence-inducing capability of a hipA allele [77].

• Principle: Cloning the hipA gene under an inducible promoter (e.g., PBAD arabinose-inducible) allows for controlled expression. Wild-type hipA overexpression typically inhibits macromolecular synthesis and induces a reversible dormant state in most cells, while mutant alleles may show altered toxicity and persistence profiles.
• Procedure:
  • Strain and Plasmid Construction: Clone the wild-type or mutant hipA gene into a plasmid with an inducible promoter (e.g., pBAD24 or pBAD33). Transform the construct into a suitable E. coli strain, ideally with the chromosomal hipBA locus deleted.
  • Induction of Toxicity: Grow the transformed strain to mid-exponential phase and induce hipA expression with the appropriate inducer (e.g., 0.2% arabinose).
  • Monitor Growth Arrest: Monitor the culture's optical density (OD600) over time. Induction of functional HipA will cause a rapid plateau or decrease in OD, indicating growth arrest [77] [40].
  • Assay for Resuscitation: After a period of arrest (e.g., 3-5 hours), wash the cells to remove the inducer and resuspend them in fresh medium. The ability of the culture to resume growth demonstrates the reversibility of the HipA-induced dormancy. Co-expression of the antitoxin gene hipB should immediately reverse the arrest [77].

The Scientist's Toolkit: Key Research Reagents

The following table compiles essential materials and reagents used in foundational hipA research, as cited in the literature.

Table 2: Research Reagent Solutions for hipA Studies

Reagent / Tool	Function in Research	Example Use Case
pBAD33_hipA Plasmid	Ectopic, arabinose-inducible expression of hipA [40].	Validating toxicity and growth arrest phenotypes of wild-type and mutant hipA [77] [40].
hipA7 Mutant Allele	A well-characterized high-persistence allele (G22S, D291A) [77].	Used as a positive control in persistence assays and to study the molecular basis of the Hip phenotype [77] [4].
pTAC24hipB / pTAC29hipB	Ectopic, IPTG-inducible expression of the antitoxin hipB [77].	Reversing HipA-induced growth arrest and confirming TA system specificity [77].
E. coli BW25113	A common K-12 derivative strain used for genetic studies [40].	Serving as a host for knockout libraries and physiological studies of persistence [40].
Lethal-dose Antibiotics (e.g., Ampicillin, Levofloxacin, Ciprofloxacin at 10-100x MIC)	Selecting for and quantifying the persister subpopulation [77] [79].	Performing time-kill curves to measure persister frequency in mutant versus wild-type strains [77] [79].

Discussion and Future Perspectives

The confirmation of hipA mutants in clinical isolates solidifies the relevance of this TA module in real-world infection scenarios, particularly in chronic and biofilm-associated diseases like urinary tract infections [4]. The clustering of mutations in the N-subdomain-1 provides a compelling structural rationale for the Hip phenotype and suggests this interface as a potential target for anti-persister therapeutics.

Future research must expand genomic surveillance to a wider range of bacterial pathogens and infection types to fully appreciate the prevalence and diversity of clinically relevant hipA alleles. Furthermore, the intriguing concept of cellular memory, wherein previous exposure to HipA-induced dormancy shortens the growth arrest period upon subsequent induction, adds a layer of complexity to the phenotype and warrants deeper mechanistic investigation [40].

From a therapeutic standpoint, targeting the HipA-HipA dimerization interface to stabilize the inactive complex could be a novel strategy to "re-sensitize" high-persister mutants to conventional antibiotics. The integration of hipA mutation screening into clinical diagnostics, while futuristic, could one day inform treatment regimens for persistent infections, moving the field closer to personalized antimicrobial therapy.

Bacterial persistence, a phenomenon of reversible antibiotic tolerance, poses a significant challenge in treating chronic and recurrent infections. The hipA (high persistence A) gene represents a pivotal discovery in understanding the genetic basis of this phenotype. This review examines the molecular mechanisms by which hipA promotes multidrug tolerance and its profound implications for treatment outcomes. We synthesize current research demonstrating how hipA activation triggers cellular dormancy through stringent response pathways, analyze emerging therapeutic strategies targeting HipA-mediated persistence, and provide technical resources for investigating this clinically significant phenotype. The evidence underscores that HipA-mediated persistence substantially contributes to treatment failure and infection relapse, necessitating novel therapeutic approaches that address this tolerance mechanism.

Bacterial persisters are non-growing or slow-growing cells that survive antibiotic exposure without genetically acquired resistance and can regrow once treatment ceases, leading to relapsing infections [2]. First documented by Bigger in 1944 when a subpopulation of Staphylococcus aureus survived penicillin exposure, persisters have since been recognized as major contributors to chronic and biofilm-associated infections that are difficult to eradicate [23] [5]. The hipA gene was the first genetic element identified to directly influence persistence frequency when Moyed and Bertrand isolated hipA7 mutant E. coli exhibiting dramatically increased survival under antibiotic pressure [6] [5]. This seminal discovery opened molecular investigation into persistence mechanisms and revealed HipA's central role in mediating multidrug tolerance through toxin-antitoxin system function [54].

HipA-mediated persistence presents distinct therapeutic challenges compared to conventional antibiotic resistance. While resistance enables growth at elevated antibiotic concentrations through specific mechanisms that neutralize drugs, persistence involves transient phenotypic tolerance across multiple antibiotic classes without changing minimum inhibitory concentrations (MIC) [80]. This tolerance arises from dormant cellular states where antibiotics targeting active metabolic processes become ineffective. Understanding HipA's molecular function is therefore crucial for addressing treatment failures in chronic infections including tuberculosis, recurrent urinary tract infections, and biofilm-associated device infections where persisters contribute significantly to relapse rates and therapeutic recalcitrance [2].

Molecular Mechanisms of HipA-Mediated Persistence

HipA as a Bacterial Kinase in Toxin-Antitoxin Systems

HipA functions as a eukaryote-like serine-threonine kinase in a type II toxin-antitoxin (TA) module with its cognate antitoxin HipB [13] [30]. In the canonical E. coli K-12 system, HipA and HipB form an inactive HipA₂B₂ heterotetrameric complex that autoregulates transcription by binding operator sequences in the hipBA promoter region [30]. Under stress conditions, degradation of the unstable HipB antitoxin liberates HipA to exert its toxic effects on cellular targets [30]. The hipA7 allele, containing two missense mutations (G22S and D291A), represents a gain-of-function variant that produces a 100- to 1,000-fold increase in persistence frequency compared to wild-type strains [54] [30].

Molecular Targets and Stringent Response Activation

HipA mediates persistence through targeted phosphorylation of essential cellular components:

• GltX Inactivation: HipA phosphorylates glutamyl-tRNA synthetase (GltX) at conserved Ser239, inhibiting its aminoacylation activity and preventing tRNA⁶ˡᵘ charging [13]. This phosphorylation event occurs specifically when GltX is bound to tRNA⁶ˡᵘ, exploiting the conformational changes that expose the target serine residue [13].

• Stringent Response Induction: Uncharged tRNA⁶ˡᵘ accumulation activates RelA via ribosomal A-site binding, triggering (p)ppGpp synthesis [13] [30]. This alarmone signaling molecule redirects cellular resources by profoundly suppressing ribosomal RNA synthesis and translation while promoting stress adaptation programs [30].

• Cellular Dormancy: The resulting stringent response leads to growth arrest and dormancy, creating a population of antibiotic-tolerant persister cells [30]. This mechanistic pathway explains how HipA activation translates into the phenotypic tolerance that characterizes persisters.

Table 1: Key Molecular Events in HipA-Mediated Persistence

Molecular Event	Biological Consequence	Persistence Outcome
HipB antitoxin degradation	HipA toxin release	TA system activation
GltX phosphorylation at Ser239	Inhibition of Glu-tRNA⁶ˡᵘ synthesis	tRNA⁶ˡᵘ charging defect
Uncharged tRNA⁶ˡᵘ accumulation	RelA activation on ribosomes	(p)ppGpp synthesis
(p)ppGpp elevation	Stringent response initiation	Growth arrest & dormancy
Translational suppression	Metabolic shutdown	Multidrug tolerance

Figure 1: HipA-Mediated Persistence Pathway. Cellular stress triggers HipB antitoxin degradation, freeing HipA to phosphorylate GltX. This inhibits tRNA⁶ˡᵘ charging, activating RelA and (p)ppGpp synthesis, ultimately inducing dormancy and antibiotic tolerance.

HipA Homologs and Functional Diversity

Genomic analyses reveal substantial diversity in HipA-homologous kinase systems across bacterial species:

• Tricistronic hipBST Operons: Found in pathogenic E. coli O127, where HipT phosphorylates tryptophanyl-tRNA synthetase (TrpS) rather than GltX, with HipS serving as the primary antitoxin and HipB augmenting neutralization [30].

• Monocistronic Operons: Including yjjJ in E. coli K-12, which lacks an adjacent antitoxin gene but contains an N-terminal HTH domain potentially enabling autoregulation [30].

• Expanded Kinase Families: Phylogenetic studies identify seven novel Hip kinase families in bacteria and archaea, some incorporating HIRAN domains for DNA binding and others with unique antitoxin combinations [30].

This phylogenetic diversity demonstrates the evolutionary expansion of HipA-like persistence mechanisms across microbial lineages, with different kinases targeting distinct aminoacyl-tRNA synthetases to achieve similar persistence outcomes through convergent stringent response activation.

Experimental Approaches for hipA Research

Persistence Detection and Quantification Methods

Research on HipA-mediated persistence employs specialized methodologies to distinguish tolerance from resistance:

• Kill Curve Assays: Stationary phase cultures are plated on antibiotic-containing agar, with penicillinase applied at designated intervals to inactivate antibiotics at specific time points [23]. Survival fractions are calculated relative to initial cell counts, generating biphasic killing curves where the initial steep slope represents death of normal cells and the flatter secondary slope indicates persister survival [23] [80].

• Minimum Inhibitory Concentration (MIC) Testing: Essential for distinguishing persistence from resistance, as hipA mutants maintain wild-type MIC values despite dramatically increased survival under antibiotic exposure [23].

• Fluorescence-Based Sorting: Using promoter-GFP fusions or dye staining to isolate and characterize rare persister subpopulations from heterogeneous cultures.

Table 2: Quantitative Persistence Metrics in hipA Mutants

Bacterial Strain	Persistence Frequency*	MIC (Ampicillin)	Key Characteristic
Wild-type E. coli	10⁻⁶ to 10⁻⁵	Unchanged	Baseline persistence
hipA7 mutant	10⁻² (10,000-fold increase)	Unchanged	Classic high-persistence mutant
metG::Tn mutant	~10⁻² (10,000-fold increase)	Unchanged	C-terminal disruption
tktA::Tn mutant	~100-fold increase	Unchanged	Metabolic flux alteration
glpD::Tn mutant	~100-fold increase	Unchanged	G3P dehydrogenase disruption

Persistence frequency measured as survival fraction after antibiotic exposure [23]

Genetic Selection and Screening Approaches

• Transposon Mutagenesis Libraries: High-density transposon-insertion mutant libraries are subjected to multiple rounds of lethal antibiotic selection (typically ampicillin), followed by microarray-based genetic footprinting to identify loci affecting persistence frequency [23]. This approach revealed that ~50 genetic loci can dramatically increase persistence when disrupted, indicating a large mutational target size for persistence [23].

• Computational Drug Screening: Structure-based virtual screening against HipA kinase domains identifies potential inhibitors, with subsequent validation through surface plasmon resonance (SPR) binding assays and ex vivo persistence reduction tests [54].

Therapeutic Implications and Intervention Strategies

Impact on Treatment Outcomes and Resistance Development

HipA-mediated persistence directly compromises antibiotic efficacy in clinical settings:

• Infection Relapse: Persisters survive antibiotic treatment and regenerate the infection once therapy ceases, causing recurrent cycles of apparent clearance followed by symptom return [2]. This pattern is particularly problematic in biofilm-associated infections where bacterial communities generate high persister frequencies [2].

• Resistance Acceleration: Recent evidence indicates that tolerance promotes resistance development by providing a larger surviving population in which resistance mutations can emerge during extended antibiotic exposure [80]. This creates a dangerous progression from transient tolerance to stable genetic resistance.

• Treatment Failure Cases: Clinical isolates from persistent infections show elevated frequencies of hipA mutants and related high-persistence phenotypes, directly linking this mechanism to recalcitrant infections in human patients [2] [5].

Anti-Persister Therapeutic Approaches

Novel strategies specifically target HipA function and persistence mechanisms:

• HipA Kinase Inhibitors: Structure-based screening identified compounds like PKUMDL-LTQ-401 that bind HipA with nanomolar affinity (Kᴅ = 35 ± 2 μM) and reduce persistence 2-3 fold at 250 μM concentration [54]. The most potent inhibitor, PKUMDL-LTQ-301, exhibits Kᴅ of 270 ± 90 nM and reduces E. coli persistence by approximately 5-fold [54].

• Metabolic Stimulation: Awakening persisters from dormancy using metabolites or nutrient pulses renders them susceptible to conventional antibiotics, particularly aminoglycosides [23]. This approach exploits the continued low-level translation in persisters to facilitate antibiotic uptake and activity.

• Combination Therapies: Simultaneously targeting growth and persistence mechanisms through drug combinations that kill both dividing cells and dormant persisters [2]. This mirrors the successful tuberculosis treatment strategy where pyrazinamide targets non-replicating persisters while other drugs act on growing populations [2].

Figure 2: Therapeutic Strategies Against HipA-Mediated Persistence. Multiple approaches target different aspects of persistence, including direct HipA inhibition, metabolic activation of dormant cells, combination therapies, and anti-virulence compounds that prevent persistence formation.

Research Reagents and Methodological Toolkit

Table 3: Essential Research Reagents for HipA-Persistence Investigations

Reagent/Cell Line	Key Features	Research Applications
E. coli MG1655 hipA7	Contains G22S and D291A mutations in hipA	Gold standard high-persistence strain for kill curve assays
E. coli ΔhipA	Complete hipA knockout	Control for HipA-specific effects in persistence studies
HipA(D309Q) mutant protein	Catalytically inactive, binds ATP (Kᴅ = 43 ± 2 μM)	SPR binding studies and inhibitor screening
Anti-(p)ppGpp antibodies	Detect stringent response activation	Measure HipA pathway activity via immunoassays
GltX S239A mutant	Phosphorylation-resistant variant	Elucidate HipA-GltX signaling specificity
[³²P]-ATP	Radiolabel for kinase assays	Measure HipA phosphorylation activity in vitro
PKUMDL-LTQ-301 compound	HipA inhibitor (Kᴅ = 270 ± 90 nM)	Experimental anti-persister therapeutic agent

HipA-mediated persistence represents a significant therapeutic challenge with profound implications for treatment outcomes across chronic and biofilm-associated infections. The molecular dissection of HipA function has revealed a sophisticated cellular strategy where targeted protein phosphorylation triggers comprehensive physiological reprogramming toward dormant, antibiotic-tolerant states. Understanding this mechanism provides critical insights for developing more effective therapeutic approaches against persistent infections.

Future research priorities include elucidating the structural basis of HipA interaction with its diverse targets, mapping the complete regulatory network controlling HipA activation and resuscitation, and translating inhibitor discoveries into clinical candidates with appropriate pharmacological properties. The expanding phylogenetic diversity of HipA homologs suggests this persistence mechanism is widespread among bacterial pathogens, necessitating broader investigation across clinically relevant species. Combining anti-persister compounds with conventional antibiotics represents a promising strategy to address both susceptible populations and tolerant persisters, potentially reducing treatment failure and resistance development. As our understanding of HipA biology deepens, so too will our capacity to overcome the therapeutic challenges posed by bacterial persistence.

The hipA gene represents a cornerstone in the study of bacterial persistence, a phenomenon of profound evolutionary and clinical significance. Initially identified in Escherichia coli through a mutant allele (hipA7) that conferred a 1,000-fold increase in multidrug tolerance, HipA was the first protein linked to the persistence phenotype [4] [6]. Persisters are dormant bacterial cells that exhibit transient, non-genetic tolerance to antibiotic treatments, complicating the eradication of chronic and recurrent infections [2]. This in-depth technical guide synthesizes current research on the HipA toxin, framing its function within the broader context of bacterial survival strategies and evolutionary adaptation. We detail the molecular mechanisms underpinning HipA-mediated persistence, explore its clinical relevance, and provide a comprehensive toolkit for researchers and drug development professionals engaged in combating antibiotic tolerance.

Molecular Mechanism of HipA-Mediated Persistence

Core Function: A Toxin in a Type II Toxin-Antitoxin System

HipA functions as the toxin component in the hipBA type II toxin-antitoxin (TA) module [4]. In this system, the HipB antitoxin protein forms a stable complex with HipA, neutralizing its toxicity and maintaining the cell in a growth-permissive state. The TA complex also acts as an auto-repressor, binding to the hipBA promoter to regulate its own transcription [4]. Under stress conditions, proteases such as Lon preferentially degrade the labile HipB antitoxin, freeing HipA to act on its cellular targets and induce a state of growth arrest [81].

Primary Target: Inhibition of Glutamyl-tRNA Synthetase

The pivotal discovery that reshaped the understanding of HipA's function was the identification of glutamyl-tRNA synthetase (GltX) as its primary cellular target [13] [25]. HipA is a serine/threonine kinase that phosphorylates GltX at a conserved serine residue (Ser239) located near the enzyme's active site [13]. This post-translational modification effectively inhibits GltX's aminoacylation activity, preventing the charging of tRNA^Glu^ with glutamate and leading to an accumulation of uncharged tRNA^Glu^ in the cell [25].

Downstream Signaling: Triggering the Stringent Response

The accumulation of uncharged tRNA^Glu^ is a potent physiological signal interpreted by the cell as nutrient starvation. This uncharged tRNA binds to and activates the RelA enzyme, which in turn synthesizes the alarmone (p)ppGpp [13] [25]. Elevated levels of (p)ppGpp initiate the stringent response, a global reprogramming of cellular metabolism that results in a dramatic downshift in growth rate and the arrest of essential processes like transcription, translation, and DNA replication [13] [2]. This induced dormancy is the direct cause of the multidrug tolerance observed in persister cells.

The following diagram illustrates this core signaling pathway:

Structural Biology and High-Persistence Mutants

Mechanisms of HipA Activation

Structural studies of higher-order HipA-HipB-promoter complexes have revealed the mechanistic basis for the regulation of HipA activity and the emergence of high-persistence (Hip) mutants. In the native complex, HipA molecules are held in an inactive state through dimerization via their N-subdomain-1 [4]. This dimerization occludes their active sites, preventing unintended toxicity [4].

Notably, classic high-persistence mutations such as G22S, P86L, and D88N map precisely to this N-subdomain-1 dimerization interface [4]. These mutations destabilize HipA-HipA dimerization, thereby unleashing the kinase activity of HipA and leading to a higher frequency of persister formation. This structural insight explains how these mutants, though far from the active site, confer a dominant Hip phenotype.

Clinical Relevance of Hip Mutants

The evolutionary success of HipA-mediated persistence is evidenced by the isolation of hipA mutants from clinical settings. Notably, sequencing of E. coli isolates from patients with recurrent urinary tract infections (UTIs) has identified the presence of both the classic hipA7 allele and the hipA(P86L) mutant [4]. Deletion of the hipA7 allele from a clinical UTI isolate resulted in a sharp decline in antibiotic tolerance, confirming its functional role in a clinically relevant infection model [4]. This demonstrates that hipA mutations are selected for in natural environments where antibiotic pressure is a key selective force.

Table 1: Characterized High-Persistence (Hip) Mutants of HipA

Mutant Allele	Amino Acid Substitution(s)	Molecular Consequence	Persistence Phenotype
hipA7	G22S, D291A	Diminished HipA-HipA dimerization, unleashing kinase activity [4]	~1,000-fold increase [4]
hipA(P86L)	P86L	Disruption of N-subdomain-1 dimerization interface [4]	High-persister phenotype similar to hipA7 [4]
hipA(D88N)	D88N	Disruption of N-subdomain-1 dimerization interface [4]	High-persister phenotype [4]

Evolutionary and Clinical Consequences of Persistence

Persistence as a Stepping Stone to Genetic Resistance

Bacterial persistence is not merely a survival mechanism in itself but also a critical facilitator of genetic resistance. There is a strong positive correlation between persistence levels and the likelihood of a population evolving genotypic resistance [82]. This relationship can be attributed to two main factors:

• Viable Cell Reservoir: Persisters provide a protected reservoir of viable cells from which resistant mutants can emerge during or after antibiotic treatment [82].
• Pleiotropic Link with Mutation Rates: Evidence suggests that the physiological state of persisters is pleiotropically linked with increased mutation rates, thereby elevating the probability that a resistance-conferring mutation will occur [82].

Mathematical models simulating infection treatment dynamics confirm that increased persister survival and mutation rates jointly accelerate the emergence of resistant populations [82].

Cellular Memory of HipA-Induced Arrest

Recent findings indicate that bacterial cells exhibit a form of "cellular memory" of previous HipA-induced growth arrest [81]. When E. coli cells undergo repeated cycles of HipA induction, arrest, and regrowth, the length of the growth arrest phase becomes progressively shorter with each successive induction [81]. This memory effect is not due to the selection of HipA-resistant mutants but represents a form of physiological adaptation that persists across multiple cell divisions [81]. This phenomenon adds a layer of complexity to the evolutionary dynamics of persistence, suggesting that past environmental exposures can shape future bacterial responses to stress.

Research Tools and Methodologies

Key Experimental Protocols

A. Isolating and Characterizing High-PersistencehipAMutants

The original and subsequent high-persistence hipA mutants were isolated using a powerful selective enrichment strategy [4] [6].

• Mutant Selection: Wild-type E. coli populations are subjected to prolonged treatment with high concentrations of antibiotics (e.g., ampicillin alone or in combination with cefotaxime).
• Cycle Enrichment: Surviving cells are harvested, cultured in fresh medium without antibiotic, and then re-challenged with the same antibiotic regimen. This cycle is repeated several times to enrich for high-persister mutants.
• Genetic Identification: The genomic DNA of enriched mutants is sequenced. Mutations in the hipA gene are identified, and their causal role is confirmed by deleting the mutant allele and demonstrating a return to wild-type persistence levels [4].

B. Demonstrating HipA-GltX Interaction via Suppression

A critical genetic experiment for validating GltX as the target of HipA involves a suppression assay [25].

• Strain Utilization: Use a strain carrying the cold-sensitive hipA7 allele (e.g., MG1655A7).
• Transformation: Transform the strain with a plasmid library for overexpression of E. coli genes or with a specific plasmid overexpressing the gltX gene.
• Phenotypic Screening: Screen for colonies that overcome the cold-sensitive growth defect induced by hipA7. The ability of GltX overexpression to suppress this phenotype provides strong genetic evidence that GltX is the key target of HipA toxicity [25].

C. Monitoring (p)ppGpp Synthesis via Radioactive Labeling

The activation of the stringent response downstream of HipA can be directly measured.

• Cell Culture and Induction: Cultures of E. coli harboring a plasmid for inducible HipA expression (e.g., pTet-hipA) are grown to an appropriate density. HipA expression is induced with anhydrotetracycline (aTc).
• Metabolic Labeling: Expose cells to 32P-labeled orthophosphate to metabolically label newly synthesized nucleotides.
• Nucleotide Extraction and Analysis: At time points post-induction, extract nucleotides from the cells. Separate the extracted nucleotides using thin-layer chromatography (TLC).
• Detection and Quantification: Visualize and quantify the synthesized (p)ppGpp spots using a phosphorimager. Overexpression of HipA leads to a clear increase in (p)ppGpp synthesis, which is abolished by co-overexpression of GltX [25].

The following workflow summarizes the key experimental approaches:

Research Reagent Solutions

Table 2: Essential Research Reagents for HipA Studies

Reagent / Tool	Function / Application in Research	Key Findings Enabled
hipA7 Mutant Strain	Model for high persistence; contains G22S and D291A mutations [4] [6]	First genetic link to persistence; established HipA's role in multidrug tolerance [6]
pTet-hipA-mcherry Plasmid	Enables controlled, ectopic overexpression of HipA for toxicity studies [25]	Demonstrated that HipA overexpression induces growth arrest and (p)ppGpp synthesis [25]
pTac-gltX Plasmid	Allows for overexpression of GltX (glutamyl-tRNA synthetase) [25]	Suppression of HipA7 toxicity and HipA-induced (p)ppGpp synthesis confirmed GltX as the primary target [13] [25]
HipA(D309Q) Mutant Protein	A catalytically compromised mutant used for structural studies (e.g., crystallography) and inhibitor screening due to retained ATP-binding affinity [54]	Elucidation of the HipA ATP-binding pocket structure; facilitated structure-based virtual screening for inhibitors [54]
HipA Inhibitors (e.g., PKUMDL-LTQ-301)	Small-molecule compounds identified via virtual screening that bind HipA and inhibit its function [54]	Proof-of-concept that inhibiting toxin activity can reduce persistence; compound PKUMDL-LTQ-301 showed KD of 270 nM and reduced persisters >5-fold [54]

Therapeutic Targeting of Persistence

The recognition of persisters as a major cause of treatment failure has spurred the search for anti-persister therapies. Targeting the HipA toxin directly represents a promising strategy. Structure-based virtual screening has identified novel HipA inhibitors, such as the compound PKUMDL-LTQ-301, which binds HipA with high affinity (KD = 270 ± 90 nM) and reduces the persister fraction in E. coli by more than five-fold [54]. Crucially, this anti-persister activity was lost in a ΔhipA strain, confirming that the effect is on-target [54]. These findings provide a framework for developing adjuvant therapies that co-administer conventional antibiotics with anti-persister compounds to eradicate both growing and dormant cell populations.

The study of HipA has been instrumental in moving the field of bacterial persistence from a descriptive phenomenon to a mechanistically understood component of bacterial biology and evolution. Its role, through the precise kinase-mediated inactivation of GltX and subsequent triggering of the stringent response, exemplifies a sophisticated adaptation for survival in fluctuating environments. The presence of hipA mutants in clinical isolates and the pleiotropic link between persistence and resistance underscore its significant evolutionary impact. Future research, building on the reagents, protocols, and structural insights detailed in this guide, will be critical for the development of novel therapeutic strategies aimed at overcoming antibiotic tolerance and curtailing the evolution of resistance.

Conclusion

The hipA gene represents a paradigm for understanding bacterial persistence, a phenotype with profound implications for treating chronic and recurrent infections. Research confirms that HipA, through its kinase activity on GltX and subsequent induction of the stringent response, provides a well-defined molecular pathway to dormancy. The clinical isolation of hipA mutants from UTIs provides compelling evidence for its role in real-world infections. Future research must focus on translating this molecular understanding into novel therapeutic strategies that either prevent persister formation or actively eradicate this dormant population. Combining anti-persister approaches with conventional antibiotics represents a promising frontier for overcoming treatment failures and combating the global challenge of antibiotic tolerance.

References

• 1. Quantitative analysis of persister fractions suggests different ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3682893/]
• 2. Bacterial persisters: molecular mechanisms and ... [https://www.nature.com/articles/s41392-024-01866-5]
• 3. Molecular mechanism and application of emerging ... [https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-024-03628-3]
• 4. HipAB-promoter structures reveal basis of heritable multidrug ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7502270/]
• 5. Heterogeneous bacterial persisters and engineering ... [https://www.sciencedirect.com/science/article/abs/pii/S1369527411001391]
• 6. hipA, a newly recognized gene of Escherichia coli K-12 ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC217749/]
• 7. A Quantitative Survey of Bacterial Persistence in the Presence ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7460088/]
• 8. Ectopic overexpression of wild-type and mutant hipA genes ... [https://pubmed.ncbi.nlm.nih.gov/16707675/]
• 9. Phenotypic Resistance to Antibiotics - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC4790337/]
• 10. An overview of the antimicrobial resistance mechanisms ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6604941/]
• 11. Antibiotics, Resistome and Resistance Mechanisms [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2018.02066/full]
• 12. Antibiotic-persistent bacterial cells exhibiting low-level ROS ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12345145/]
• 13. Molecular Mechanism of Bacterial Persistence by HipA [https://www.sciencedirect.com/science/article/pii/S109727651300645X]
• 14. Persistence and Culturability of Escherichia coli under ... [https://www.mdpi.com/2079-6382/13/9/863]
• 15. Lineage-dependent variations in single-cell antibiotic ... [https://www.nature.com/articles/s41467-025-59807-x]
• 16. Phenotypic convergence of bacterial adaption to sub-lethal ... [https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2022.913415/full]
• 17. Bacterial toxin-antitoxin modules: classification, functions, and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8610362/]
• 18. Structure, Biology, and Therapeutic Application of Toxin ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5086665/]
• 19. Regulation of the Escherichia coli HipBA toxin-antitoxin system by proteolysis - PubMed [https://pubmed.ncbi.nlm.nih.gov/22720069/]
• 20. Regulation of the Escherichia coli HipBA Toxin-Antitoxin ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0039185]
• 21. hipBA toxin-antitoxin systems mediate persistence in ... [https://www.nature.com/articles/s41598-020-59283-x]
• 22. The Haemophilus influenzae HipBA toxin–antitoxin system adopts an unusual three-com­ponent regulatory mechanism - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC9438503/]
• 23. Large mutational target size for rapid emergence of bacterial ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3411964/]
• 24. Molecular mechanism of bacterial persistence by HipA [https://pubmed.ncbi.nlm.nih.gov/24095282/]
• 25. HipA-mediated antibiotic persistence via phosphorylation ... [https://www.nature.com/articles/ncomms4001]
• 26. HipA-Mediated Phosphorylation of SeqA Does not Affect ... [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2018.02637/full]
• 27. HipA-mediated antibiotic persistence via phosphorylation ... [https://pubmed.ncbi.nlm.nih.gov/24343429/]
• 28. Role of RelA-synthesized (p)ppGpp and ROS-induced ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11015494/]
• 29. Structural Basis for Regulation of the Opposing (p)ppGpp ... [https://www.sciencedirect.com/science/article/pii/S2211124720311463]
• 30. Phylogeny Reveals Novel HipA-Homologous Kinase ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8262856/]
• 31. Targeted intervention in the metabolism of bacteria [https://www.helmholtz-hips.de/en/news-events/news/detail/news/targeted-intervention-in-the-metabolism-of-bacteria/]
• 32. Activating the hidden pharmaceutical potential of bacteria [https://www.helmholtz-hzi.de/en/media-center/newsroom/news-detail/activating-the-hidden-pharmaceutical-potential-of-bacteria/]
• 33. An innovative antibiotic class for drug-resistant bacteria [https://www.helmholtz-hips.de/en/news-events/news/detail/news/an-innovative-antibiotic-class-for-drug-resistant-bacteria/]
• 34. An innovative class of antibiotics to combat drug-resistant ... [https://www.dzif.de/en/innovative-class-antibiotics-combat-drug-resistant-bacteria]
• 35. Stochastic induction of persister cells by HipA through (p ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4413331/]
• 36. An Experimental Framework for Quantifying Bacterial ... [https://www.sciencedirect.com/science/article/pii/S0006349517305519]
• 37. In Vitro Persistence Level Reflects In Vivo Antibiotic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10269860/]
• 38. Regulation of phenotypic variability by a threshold-based ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2906590/]
• 39. New kinase regulation mechanism found in HipBA [https://pubmed.ncbi.nlm.nih.gov/19622872/]
• 40. Cellular Memory of HipA-Induced Growth Arrest [https://pmc.ncbi.nlm.nih.gov/articles/PMC8705531/]
• 41. A Quantitative Framework for Evaluating Single-Cell Data ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7305633/]
• 42. ezSingleCell: an integrated one-stop single-cell and spatial ... [https://www.nature.com/articles/s41467-024-48188-2]
• 43. Generating Transposon Insertion Libraries in Gram ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7861349/]
• 44. Mechanisms of antimicrobial resistance in biofilms [https://www.nature.com/articles/s44259-024-00046-3]
• 45. Microbial Biofilm: A Review on Formation, Infection, Antibiotic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10305407/]
• 46. Visualisation and biovolume quantification in the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8160185/]
• 47. Quantitative image analysis of microbial communities with ... [https://www.nature.com/articles/s41564-020-00817-4]
• 48. High Persister Mutants in Mycobacterium tuberculosis [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0155127]
• 49. Experts See 17 Laboratory Trends Dominating 2025 [https://clpmag.com/diagnostic-technologies/experts-see-17-laboratory-trends-dominating-2025/]
• 50. Artificial intelligence in healthcare and medicine: clinical ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12455834/]
• 51. Recent Advances in Bacterial Persistence Mechanisms - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10531727/]
• 52. Relationship between the Viable but Nonculturable State ... [https://pubmed.ncbi.nlm.nih.gov/30082460/]
• 53. Viable but nonculturable (VBNC) state, an underestimated ... [https://www.sciencedirect.com/science/article/abs/pii/S0966842X23001476]
• 54. Novel Inhibitors of Toxin HipA Reduce Multidrug Tolerant ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4867474/]
• 55. Molecular Mechanisms Underlying Bacterial Persisters [https://www.sciencedirect.com/science/article/pii/S0092867414002979]
• 56. Growth productivity as a determinant of the inoculum effect for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9750144/]
• 57. Effects of Growth Medium, Inoculum Size, and Incubation ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC546801/]
• 58. Recent Advances in Bacterial Persistence Mechanisms [https://www.mdpi.com/1422-0067/24/18/14311]
• 59. Evolution of Bacterial Tolerance Under Antibiotic Treatment ... [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.617412/full]
• 60. Predicting toxins found in toxin–antitoxin systems with a ... [https://www.nature.com/articles/s41598-020-73887-3]
• 61. Kinase Activity of Overexpressed HipA Is Required for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC1698217/]
• 62. Unrelated toxin–antitoxin systems cooperate to induce ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4528579/]
• 63. Molecular mechanisms of multiple toxin–antitoxin systems ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3703989/]
• 64. Identification and genetic dissection of convergent persister ... [https://www.nature.com/articles/s41586-024-08124-2]
• 65. MqsR/MqsA Toxin/Antitoxin System Regulates Persistence ... [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2017.00840/full]
• 66. Insights from Escherichia coli as a Model Organism [https://www.mdpi.com/2076-2607/13/1/51]
• 67. Quantitative analysis of persister fractions suggests different ... [https://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-13-25]
• 68. Protocol for assessing single-cell persister recovery ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11015153/]
• 69. Establishment of a Method To Rapidly Assay Bacterial ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3754326/]
• 70. Flow-cytometry analysis reveals persister resuscitation ... [https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01888-3]
• 71. Incidence of Urinary Tract Infection Among Patients [https://pmc.ncbi.nlm.nih.gov/articles/PMC10134187/]
• 72. Escherichia coli K-12 substr. MG1655 hipA [https://biocyc.org/gene?orgid=ECOLI&id=EG10443]
• 73. Evidence for a Functional HipBA Toxin–Antitoxin System in ... [https://www.mdpi.com/1422-0067/26/7/3366]
• 74. Persistence Increases in the Absence of the Alarmone ... [https://www.nature.com/articles/srep20519]
• 75. (p)ppGpp and Its Role in Bacterial Persistence [https://pmc.ncbi.nlm.nih.gov/articles/PMC7508602/]
• 76. Metabolite-driven reprogramming of bacterial persisters [https://www.sciencedirect.com/science/article/abs/pii/S1368764625001256]
• 77. Ectopic Overexpression of Wild-Type and Mutant hipA ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC1482909/]
• 78. A genome-wide scan of wastewater E. coli for genes under ... [https://www.nature.com/articles/s41598-022-11432-0]
• 79. Genome Analysis of Pseudomonas aeruginosa Strains ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10051920/]
• 80. Evolution of Bacterial Tolerance Under Antibiotic Treatment ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7952611/]
• 81. Cellular Memory of HipA-Induced Growth Arrest [https://www.mdpi.com/2076-2607/9/12/2594]
• 82. Bacterial persistence promotes the evolution of antibiotic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6474225/]